

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.

THIS PAGE BLANK (USPTO)



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/12, C07K 14/705, 14/52, 16/28, 16/18, G01N 33/68</b>	<b>A2</b>	<b>(11) International Publication Number: WO 99/11791</b> <b>(43) International Publication Date: 11 March 1999 (11.03.99)</b>
<b>(21) International Application Number:</b> PCT/US98/18393 <b>(22) International Filing Date:</b> 4 September 1998 (04.09.98)  <b>(30) Priority Data:</b> 08/924,634 5 September 1997 (05.09.97) US  <b>(71) Applicant:</b> UNIVERSITY OF WASHINGTON [US/US]; Suite 200, 1107 N.E. 45th Street, Seattle, WA 98105-4631 (US). <b>(72) Inventor:</b> CHAUDHARY, Preet, M.; 4540 8th Avenue N.E. #402, Seattle, WA 98105 (US). <b>(74) Agents:</b> GASHLER, Andrea, L. et al.; Campbell & Flores LLP, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).	<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
<b>(54) Title:</b> TUMOR NECROSIS FACTOR FAMILY RECEPTORS AND LIGANDS, ENCODING NUCLEIC ACIDS AND RELATED BINDING AGENTS  <b>(57) Abstract</b> <p>The invention provides novel receptors of the tumor necrosis factor receptor family as well as ligands of the tumor necrosis factor family. In addition to the isolated receptors and ligands of the invention, there are provided encoding nucleic acids and related selective binding agents.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



TUMOR NECROSIS FACTOR FAMILY RECEPTORS AND LIGANDS,  
ENCODING NUCLEIC ACIDS AND RELATED BINDING AGENTS

BACKGROUND OF THE INVENTION

This invention relates to molecules involved in  
5 apoptosis and more specifically to tumor necrosis family  
receptors and ligands.

The tumor necrosis factor (TNF) family of  
ligands are a superfamily of polypeptides involved in  
cell-cell signaling. The prototypic TNF molecule was  
10 first identified by its ability to kill a variety of  
transformed cell lines. In addition to their role in  
cell survival and death, TNF-like molecules and their  
cognate receptors are now known to be involved in the  
regulation of a variety of cellular functions including  
15 cellular proliferation, differentiation and cytokine  
secretion.

Ligands of the TNF superfamily are type II  
membrane glycoproteins with a large C-terminal  
extracellular domain, a single transmembrane spanning  
20 region and a variable cytoplasmic domain. Like the  
prototypic TNF- $\alpha$  molecule, most are acidic molecules with  
approximately 20% sequence homology in the extracellular  
receptor-binding domain. The conservation of the more  
variable cytoplasmic domains among species homologs  
25 indicates that the cytoplasmic domains also can serve an  
important function in signal transduction. The TNFR  
ligand family includes TNF- $\alpha$ , TNF- $\beta$ , LT $\beta$ , FAS ligand,  
CD27 ligand, CD30 ligand, CD40 ligand, OX40 ligand and  
4-1BB ligand. Although ligands of the TNF family are  
30 typically expressed on the cell surface, soluble forms of  
TNF- $\alpha$ , TNF- $\beta$  and FAS ligand also have been identified.

TNF receptor family members generally are type I membrane glycoproteins with sequence homology typically confined to the extracellular domain. This amino-terminal extracellular domain includes a variable number of cysteine-rich pseudo repeats, which are motifs of approximately 40 amino acids containing about six cysteine residues. Numerous cellular and viral members of the TNF receptor superfamily have been described, including TNFR-1 and TNFR-2, TNFR-RP/TNFR-3, nerve growth factor receptor (NGFR), CD27, CD30, CD40, 4-1BB, OX-40, FAS/APO-1 (CD95), DR3 (Wsl-1/APO-3/TRAMP) and DR4. In addition, related viral proteins PV-T2 and PV-A53R encode soluble secreted members of the TNF receptor family.

Several of the tumor necrosis factor receptors function in the process of regulated cell death, termed programmed cell death, or "apoptosis." TNFR-1, FAS/APO-1 and DR3 are TNF receptors that transmit a suicidal signal through a conserved 80 amino acid cytoplasmic region known as a "death domain." Cytoplasmic death-domain containing proteins including FADD/MORT1 (Fas-associated protein with death domain) and TRADD (TNFR-1-associated death domain protein) act as intracellular adaptor molecules in transmitting the ligand-dependent apoptotic signal initiated by a "death receptor." The FAS/APO-1 receptor appears to directly interact with FADD/MORT1, while other death receptors such as TNFR-1 and DR3 associate with TRADD, which acts as an adaptor molecule and recruits FADD/MORT. Despite its sequence homology to the similar domains present in the death receptors, the death domain of FADD does not induce apoptosis when over-expressed in mammalian cells and blocks apoptosis mediated by full-length FADD in a dominant negative fashion. However, FADD possesses another conserved domain denoted a "death effector domain" (DED), which

mediates apoptosis when over-expressed in mammalian cells. Through its DED, FADD binds to homologous domains present in the cysteine protease (caspase) FLICE/MACH1 (caspase 8). FLICE/MACH1 is the most proximal caspase in a cascade of cysteine proteases that are triggered by ligand-dependent activation of the death receptors, ultimating resulting in programmed cell death.

In addition to mediating apoptosis through FADD, the TRADD adaptor molecule can recruit other molecules to the aggregated receptor complex of TNFR-1 or DR3, including the death domain-containing protein RIP (receptor-interacting protein) and TRAF2, which lacks a death domain. While recruitment of FADD leads to activation of caspases and eventual cell death, recruitment of RIP and TRAF2 leads to activation of the NF- $\kappa$ B (nuclear factor kappa-B) pathway, which may protect cells from TNF-induced apoptosis.

Programmed cell death plays a major role throughout development, as well as in the homeostatic control of cell numbers and in defense against intracellular pathogens. Furthermore, abnormalities in programmed cell death contribute to the pathogenesis of a number of diseases. For example, the failure of cells to undergo apoptotic cell death can be involved in cancers such as breast, prostate and ovarian cancer, in autoimmune diseases and in viral infections. Furthermore, a number of diseases are characterized by excessive apoptosis including acquired immunodeficiency syndrome (AIDS); neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and retinitis pigmentosa; osteoporosis; ischemic injury; vasculitis; hepatic necrosis; and cerebral or myocardial infarction. Excessive cell death also can contribute to

organ-specific autoimmune diseases such as Hashimoto thyroiditis. Therapies which are specifically designed to modulate apoptotic pathways can change the natural progression of these and other pathologies characterized  
5 by inadequate or excessive apoptosis.

Unfortunately, the ability to provide effective therapeutic intervention is limited by the fact that critical polypeptide receptors and ligands involved in the process of apoptosis remain to be isolated. For  
10 example, novel TNF superfamily receptors, which can play a critical role in regulating apoptosis in particular cell types or under certain conditions, remain to be isolated.

Thus, there exists a need to identify and  
15 isolate novel TNF superfamily receptors and ligands and their encoding nucleic acids. The present invention satisfies this need and provides related advantages as well.

#### SUMMARY OF THE INVENTION

20 The invention provides novel receptors of the tumor necrosis factor receptor family as well as ligands of the tumor necrosis factor family. In addition to the isolated receptors and ligands of the invention, there are provided encoding nucleic acids and related selective  
25 binding agents.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Alignment of the extracellular domains of several representative tumor necrosis family receptors. Alignment was done by pileup program of GCG

software (Genetic Computer Group, Madison, WI). Dominant residues are shown in upper case, or determined by the pretty program of the GCG software.

Figure 2. hAPO8 nucleotide sequence SEQ ID NO:1 and amino acid sequence SEQ ID NO:2.

Figure 3. APO8-related polypeptide (APO8RP) nucleotide sequence SEQ ID NO:3 and amino acid sequence SEQ ID NO:4.

Figure 4. (A) Alignment of the predicted amino acid sequence of APO8 with APO8RP. Identical amino acids are shaded black and homologous residues are shaded gray. Predicted signal peptides, transmembrane regions (TM regions) and death domains are indicated. (B) Sequence alignment of the death domains of APO8, DR4, DR3, TNFR-1 and FAS/APO-1. Residues identical in more than 30% of sequences are shaded black and those homologous in greater than 30% of sequences are shaded gray. Residues corresponding to the site of the *lpr* mutation in the murine FAS receptor are indicated by a  $\Delta$  symbol.

Figure 5. (A) Induction of apoptosis in MCF-7 cells by overexpression of either the full-length APO8 construct or APO8 mutant constructs. (B) Inhibition of APO8, APO8RP and DR3 induced apoptosis by progressive increasing amounts of dominant negative FADD (DN-FD) in 293T cells. The DNA ratio of receptor to DN-FADD is shown in parenthesis. © Inhibition of APO8-induced apoptosis in MCF-7 cells by dominant negative FADD (DN-FD), dominant negative FLICE (FL-C360S) and the cysteine protease inhibitors CrmA and z-VAD-fmk. (D) APO8 and APO8RP activate the NF- $\kappa$ B pathway. Shown is

the relative luciferase activity from an NF- $\kappa$ B luciferase reporter in 293T cells cotransfected with the indicated reporter construct.

Figure 6. hAPO9 nucleotide sequence SEQ ID NO:5 and amino acid sequence SEQ ID NO:6.

Figure 7. (A) mAPO4- $\alpha$  long nucleotide sequence SEQ ID NO:7 and amino acid sequence SEQ ID NO:8. (B) mAPO4- $\alpha$  short nucleotide sequence SEQ ID NO:9 and amino acid sequence SEQ ID NO:10. (C) hAPO4- $\alpha$  nucleotide sequence SEQ ID NO:11 and amino acid sequence SEQ ID NO:12. (D) rAPO4- $\alpha$  nucleotide sequence SEQ ID NO:13 and amino acid sequence SEQ ID NO:14. (E) mAPO4- $\gamma$  nucleotide sequence SEQ ID NO:31 and amino acid sequence SEQ ID NO:32.

Figure 8. mAPO4- $\beta$  nucleotide sequence SEQ ID NO:15 and amino acid sequence SEQ ID NO:16.

Figure 9. hAPO6 nucleotide sequence SEQ ID NO:17 and amino acid sequence SEQ ID NO:18.

Figure 10. Alignment of representative ligands of the tumor necrosis factor family. Residues identical in more than 30% of sequences are shaded black and those homologous in greater than 30% of sequences are shaded gray.

Figure 11. (A) hTNRL1- $\alpha$  nucleotide sequence SEQ ID NO:17 and amino acid sequence SEQ ID NO:20. (B) mTNRL1- $\alpha$  nucleotide sequence SEQ ID NO:21 and amino acid sequence SEQ ID NO:22.

Figure 12. (A) hTNRL1- $\beta$  nucleotide sequence SEQ ID NO:23 and amino acid sequence SEQ ID NO:24. (B) mTNRL1- $\beta$  nucleotide sequence SEQ ID NO:25 and amino acid sequence SEQ ID NO:26.

5 Figure 13. (A) hTNRL3 nucleotide sequence SEQ ID NO:27 and amino acid sequence SEQ ID NO:28. (B) mTNRL3 nucleotide sequence SEQ ID NO:29 and amino acid sequence SEQ ID NO:30.

Figure 14. (A) Induction of apoptosis in 293T  
10 cells by expression of full-length human APO4 (hAPO4). Inhibition of APO4-induced apoptosis by various inhibitors of the caspase or JNK pathway are also shown. (B) hAPO4 activates the JNK pathway. Shown is the relative luciferase activity from a c-Jun transactivating  
15 reporter in 293T cells cotransfected with hAPO4 in the presence or absence of the indicated inhibitor plasmid (JBD of JIP-1, MEKK1-D1369A, or DN-TRAF2). (C) hAPO4 activates the NF- $\kappa$ B pathway. Shown is the relative luciferase activity from an NF- $\kappa$ B reporter construct in  
20 293T cells cotransfected with hAPO4 and empty vector, dominant negative TRAF2 (DN-TRAF2) or I $\kappa$ B $\alpha$ -S32/36A.

#### DETAILED DESCRIPTION OF THE INVENTION

Members of the TNFR family are type I  
25 transmembrane receptors characterized by the presence of cysteine-rich pseudo-repeats in the extracellular domain. These cysteine rich regions, which are motifs of approximately 40 amino acids with about 6 cysteines, are involved in ligand binding. The average homology in the  
30 cysteine-rich extracellular region is in the range of 25% to 30%. In addition to a signal peptide, a large extracellular domain and hydrophobic transmembrane

region, receptors of the TNF family have cytoplasmic domains, which function in transmitting a ligand-dependent signal.

The TNF receptor superfamily contains at least  
5 10 different cellular membrane proteins and several viral proteins encoding TNF receptor related molecules. The first cloned receptor of this family was the nerve growth factor receptor (NGFR), and the TNF receptor superfamily of type I transmembrane receptors now includes TNFR-1 and  
10 TNFR-2, TNFR-RP/TNFR-3, nerve growth factor receptor (NGFR), CD27, CD30, CD40, 4-1BB, OX-40, FAS/APO-1 (CD95), DR3 (Wsl-1/APO-3/TRAMP) and DR4. In addition, related viral proteins PV-T2 and PV-A53R encode soluble secreted members of the TNF receptor family. Several members such  
15 as TNFR-1, TNFR-2 and NGFR have a broad tissue distribution, while CD27, CD30, CD40, 4-1BB and OX40 are chiefly restricted to cells of the lymphoid or hematopoietic systems.



Table 1				
PERCENTAGE AMINO ACID IDENTITY AND SIMILARITY BETWEEN VARIOUS RECEPTORS IN THE EXTRACELLULAR DOMAIN				
Receptor	hAPO8 (SIN:2)	hAPO9 (SIN:6)	mAPO4- $\alpha$ L (SIN:8)	hAPO6 (SIN:18)
5 TNFR1	27.3 (46.5)	21.8 (40.0)	20.1 (39.0)	17.0 (32.0)
TNFR2	25.8 (45.1)	21.9 (41.0)	22.4 (41.4)	33.1 (45.0)
Fas	25.1 (45.5)	27.2 (40.9)	23.0 (43.4)	20.4 (38.7)
DR3	21.5 (40.2)	21.6 (36.6)	23.6 (45.9)	28.4 (49.6)
DR4	58.1 (70.6)	57.0 (71.7)	20.4 (36.6)	16.8 (33.7)
10	* Percentage similarity is shown in parenthesis			

The present invention is directed to the discovery of several new receptors belonging to the TNF family, designated an APO8 polypeptide, an APO8 related polypeptide (APO8RP), an APO9 polypeptide, an APO4 polypeptide, and an APO6 polypeptide. In general, the receptors of the invention are transmembrane proteins with large extracellular ligand-binding domains sharing 16-60% sequence identity in this region with other members of the TNF receptor family (Figure 1 and Table 1 above). A preferred method for determining amino acid identity is by pairwise alignment using the gap program of GCG software (Genetic Computer Group, Madison, WI) using the default parameters.

The present invention provides an isolated APO8 polypeptide, which is a novel TNF receptor having substantially the same amino acid sequence as APO8, or an active fragment thereof. An isolated APO8 polypeptide of  
5 the invention can have substantially the same amino acid sequence as the APO8 sequence SEQ ID NO:2 shown in Figure 2.

An exemplary human APO8 polypeptide (hAPO8) is provided herein. hAPO8 is a widely expressed polypeptide  
10 containing structural features reminiscent of known "death receptors," including an intracellular death domain. As disclosed herein, overexpression of hAPO8 results in apoptosis, which is caspase-dependent and also dependent upon the FADD/MORT adaptor molecule  
15 (Example II). hAPO8 also activates NF- $\kappa$ B expression through the TRADD adaptor molecule and, thus, can have anti-apoptotic activity. As further disclosed herein, hAPO8 interacts directly with TRADD, thereby recruiting FADD/MORT. The hAPO8 polypeptide of the invention can be  
20 useful in identifying selective enhancers or inhibitors of APO8 activity, which can be used as novel therapeutics for the management of APO8-mediated diseases or diseases involving the dysfunction of programmed cell death. In addition, nucleic acid molecules encoding hAPO8 or  
25 apoptotic fragments of hAPO8 can themselves be used as inducers or inhibitors of programmed cell death.

The term "isolated," as used herein in reference to a polypeptide of the invention, means a polypeptide that is in a form that is relatively free  
30 from contaminating lipids, unrelated polypeptides, nucleic acids and other cellular material normally associated with the polypeptide in a cell.

As used herein, the term "APO8" means an APO8 polypeptide and includes polypeptides having substantially the same amino acid sequence as the hAPO8 polypeptide having amino acid sequence SEQ ID NO:2.

5 hAPO8 is a transmembrane protein of 411 amino acids having the amino acid sequence shown in Figure 2. hAPO8 contains an N-terminal signal peptide of 51 amino acids, a large extracellular domain with characteristic TNF receptor family cysteine-rich regions, a hydrophobic  
10 transmembrane domain of 27 amino acids (residues 185 to 212) and a C-terminal cytoplasmic domain (residues 213 to 411). The APO8 cytoplasmic domain includes a "death domain," which is a conserved domain of about 80 amino acids present in pro-apoptotic TNF receptors such as  
15 TNFR-1, FAS/APO-1 and DR3 and that is required for apoptosis. Death domains also are present in several cytoplasmic proteins, and a homotypic association between death domains appears responsible for the interaction of these cytoplasmic proteins with TNFR-1, FAS/APO-1 and  
20 DR3.

As disclosed in Example I, hAPO8 RNA is expressed in a variety of tissues, with a particularly high level of expression observed in peripheral blood lymphocytes (PBL). The results disclosed in Example II  
25 demonstrate that the hAPO8 polypeptide of the invention exhibits caspase-dependent apoptotic activity and activates NF- $\kappa$ B gene expression. Thus, hAPO8 is a TNF family receptor, which, like TNFR-1 and DR3, activates NF- $\kappa$ B expression and promotes apoptosis through a cascade  
30 of cysteine proteases.

The term APO8 encompasses a polypeptide having the sequence of the naturally occurring human APO8 polypeptide (SEQ ID NO:2) and is intended to include

related polypeptides having substantial amino acid sequence similarity to hAPO8 (SEQ ID NO:2). Such related polypeptides exhibit greater sequence similarity to hAPO8 than to other polypeptides containing cysteine-rich  
5 pseudo-repeats or other death domain containing polypeptides and include alternatively spliced forms of hAPO8, species homologues, and isotype variants of the amino acid sequence shown in Figure 2. The hAPO8 polypeptide disclosed herein has about 58% amino acid  
10 identity and about 71% amino acid similarity with the Death Receptor (DR4). As used herein, the term APO8 describes polypeptides generally having an amino acid sequence with greater than about 65% amino acid sequence identity with hAPO8 (SEQ ID NO:2), preferably greater  
15 than about 75% amino acid identity with hAPO8 (SEQ ID NO:2), more preferably greater than about 85% amino acid identity with hAPO8 (SEQ ID NO:2), and includes polypeptides having greater than about 90%, 95% or 97% amino acid identity with hAPO8 (SEQ ID NO:2).

20           The present invention also provides active fragments of the APO8 polypeptide of the invention. In general, the term "active fragment" means a polypeptide fragment having substantially the same amino acid sequence as a portion of the indicated polypeptide of the  
25 invention, provided that the fragment retains at least one biological activity of the polypeptide. A portion of a polypeptide generally has an amino acid sequence of about 15 to about 400 contiguous residues and can have, for example, an amino acid sequence of at least about 18,  
30 20, 25, 30, 35, 40, 50, 100, 150 or 200 contiguous residues. As described further below, the invention also provides active segments of the APO8 polypeptide of the invention. In general, an active segment is characterized, in part, by having substantially the same

amino acid sequence as a portion of the indicated polypeptide. Such an active segment generally has an amino acid sequence of about 15 to about 400 contiguous residues and can have, for example, an amino acid  
5 sequence of at least about 18, 20, 25, 30, 35, 40, 50  
100, 150 or 200 contiguous residues.

As used herein, an "active fragment of an APO8 polypeptide" is synonymous with "active fragment of APO8" or "active APO8 fragment" and means a polypeptide  
10 fragment having substantially the same amino acid sequence as a portion of an APO8 polypeptide, provided that the fragment retains at least one biological activity of an APO8 polypeptide. An active fragment of an APO8 polypeptide can have, for example, an amino acid  
15 sequence that is identical or substantially the same as a portion of the amino acid sequence of hAPO8 (SEQ ID NO:2), provided that the fragment retains at least one biological activity of an APO8 polypeptide. A biological activity of APO8 can be, for example, the ability to bind  
20 ligand, bind TRADD or RIP, induce or suppress apoptosis, activate NF- $\kappa$ B expression, or induce or suppress cell proliferation, differentiation or cytokine secretion. Particularly useful active fragment of APO8 are polypeptide fragments having pro-apoptotic or  
25 anti-apoptotic activity. A biological activity of an APO8 polypeptide or fragment can be routinely assayed; for example, apoptotic activity can be analyzed by transfecting an APO8 encoding nucleic acid and measuring the number of cells with apoptotic morphology, as set  
30 forth in Example II.

An "active fragment of an APO8 polypeptide" also can be an active APO8 segment, which is a polypeptide portion having substantially the same amino

acid sequence as a portion of an APO8 polypeptide, provided that the segment does not consist of the identical amino acid sequence encoded by an expressed sequence tag having GenBank accession number AA223122 or  
5 AA232440 and provided that the segment retains at least one biological activity of an APO8 polypeptide. An active APO8 segment can have, for example, an amino acid sequence that is identical or substantially the same as a portion of the amino acid sequence of hAPO8 (SEQ ID  
10 NO:2), provided that the segment does not consist of the identical amino acid sequence encoded by an expressed sequence tag having GenBank accession number AA223122 or AA232440 and provided that the segment retains at least one biological activity of an APO8 polypeptide.

15 In one embodiment, the invention provides active fragments that are soluble, extracellularly expressed forms of the receptors of the invention. Such a soluble active fragment includes the receptor ligand binding domain. Such a soluble active fragment can be an  
20 inhibitory polypeptide that binds ligand and opposes the biological function of full-length or membrane-bound receptor. For example, as disclosed herein, APO8 induces caspase-dependent apoptosis when expressed in BHK cells; a soluble form of the APO8 receptor can compete for  
25 binding to an APO8 ligand and reduce or inhibit the pro-apoptotic activity of APO8. Another use of such soluble forms of the receptors of the invention can be to transduce a signal across the surface of a cell which expresses the cognate ligand of the receptor. One  
30 skilled in the art understands that a soluble receptor can act in a systemic fashion, for example, to block the activity of full-length or membrane-bound receptors wherever the full-length receptor is expressed.

As used herein, the term "soluble" refers to a polypeptide that is not membrane bound. A particularly useful soluble polypeptide of the invention is secreted and, thus, expressed extracellularly.

5            Provided herein is a soluble APO8 active fragment that includes an APO8 ligand binding domain. A soluble APO8 active fragment of the invention can be, for example, a truncated polypeptide encoding the extracellular domain of APO8. Such a soluble APO8 active  
10 fragment can have, for example, substantially the same amino acid sequence as the signal peptide and ligand-binding domain of hAPO8 (amino acids 1 to 184 of hAPO8 shown in Figure 1). One skilled in the art understands that a soluble APO8 active fragment is  
15 distinguished from a membrane-bound fragment by the deletion or inactivation of the transmembrane domain, which is shown as amino acids 185 to 212 in Figure 2. A soluble APO8 active fragment also can be, for example, an active APO8 segment. Active APO8 segments are described  
20 hereinabove.

The present invention also provides an isolated APO8-related polypeptide, which is a novel TNF superfamily receptor having substantially the same amino acid sequence as APO8 or an APO8-related polypeptide. An  
25 isolated APO8 related polypeptide of the invention can have substantially the same amino acid sequence as the APO8 sequence SEQ ID NO:2 shown in Figure 2 or substantially the same amino acid sequence as the APO8RP sequence SEQ ID NO:4 shown in Figure 3. An APO8-related  
30 polypeptide is characterized, in part, by the ability to induce FADD-dependent apoptosis or the ability to activate NF- $\kappa$ B. As disclosed herein, APO8 and APO8RP activate NF- $\kappa$ B by a TRADD dependent pathway. As further

disclosed herein, APO8 and APO8RP interact directly with TRADD in co-immunoprecipitation experiments, and FADD is indirectly recruited to APO8 or APO8RP through TRADD. An APO8-related polypeptide of the invention can be useful  
5 in diagnosing an APO8-related polypeptide-mediated disease or in treating or reducing the severity of such a disease, as described further below.

hAPO8 related polypeptides include hAPO8RP, a polypeptide of 410 amino acids, and hAPO8, a polypeptide  
10 of 411 amino acids. hAPO8RP (SEQ ID NO:4) and hAPO8 (SEQ ID NO:2) share an amino-terminal signal peptide of 51 amino acids with about 53% amino acid identity (see Figure 4A). An APO8 related polypeptide of the invention is characterized, in part, in that the amino-terminal 50  
15 residues of the mature polypeptide (residues 52 to 101) have at least about 30% amino acid identity with SEQ ID NO:2. Although the DR4 sequence described in Pan et al., Science 276:111-113 (1997) shares some similarity with hAPO8 and hAPO8RP, the DR4 sequence has only about 28%  
20 amino acid identity in the amino-terminal region of the mature polypeptide (shown as SEQ ID NO:2). Thus, DR4 is not an APO8-related polypeptide, as defined herein.

The term APO8-related polypeptide encompasses a polypeptide having the sequence of the naturally  
25 occurring human APO8 polypeptide (SEQ ID NO:2) or the naturally occurring APO8-related polypeptide (APO8RP; SEQ ID NO:4) and is intended to include related polypeptides having substantial amino acid sequence similarity to hAPO8 (SEQ ID NO:2) or hAPO8RP (SEQ ID NO:4). Such  
30 related polypeptides exhibit greater sequence similarity to hAPO8 or hAPO8RP than to other polypeptide containing cysteine-rich pseudo-repeats such as TNFR-1 or DR4 and include alternatively spliced forms of hAPO8 and hAPO8RP,



species homologues, and isotype variants of the amino acid sequences shown in Figures 2 and 3A. As used herein, the term APO8-related polypeptide describes a polypeptide generally having an amino acid sequence with greater than about 50% amino acid sequence identity with hAPO8 (SEQ ID NO:2) and, in particular, having a sequence in which the amino terminal 50 residues of the mature polypeptide have at least about 30% identity with amino acids 52 to 101 of SEQ ID NO:2. An APO8-related polypeptide preferably has an amino acid sequence in which the amino terminal 50 residues of the mature polypeptide have at least about 50% amino acid identity with amino acids 52 to 101 of SEQ ID NO:2, more preferably greater than about 75% amino acid identity with amino acids 52 to 101 of SEQ ID NO:2, and can be a polypeptide in which the amino terminal 50 residues of the mature polypeptide have greater than about 85%, 90%, 95% or 97% amino acid identity with amino acids 52 to 101 of SEQ ID NO:2. One skilled in the art understands that the term APO8-related polypeptide encompasses fusion proteins, in which a heterologous polypeptide sequence is fused N- or C- terminally, or is fused internally, for example, near the cleavage site of the signal peptide.

The present invention also provides an isolated APO9 polypeptide having substantially the same amino acid sequence as APO9, or an active fragment thereof. An isolated APO9 polypeptide of the invention can have substantially the same amino acid sequence as the human APO9 sequence SEQ ID NO:6 shown in Figure 6.

As used herein, the term "APO9" means an APO9 polypeptide and includes polypeptides having substantially the same amino acid sequence as the hAPO9 polypeptide having amino acid sequence SEQ ID NO:6. A

short, alternatively spliced form of hAPO9 having 259 amino acids is shown in Figure 6. This hAPO9 sequence contains an amino-terminal signal peptide (residues 1 to 22), a large extracellular ligand binding domain with  
5 characteristic TNF receptor family cysteine-rich regions (residues 23 to 241) and a hydrophobic membrane-anchoring domain (residues 242 to 259) at the 3' end. The hAPO9 extracellular domain has significant homology to other TNF receptor polypeptides as shown in Figure 1. Human  
10 APO9 is most closely related to the DR4 death receptor, with 57% amino acid sequence identity and 71% amino acid sequence similarity in the extracellular domain. A stop codon is present immediately after the membrane-anchoring domain such that the short form of hAPO9 shown in Figure  
15 6 lacks a cytoplasmic domain. Alternatively spliced, full-length forms of APO9 having a cytoplasmic signaling domain can mediate apoptosis; their function can be opposed by the short APO9 form shown in Figure 6.

The term APO9 encompasses a polypeptide having  
20 the sequence of the naturally occurring human APO9 polypeptide (SEQ ID NO:6) and is intended to include related polypeptides having substantial amino acid sequence similarity to hAPO9 (SEQ ID NO:6). Such related polypeptides exhibit greater sequence similarity to hAPO9  
25 than to members of the TNF receptor superfamily and include alternatively spliced forms of hAPO9, full-length forms having a cytoplasmic signaling domain, species homologues, and isotype variants of the amino acid sequence shown in Figure 6. Such full-length forms or  
30 APO9 species homologues can be readily obtained by the skilled artisan using routine molecular techniques, for example, by screening an appropriate cDNA library with a portion of SEQ ID NO:5 as a probe. As used herein, the term APO9 describes polypeptides generally having an

amino acid sequence with greater than about 65% amino acid sequence identity in the extracellular domain and transmembrane domain with hAPO9 (SEQ ID NO:6), preferably greater than about 75% amino acid identity in the  
5 extracellular domain and transmembrane domain with hAPO9 (SEQ ID NO:6), more preferably greater than about 85% amino acid identity in the extracellular domain and transmembrane domain with hAPO9 (SEQ ID NO:6), and includes polypeptides having greater than about 90%, 95%  
10 or 97% amino acid identity in the extracellular domain and transmembrane domain with hAPO9 (SEQ ID NO:6).

The present invention also provides active fragments of the APO9 polypeptide of the invention. As used herein, the term "active fragment of an APO9  
15 polypeptide" is synonymous with "active fragment of APO9" or "active APO9 fragment" and means a polypeptide fragment having substantially the same amino acid sequence as a portion of an APO9 polypeptide, provided that the fragment retains at least one biological  
20 activity of an APO9 polypeptide. An active fragment of an APO9 polypeptide can have, for example, an amino acid sequence that is identical or substantially the same as a portion of the amino acid sequence of hAPO9 (SEQ ID NO:6), provided that the fragment retains at least one  
25 biological activity of an APO9 polypeptide. A biological activity of APO9 can be, for example, the ability to bind ligand, the ability to induce or suppress apoptosis or the ability to induce or suppress cell proliferation, differentiation or cytokine secretion. A biological  
30 activity of an APO9 polypeptide or fragment can be routinely assayed; for example, apoptotic activity can be analyzed by transfecting an APO9 encoding nucleic acid and measuring the number of cells with apoptotic morphology, as set forth in Example II.

An "active fragment of an APO9 polypeptide" can be an active APO9 segment, which is a polypeptide portion having substantially the same amino acid sequence as a portion of an APO9 polypeptide, provided that the segment  
5 does not consist of the identical amino acid sequence by an expressed sequence tag having GenBank accession number AA031883, AA150849, T71406 or R10995 and provided that the segment retains at least one biological activity of an APO9 polypeptide. An active APO9 segment can have,  
10 for example, an amino acid sequence that is identical or substantially the same as a portion of the amino acid sequence of hAPO9 (SEQ ID NO:6), provided that the segment does not consist of the identical amino acid sequence encoded by an expressed sequence tag having  
15 GenBank accession number AA031883, AA150849, T71406 or R10995 and provided that the segment retains at least one biological activity of an APO9 polypeptide.

In one embodiment, the invention provides a soluble APO9 active fragment that includes an APO9 ligand  
20 binding domain. A soluble APO9 active fragment of the invention can be, for example, a truncated polypeptide encoding the extracellular domain of APO9. An exemplary soluble APO9 active fragment is provided in Figure 1 as amino acids 1 to 241 of hAPO9 and includes the signal  
25 peptide and ligand binding domain. One skilled in the art understands that a soluble APO9 active fragment is distinguished from a membrane-bound fragment of APO9 by the deletion or inactivation of the hydrophobic membrane-anchoring domain, shown as amino acids 242 to  
30 259 in Figure 6. A soluble APO9 active fragment also can be, for example, an active APO9 segment. Active APO9 segments are described hereinabove.

The present invention also provides an isolated APO4 polypeptide having substantially the same amino acid sequence as an APO4 polypeptide, or an active fragment thereof. An isolated APO4 polypeptide of the invention  
5 can have substantially the same amino acid sequence as murine APO4- $\alpha$ L (SEQ ID NO:8) shown in Figure 7A, murine APO4- $\alpha$ S (SEQ ID NO:10) shown in Figure 7B, human APO4- $\alpha$  (SEQ ID NO:12) shown in Figure 7C, or rat APO4- $\alpha$  (SEQ ID NO:14) shown in Figure 7D. An isolated APO4 polypeptide  
10 of the invention also can have substantially the same amino acid sequence as murine APO4- $\beta$  (SEQ ID NO:16) as shown in Figure 8.

As used herein, the term "APO4 polypeptide" means an APO4- $\alpha$  or APO4- $\beta$  polypeptide and includes  
15 polypeptides having substantially the same amino acid sequence as the mAPO4- $\alpha$ L polypeptide (SEQ ID NO:8), the mAPO4- $\alpha$ S polypeptide (SEQ ID NO:10), the hAPO4- $\alpha$  polypeptide (SEQ ID NO:12), the rAPO4- $\alpha$  polypeptide (SEQ ID NO:14) or the mAPO4- $\beta$  polypeptide (SEQ ID NO:16).  
20 Murine APO4- $\alpha$  is an alternatively spliced protein including an amino-terminal signal peptide, cysteine-rich pseudo-repeats characteristic of the TNF receptor family and a highly hydrophobic stretch of amino acids representing a transmembrane domain. The short mAPO4- $\alpha$   
25 isoform (mAPO4- $\alpha$ S) is encoded by an open reading frame of 214 amino acids and includes a short cytoplasmic tail, while the long mAPO4- $\alpha$ L isoform (mAPO4- $\alpha$ L) is a polypeptide of 416 amino acids with a unique cytoplasmic tail having no significant homology to other members of  
30 the TNF receptor family. The truncated mAPO4- $\alpha$ S polypeptide can compete for binding to an APO4- $\alpha$  ligand, thereby opposing the function of a long form of APO4- $\alpha$  such as mAPO4- $\alpha$ L.

Human APO4- $\alpha$  (hAPO4- $\alpha$ ) is another APO4 polypeptide of the invention. The nucleotide sequence encoding hAPO4- $\alpha$  is shown in Figure 7C. This sequence encodes an hAPO4- $\alpha$  polypeptide of 423 amino acids with  
5 70.7% amino acid identity and 81.1% amino acid similarity to mAPO4- $\alpha$ . As shown in Figure 7C, the hAPO4- $\alpha$  polypeptide possesses a signal peptide (residues 1 to 23), a putative transmembrane domain (residues 178 to 191) and the characteristic cytoplasmic domain of APO4  
10 polypeptides. Rat APO4- $\alpha$  (rAPO4- $\alpha$ ) is another APO4 polypeptide of the invention. The available sequence of the rAPO4- $\alpha$  cDNA is shown in Figure 7D. The cytoplasmic tail of rAPO4- $\alpha$  contains the unique APO4 cytoplasmic domain and is 80% identical with mAPO4- $\alpha$  at the amino  
15 acid level. Murine APO4- $\beta$  (mAPO4- $\beta$ ) is another APO4 polypeptide of the invention; the available sequence of mAPO4- $\beta$  is shown in Figure 8. Finally, murine APO4- $\gamma$  (mAPO4- $\gamma$ ) is another APO4 peptide of the invention whose sequence is shown in Figure 7E. mAPO4- $\gamma$  lacks a  
20 transmembrane domain and therefore represents a soluble receptor which can compete for binding to the APO4 ligand, thereby opposing the function of the long forms of mAPO4 such as mAPO4- $\alpha$ L.

The term APO4 polypeptide encompasses a  
25 polypeptide having the sequence of naturally occurring murine APO4- $\alpha$ L (SEQ ID NO:8) or APO4- $\alpha$ S (SEQ ID NO:10), naturally occurring human APO4- $\alpha$  (SEQ ID NO:12) or rat APO4- $\alpha$  (SEQ ID NO:14) or naturally occurring murine APO4- $\beta$  (SEQ ID NO:16) or naturally occurring murine APO4-  
30  $\gamma$  (SEQ ID NO:32) and is intended to include related polypeptides having substantial amino acid sequence similarity to SEQ ID NOS:8, 10, 12, 14, 16 or 32. Such related polypeptides exhibit greater sequence similarity to mAPO4- $\alpha$ L, mAPO4- $\alpha$ S, hAPO4- $\alpha$ , rAPO4- $\alpha$ , mAPO4- $\beta$  or

mAPO4- $\gamma$  than to other TNF family receptors and include alternatively spliced forms of human, murine or rat APO4- $\alpha$ , APO4- $\beta$  or APO4- $\gamma$  full-length forms of APO4, species homologues, and isotype variants of the amino acid sequences shown in Figures 7 and 8. As used herein, the term APO4 polypeptide describes polypeptides generally including an amino acid region with greater than about 35% amino acid sequence identity with mAPO4- $\alpha$ L (SEQ ID NO:8), mAPO4- $\alpha$ S (SEQ ID NO:10), hAPO4- $\alpha$  (SEQ ID NO:12), rAPO4- $\alpha$  (SEQ ID NO:14) or mAPO4- $\beta$  (SEQ ID NO:16). In particular, an APO4 polypeptide can have greater than about 55% amino acid identity, preferably greater than about 65% amino acid identity, more preferably greater than about 75% amino acid identity, still more preferably greater than about 85% amino acid identity and most preferably greater than about 90%, 95% or 97% amino acid identity with mAPO4- $\alpha$ L (SEQ ID NO:8), mAPO4- $\alpha$ S (SEQ ID NO:10), hAPO4- $\alpha$  (SEQ ID NO:12), rAPO4- $\alpha$  (SEQ ID NO:14), mAPO4- $\beta$  (SEQ ID NO:16) or mAPO4- $\gamma$  (SEQ ID NO:32).

The present invention also provides active fragments of the APO4 polypeptides of the invention. As used herein, the term "active fragment of an APO4 polypeptide" is synonymous with "active fragment of APO4" or "active APO4 fragment" and means a polypeptide fragment having substantially the same amino acid sequence as a portion of an APO4- $\alpha$ , APO4- $\beta$  or APO4- $\gamma$  polypeptide, provided that the fragment retains at least one biological activity of an APO4 polypeptide. An active fragment of an APO4 polypeptide can have, for example, an amino acid sequence that is identical or substantially the same as a portion of the amino acid sequence of mAPO4- $\alpha$ L (SEQ ID NO:8), mAPO4- $\alpha$ S (SEQ ID NO:10), hAPO4- $\alpha$  (SEQ ID NO:12), rAPO4- $\alpha$  (SEQ ID NO:14), mAPO4- $\beta$  (SEQ ID NO:16), or APO4- $\gamma$  (SEQ ID NO:32),

provided that the fragment retains at least one biological activity of an APO4 polypeptide. A biological activity of an APO4 polypeptide can be, for example, the ability to bind an APO4 ligand, the ability to induce or suppress apoptosis, the ability to activate the JNK pathway, or the ability to induce or suppress cell proliferation, differentiation or cytokine secretion. A biological activity of an APO4 polypeptide or fragment can be routinely assayed; for example, apoptotic activity can be analyzed by transfecting an APO4 encoding nucleic acid and measuring the number of cells with apoptotic morphology, as set forth in Example II.

An active fragment of APO4 also be, for example, a cytoplasmic fragment of APO4. An active fragment of APO4 can be an N-terminal fragment having the amino terminal 355 amino acids of APO4, which was able to activate the JNK pathway in 293 EBNA cells.

An "active fragment of an APO4 polypeptide" also can be an active segment of an APO4 polypeptide. Such an active segment is a polypeptide portion having substantially the same amino acid sequence as a portion of an APO4 polypeptide, provided that the segment does not consist of the identical amino acid sequence encoded by an expressed sequence tag having GenBank accession number AA036247, AA003356, W55289, AA445805 or W56629 and provided that the segment retains at least one biological activity of an APO4 polypeptide. An active APO4 polypeptide segment can have, for example, an amino acid sequence that is identical or substantially the same as a portion of the amino acid sequence of mAPO4- $\alpha$ L (SEQ ID NO:8), mAPO4- $\alpha$ S (SEQ ID NO:10), hAPO4- $\alpha$  (SEQ ID NO:12), rAPO4- $\alpha$  (SEQ ID NO:14), mAPO4- $\beta$  (SEQ ID NO:16) or APO4- $\gamma$  (SEQ ID NO:32), provided that the segment does not



consist of the identical amino acid sequence encoded by an expressed sequence tag having GenBank accession number AA036247, AA003356, W55289, AA445805 or W56629 and provided that the segment retains at least one biological activity of an APO4 polypeptide.

In one embodiment, the invention provides a soluble active fragment of an APO4 polypeptide. Such a soluble active fragment includes the ligand binding domain of an APO4 polypeptide and can be, for example, a truncated polypeptide encoding the extracellular domain of an APO4 polypeptide. A soluble active fragment of an APO4 polypeptide can have, for example, substantially the same amino acid sequence as the signal peptide and ligand-binding domain of mAPO4- $\alpha$  (amino acids 1 to 177 of mAPO4- $\alpha$  shown in Figure 7A) or substantially the same sequence as mAPO4- $\gamma$  (Figure 7E) or substantially the same sequence as the signal peptide and ligand-binding domain of hAPO4- $\alpha$  (amino acids 1 to 177 of hAPO4- $\alpha$  shown in Figure 7C). A specific example of such a soluble fragment is mAPO4- $\gamma$ . One skilled in the art understands that a soluble active fragment of an APO4 polypeptide is distinguished from a membrane-bound form by deletion or inactivation of the transmembrane domain. The transmembrane domain of murine APO4- $\alpha$  is shown in Figure 7A as amino acids 173 to 191, and the transmembrane domain of human APO4- $\alpha$  is shown in Figure 7C as amino acids 178 to 191. A soluble active fragment of an APO4 polypeptide also can be, for example, an active segment of an APO4 polypeptide. Such active segments of APO4 polypeptides are described hereinabove.

In another embodiment, the invention provides an APO4-related polypeptide, which has a sequence with substantial similarity to the unique cytoplasmic domain

of an APO4 polypeptide. The APO4 cytoplasmic domain is a conserved region that can function to promote self-association or association with a different protein. The APO4 cytoplasmic domain also can promote

5 ligand-dependent cell survival, proliferation, differentiation or death. An APO4-related polypeptide can be, for example, a transmembrane receptor including a cytoplasmic domain having substantial similarity to the cytoplasmic domain of mAPO4- $\alpha$ L or hAPO4- $\alpha$ . The

10 extracellular domain of an APO4-related polypeptide receptor can be substantially the same as, or can be entirely different than the extracellular domain of an APO4 polypeptide. APO4-related polypeptides also include intracellularly expressed polypeptides that contain one

15 or more APO4 cytoplasmic domains. An APO4 cytoplasmic domain can have, for example, the amino acid sequence shown as amino acids 192 to 416 in Figure 7A, the amino acid sequence shown as amino acids 192 to 423 in Figure 7C, or an amino acid sequence with substantial similarity

20 to one of these sequences.

The invention further provides an isolated APO6 polypeptide having substantially the same amino acid sequence as APO6, or an active fragment thereof. An isolated APO6 polypeptide of the invention can have, for

25 example, substantially the same amino acid sequence as the human APO6 sequence SEQ ID NO:18 shown in Figure 9.

As used herein, the term "APO6" means an APO6 polypeptide and includes polypeptides having substantially the same amino acid sequence as the hAPO6

30 polypeptide having amino acid sequence SEQ ID NO:18. A partial nucleotide sequence encoding hAPO6, which lacks 5' and 3' sequence, is shown in Figure 9. The available hAPO6 sequence shows about 33% homology to the

extracellular domain of TNFR-2. The partial APO6 sequence shown in Figure 9 can be part of a full-length APO6 transmembrane receptor.

The term APO6 encompasses a polypeptide having  
5 the sequence of the naturally occurring human APO6 polypeptide (SEQ ID NO:18) and is intended to include related polypeptides having substantial amino acid sequence similarity to hAPO6 (SEQ ID NO:18). Such related polypeptides exhibit greater sequence similarity  
10 to hAPO6 than to other members of the TNF receptor superfamily and include alternatively spliced forms of hAPO6, full-length forms of APO6 having a cytoplasmic signaling domain, species homologues, and isotype variants of the amino acid sequence shown in Figure 9.  
15 Such full-length forms or APO6 species homologues can be readily obtained by the skilled artisan using routine molecular techniques, for example, by screening an appropriate cDNA library with a portion of SEQ ID NO:17 as a probe. As used herein, the term APO6 describes  
20 polypeptides generally having an amino acid sequence with greater than about 40% amino acid identity with the extracellular domain of hAPO6 (SEQ ID NO:18), preferably greater than about 65% amino acid identity with the extracellular domain of hAPO6 (SEQ ID NO:18), more  
25 preferably greater than about 75% amino acid identity with the extracellular domain of hAPO6 (SEQ ID NO:18), still more preferably greater than about 75% amino acid identity with the extracellular domain of hAPO6 (SEQ ID NO:18), and most preferably about 90%, 95% or 97% amino  
30 acid identity with the extracellular domain of hAPO6 (SEQ ID NO:18).

The present invention also provides active fragments of the APO6 polypeptide of the invention. As

used herein, the term "active fragment of an APO6 polypeptide" is synonymous with "active fragment of APO6" or "active APO6 fragment" and means a polypeptide fragment having substantially the same amino acid sequence as a portion of an APO6 polypeptide, provided that the fragment retains at least one biological activity of an APO6 polypeptide. An active fragment of an APO6 polypeptide can have, for example, an amino acid sequence that is identical or substantially the same as a portion of an amino acid sequence of hAPO6 (SEQ ID NO:18), provided that the fragment retains at least one biological activity of an APO6 polypeptide. Biological activities of APO6 include the ability to bind an APO6 ligand, the ability to induce or suppress apoptosis and the ability to induce or suppress cell proliferation, differentiation or cytokine secretion. A biological activity of an APO6 polypeptide or fragment can be routinely assayed; for example, apoptotic activity can be analyzed by transfecting an APO6 encoding nucleic acid and measuring the number of cells with apoptotic morphology, as set forth in Example II.

An active fragment of an APO6 polypeptide also can be an active APO6 segment, which is a polypeptide segment having substantially the same amino acid sequence as a portion of an APO6 polypeptide, provided that the segment does not consist of the identical amino acid sequence encoded by an expressed sequence tag having GenBank accession number AA025673, AA025672, AA155701, AA155646, W67560 or AA158406 and provided that the segment retains at least one biological activity of an APO6 polypeptide. An active APO6 segment can have, for example, an amino acid sequence that is identical or substantially the same as a portion of the amino acid sequence of hAPO6 (SEQ ID NO:18), provided that the

segment does not consist of the identical amino acid sequence encoded by an expressed sequence tag having GenBank accession number AA025673, AA025672, AA155701, AA155646, W67560 or AA158406 and provided that the  
5 segment retains at least one biological activity of an APO6 polypeptide.

In one embodiment, the invention provides a soluble APO6 active fragment that includes an APO6 ligand binding domain. A soluble APO6 active fragment can be,  
10 for example, a truncated polypeptide encoding the extracellular domain of an APO6 polypeptide. A soluble APO6 active fragment can have, for example, substantially the same amino acid sequence as amino acids 1 to 168 of the hAPO6 sequence shown in Figure 1. Soluble APO6  
15 active fragments are distinguished from membrane-bound forms by the absence of a functional transmembrane domain. A soluble APO6 active fragment also can be, for example, an active APO6 segment. Active APO6 segments are described hereinabove.

20 Ligands of the TNF ligand superfamily are acidic, TNF-like molecules with approximately 20% sequence homology in the extracellular receptor-binding domain. Most exist principally as type II membrane glycoproteins, with the biologically active form a  
25 trimeric or multimeric complex. Like the prototypic TNF- $\alpha$  molecule, most have a large C-terminal extracellular domain, a single transmembrane spanning region and a variable amino-terminal cytoplasmic domain. The TNFR ligand family includes TNF- $\alpha$ , TNF- $\beta$ , LT $\beta$ , FAS  
30 ligand, CD27 ligand, CD30 ligand, CD40 ligand, 4-1BB ligand, OX40 ligand and FAS/APO-1 ligand. Although members of the TNF ligand superfamily typically are cell

surface-expressed molecules, soluble forms of TNF- $\alpha$ , TNF- $\beta$  and FAS ligand also have been identified.

Disclosed herein is subfamily of polypeptide ligands designated the tumor necrosis factor related ligand 1 (TNRL1) subfamily. Thus, the present invention provides an isolated TNRL1 polypeptide having substantially the same amino acid sequence as TNRL1, or an active fragment thereof. An isolated TNRL1 polypeptide of the invention can have, for example, substantially the same amino acid sequence as the sequence of human TNRL1- $\alpha$  (SEQ ID NO:20); murine TNRL1- $\alpha$  (SEQ ID NO:22); human TNRL1- $\beta$  (SEQ ID NO:24) or murine TNRL1- $\beta$  (SEQ ID NO:26).

As used herein, the term "TNRL1" means a TNRL1 polypeptide and includes polypeptides having substantially the same amino acid sequence as the hTNRL1- $\alpha$  polypeptide having amino acid sequence SEQ ID NO:20; the mTNRL1- $\alpha$  polypeptide having amino acid sequence SEQ ID NO:22; the hTNRL1- $\beta$  polypeptide having amino acid sequence SEQ ID NO:24; and the mTNRL1- $\beta$  polypeptide having amino acid sequence SEQ ID NO:26. Human TNRL1- $\alpha$  (hTNRL1- $\alpha$ ) is a polypeptide of at least 230(?) amino acids; the available hTNRL1- $\alpha$  nucleotide (SEQ ID NO:19) and amino acid sequence (SEQ ID NO:20) are shown in Figure 11A. Human TNRL1- $\alpha$  (SEQ ID NO:20) exhibits about 25% amino acid identity and about 49% amino acid similarity to TNF- $\alpha$ .

Murine TNRL1- $\alpha$  (mTNRL1- $\alpha$ ) is the homolog of human TNRL1- $\alpha$  and also is an TNRL1 polypeptide of the invention. mTNRL1- $\alpha$  is a polypeptide of at least 290 amino acids; the available mTNRL1- $\alpha$  nucleotide (SEQ ID NO:21) and amino acid sequence (SEQ ID NO:22) are shown

in Figure 11B. Murine TNRL1- $\alpha$  (SEQ ID NO:22) is about 68% identical and 81% similar to human TNRL1- $\alpha$  at the amino acid level.

Human TNRL1- $\beta$  (hTNRL1- $\beta$ ) also is a TNRL1  
5 polypeptide of the invention. Human TNRL1- $\beta$  is a polypeptide of 250 amino acids; the hTNRL1- $\beta$  nucleotide sequence (SEQ ID NO:23) and amino acid sequence (SEQ ID NO:24) are shown in Figure 12A. The hTNRL1- $\beta$  polypeptide (SEQ ID NO:24) is about 31% identical and 55% similar to  
10 hTNRL1- $\alpha$  at the amino acid level and is more distantly related to TNF- $\alpha$  (see Figure 10).

Murine TNRL1- $\beta$  (mTNRL1- $\beta$ ), the homolog of human TNRL1- $\beta$ , also is a TNRL1 polypeptide of the invention. The nucleotide (SEQ ID NO:25) and corresponding amino  
15 acid sequence (SEQ ID NO:26) of full-length mTNRL1- $\beta$  are shown in Figure 12B.

The term TNRL1 encompasses a polypeptide having the sequence of the naturally occurring human TNRL1- $\alpha$  polypeptide SEQ ID NO:20, the murine TNRL1- $\alpha$  polypeptide  
20 SEQ ID NO:22, the human TNRL1- $\beta$  polypeptide SEQ ID NO:24, or the murine TNRL1- $\beta$  polypeptide SEQ ID NO:26 and is intended to include related polypeptides having substantial amino acid sequence similarity to hTNRL1- $\alpha$ , mTNRL1- $\alpha$ , hTNRL1- $\beta$  or mTNRL1- $\beta$ . Such related  
25 polypeptides exhibit greater sequence similarity to hTNRL1- $\alpha$ , mTNRL1- $\alpha$ , hTNRL1- $\beta$  or mTNRL1- $\beta$  than to other members of the TNF ligand superfamily, such as TNF- $\alpha$ , and include alternatively spliced forms of hTNRL1- $\alpha$ , full-length forms of hTNRL1- $\alpha$ , mTNRL1- $\alpha$ , hTNRL1- $\beta$  or mTNRL1- $\beta$ ,  
30 species homologues, and isotype variants of the amino acid sequences shown in Figures 11 and 12. As used herein, the term TNRL1 describes polypeptides generally

having an amino acid sequence with greater than about 30% amino acid identity with hTNRL1- $\alpha$  (SEQ ID NO:20), mTNRL1- $\alpha$  (SEQ ID NO:22), hTNRL1- $\beta$  (SEQ ID NO:24) or mTNRL1- $\beta$  (SEQ ID NO:26), preferably greater than about 35% amino acid identity with hTNRL1- $\alpha$  (SEQ ID NO:20), mTNRL1- $\alpha$  (SEQ ID NO:22), hTNRL1- $\beta$  (SEQ ID NO:24) or mTNRL1- $\beta$  (SEQ ID NO:26), more preferably greater than about 45% amino acid identity with hTNRL1- $\alpha$  (SEQ ID NO:20), mTNRL1- $\alpha$  (SEQ ID NO:22), hTNRL1- $\beta$  (SEQ ID NO:24) or mTNRL1- $\beta$  (SEQ ID NO:26), and most preferably about 65%, 75%, 85%, 90%, 95% or 97% amino acid identity with hTNRL1- $\alpha$  (SEQ ID NO:20), mTNRL1- $\alpha$  (SEQ ID NO:22), hTNRL1- $\beta$  (SEQ ID NO:24) or mTNRL1- $\beta$  (SEQ ID NO:26).

The present invention also provides an isolated TNRL1 polypeptide having substantially the same amino acid sequence as TNRL1, or an active fragment of a TNRL1 polypeptide of the invention. An isolated TNRL1 polypeptide of the invention can have, for example, substantially the same amino acid sequence as the human TNRL1 (SEQ ID NO:20) shown in Figure 11.

The present invention also provides active fragments of a TNRL1 polypeptide of the invention. As used herein, the term "active fragment of a TNRL1 polypeptide" is synonymous with "active fragment of TNRL1" or "active TNRL1 fragment" and means a polypeptide fragment having substantially the same amino acid sequence as a portion of a TNRL1 polypeptide, provided that the fragment retains at least one biological activity of a TNRL1 polypeptide. An active fragment of a TNRL1 polypeptide can have, for example, an amino acid sequence that is identical or substantially the same as a portion of the amino acid sequence of hTNRL1- $\alpha$  (SEQ ID NO:20), mTNRL1- $\alpha$  (SEQ ID NO:22), hTNRL1- $\beta$  (SEQ ID NO:24)



or mTNRL1- $\beta$  (SEQ ID NO:26), provided that the fragment retains at least one biological activity of a TNRL1 polypeptide. A biological activity of a TNRL1 polypeptide can be, for example, the ability to bind a  
5 TNRL1 receptor, the ability to induce or suppress apoptosis or the ability to induce or suppress cell proliferation, differentiation or cytokine secretion. A biological activity of a TNRL1 polypeptide or fragment can be routinely assayed; for example, apoptotic activity  
10 can be analyzed by treating BJAB cells with polypeptide and assaying cell survival as set forth in Example VI.

An "active fragment of a TNRL1 polypeptide" also can be an active TNRL1 segment, which is a polypeptide segment having substantially the same amino  
15 acid sequence as a portion of a TNRL1 polypeptide, provided that the segment does not consist of the identical amino acid sequence encoded by an expressed sequence tag having GenBank accession number AA166695, T87299, R16882, AA254047, AA056924, AA057069, N91002,  
20 N79018 or AA497494 or TIGR sequence number M78231 and provided that the segment retains at least one biological activity of a TNRL1 polypeptide. An active TNRL1 segment can have, for example, an amino acid sequence that is identical or substantially the same as a portion  
25 of the amino acid sequence of hTNRL1- $\alpha$  (SEQ ID NO:20), mTNRL1- $\alpha$  (SEQ ID NO:22), hTNRL1- $\beta$  (SEQ ID NO:24) or mTNRL1- $\beta$  (SEQ ID NO:26), provided that the segment does not consist of the identical amino acid sequence encoded by an expressed sequence tag having GenBank accession  
30 number AA166695, T87299, R16882, AA254047, AA056924, AA057069, N91002, N79018 or AA497494 or TIGR sequence number M78231 and provided that the segment retains at least one biological activity of a TNRL1 polypeptide.

In one embodiment, the invention provides a soluble active fragment of a TNRL1 ligand of the invention, where the active fragment includes the TNRL1 receptor binding domain. A TNRL1 ligand of the invention  
5 can be, for example, a membrane-bound ligand that transduces a signal when the cell on which it is expressed contacts a cell bearing its cognate receptor or, alternatively, a soluble form of TNRL1 can be expressed extracellularly and bind a distant  
10 receptor-bearing cell. Such a soluble TNRL1 active fragment can have the activity of a full-length TNRL1 of the invention or can be an inhibitory polypeptide that opposes the biological function of full-length ligand.

Thus, the invention provides a soluble TNRL1  
15 active fragment that includes a TNRL1 receptor binding domain. A soluble TNRL1 active fragment can be, for example, a truncated polypeptide encoding the extracellular domain of a TNRL1 polypeptide and can have, for example, an amino acid sequence that is identical or  
20 substantially the same as amino acids 22 to 225 of hTNRL1- $\alpha$ , amino acids 32 to 243 of mTNRL1- $\alpha$ , amino acids 50 to 250 of hTNRL1- $\beta$  or amino acids 42 to 241 of mRNRL- $\beta$ , shown in Figure 10. One skilled in the art understands that soluble TNRL1 active fragments lack a  
25 functional TNRL1 transmembrane domain. A soluble TNRL1 active fragment also can be an active TNRL1 segment. Segments having an amino acid sequence identical to the amino acid sequence encoded by an expressed sequence tag having GenBank accession number AA166695, T87299, R16882,  
30 AA254047, AA056924, AA057069, N91002, N79018 or AA497494 or TIGR sequence number M78231 are excluded from the definition of an active TNRL1 segment, as defined herein.

The present invention further provides an isolated TNRL3 polypeptide having substantially the same amino acid sequence as TNRL3, or an active fragment thereof. An isolated TNRL3 polypeptide of the invention  
5 can have, for example, substantially the same amino acid sequence as the human TNRL3 (SEQ ID NO:28) or murine TNRL3 (SEQ ID NO:30) sequence shown in Figure 13.

As used herein, the term "TNRL3" means a TNRL3 polypeptide and includes polypeptides having  
10 substantially the same amino acid sequence as the hTNRL3 polypeptide having amino acid sequence SEQ ID NO:28 or the mTNRL3 polypeptide having amino acid sequence SEQ ID NO:30. A partial nucleotide sequence encoding the 3' portion of hTNRL3 is shown in Figure 13A. The available  
15 sequence shows homology to TRAIL ligand and to other members of the TNF ligand superfamily (see Figure 10). The murine TNRL3 homolog, mTNRL3, also is a TNRL3 polypeptide of the invention. The partial nucleotide and amino acid sequence of murine TNRL3 lacks some 5'  
20 sequence; the available sequence is shown in Figure 13B.

The term TNRL3 encompasses a polypeptide having the sequence of naturally occurring human TNRL3 (SEQ ID NO:28) or murine TNRL3 (SEQ ID NO:30) and is intended to include related polypeptides having substantial amino  
25 acid sequence similarity to the human or murine TNRL3 polypeptides SEQ ID NOS:28 or 30. Such related polypeptides exhibit greater sequence similarity to hTNRL3 or mTNRL3 than to other members of the TNF ligand superfamily such as TRAIL and include alternatively  
30 spliced forms of hTNRL3 or mTNRL3, species homologues, full-length forms and isotype variants of the amino acid sequences shown in Figure 13. As used herein, the term TNRL3 describes polypeptides generally having an amino

acid sequence with greater than about 30% amino acid sequence identity with hTNRL3 or mTNRL3 (SEQ ID NO:28 or SEQ ID NO:30), preferably greater than about 35% amino acid identity with hTNRL3 or mTNRL3, more preferably greater than about 45% amino acid identity with hTNRL3 or mTNRL3 (SEQ ID NO:28 or SEQ ID NO:30), still more preferably greater than about 65% amino acid identity with hTNRL3 or mTNRL3 (SEQ ID NO:28 or SEQ ID NO:30), and most preferably about 75%, 85%, 90%, 95% or 97% amino acid identity with hTNRL3 or mTNRL3 (SEQ ID NO:28 or SEQ ID NO:30).

Further provided herein is an active fragment of a TNRL3 polypeptide of the invention. As used herein, the term "active fragment of an TNRL3 polypeptide" is synonymous with "active fragment of TNRL3" or "active TNRL3 fragment" and means a polypeptide fragment having substantially the same amino acid sequence as a portion of a TNRL3 polypeptide, provided that the fragment retains at least one biological activity of a TNRL3 polypeptide. An active fragment of a TNRL3 polypeptide can have, for example, substantially the same amino acid sequence as a portion of hTNRL3 (SEQ ID NO:28) or mTNRL3 (SEQ ID NO:30), provided that the fragment retains at least one biological activity of a TNRL3 polypeptide. A biological activity of a TNRL3 polypeptide can be, for example, the ability to bind a TNRL3 receptor, the ability to induce or suppress apoptosis or the ability to induce or suppress cell proliferation, differentiation or cytokine secretion. A biological activity of a TNRL3 polypeptide or fragment can be routinely assayed; for example, apoptotic activity can be analyzed by treating BJAB cells with polypeptide and assaying cell survival as set forth in Example VI.

An "active fragment of a TNRL3 polypeptide" also can be an active TNRL3 segment, which is a polypeptide segment having substantially the same amino acid sequence as a portion of a TNRL3 polypeptide, provided that the segment does not consist of the amino acid sequence, or a segment thereof, encoded by an expressed sequence tag having GenBank accession number R55285, N35070, C00994 or AA221610 and provided that the segment retains at least one biological activity of a TNRL3 polypeptide. An active TNRL3 segment can have, for example, an amino acid sequence that is identical or substantially the same as a portion of the amino acid sequence of hTNRL3 (SEQ ID NO:28) or mTNRL3 (SEQ ID NO:30), provided that the segment does not consist of the amino acid sequence, or a segment thereof, encoded by an expressed sequence tag having GenBank accession number R55285, N35070, C00994 or AA221610 and provided that the segment retains at least one biological activity of a TNRL3 polypeptide.

In one embodiment, the invention provides a soluble TNRL3 active fragment that includes a TNRL3 receptor binding domain. Such a soluble TNRL3 active fragment can be, for example, a truncated polypeptide encoding the extracellular domain of a TNRL3 polypeptide. Soluble TNRL3 active fragments can have, for example, an amino acid sequence that is identical or substantially the same as amino acids 4 to 208 of hTNRL3 or amino acids 7 to 211 of mTNRL3, as shown in Figure 10. Such a soluble TNRL3 active fragment lacks a functional transmembrane domain. A soluble TNRL3 active fragment also can be, for example, an active TNRL3 segment. Such active TNRL3 segments are described hereinabove.

As used herein, the term "substantially the same amino acid sequence," when used in reference to a polypeptide, fragment or segment of the invention, is intended to mean a polypeptide, fragment or segment having an identical amino acid sequence, or a polypeptide, fragment or segment having a similar, non-identical sequence that is considered by those skilled in the art to be a functionally equivalent amino acid sequence. For example, polypeptide including substantially the same amino acid sequence as APO8 can have an amino acid sequence identical to the sequence of hAPO8 (SEQ ID NO:2) shown in Figure 2, or a similar, non-identical sequence that is functionally equivalent. An amino acid sequence that is "substantially the same" can have one or more modifications such as amino acid additions or substitutions relative to the amino acid sequence shown, provided that the modified polypeptide retains substantially at least one biological activity of the polypeptide. Biological activities of the polypeptides of the invention are described herein; for example, biological activities of APO8 include the ability to bind an APO8 ligand, bind the TRADD or RIP adaptor molecules, induce or suppress apoptosis, activate NF- $\kappa$ B expression, or induce or suppress cell proliferation, differentiation or cytokine secretion. Comparison of sequences for substantial similarity can be performed between two sequences of any length and usually is performed with nucleotide sequences of between 5 and 3500 nucleotides, preferably between about 10 and 300 nucleotides and more preferably between about 15 and 50 nucleotides. Comparison for substantial similarity between amino acid sequences is usually performed with sequences between about 6 and 1200 residues, preferably between about 10 and 100 residues and more preferably between about 25 and 35 residues. Such comparisons for

substantial similarity are performed using methodology routine in the art.

Therefore, it is understood that limited modifications can be made without destroying the biological function of a polypeptide or ligand of the invention. For example, minor modifications of hAPO8 (SEQ ID NO:2) that do not destroy polypeptide activity also fall within the definition of APO8 and within the definition of the polypeptide claimed as such.

10 Similarly, minor modifications of hAPO9 that do not destroy polypeptide activity fall within the definition of APO9; minor modifications of mAPO4- $\alpha$ L, mAPO4- $\alpha$ S, hAPO4- $\alpha$ , rAPO4- $\alpha$  or mAPO4- $\beta$  that do not destroy polypeptide activity fall within the definition of an

15 APO4 polypeptide; and minor modifications of hAPO6 that do not destroy polypeptide activity fall within the definition of APO6. Similarly, minor modifications of hTNRL1- $\alpha$ , mTNRL1- $\alpha$ , hTNRL1- $\beta$  or mTNRL1- $\beta$  that do not destroy polypeptide activity fall within the definition

20 of TNRL1, and minor modifications of hTNRL3 and mTNRL3 that do not destroy polypeptide activity fall within the definition of TNRL3. Also, for example, genetically engineered fusion proteins that retain at least one measurable biological activity of a polypeptide of the

25 invention fall within the definition of the polypeptides claimed as such.

It is understood that minor modifications of primary amino acid sequence can result in polypeptides which have substantially equivalent or enhanced function

30 as compared to the APO8 polypeptide sequence set forth in Figure 2, substantially equivalent or enhanced function as compared to the hAPO9 sequence set forth in Figure 6, substantially equivalent or enhanced function as compared

to the APO4 polypeptide sequences set forth in Figures 6, 7 and 8, or substantially equivalent or enhanced function as compared to the hAPO6 sequence set forth in Figure 9. Also, minor modifications of primary amino acid sequence  
5 can result in polypeptides having substantially equivalent or enhanced function as compared to the TNRL1 polypeptide sequences shown in Figures 11 and 12, or in polypeptides having substantially equivalent or enhanced function as compared to the TNRL3 polypeptide sequences  
10 shown in Figure 13. These modifications can be deliberate, as through site-directed mutagenesis, or can be accidental such as through mutation in hosts harboring an encoding nucleic acid. All such modified polypeptides are included in the definition of an APO8 polypeptide as  
15 long as at least one biological function of APO8 is retained. Similarly, all such modified polypeptides are included in the definition of an APO9, APO4, APO6, TNRL1 or TNRL3 polypeptide as long as at least one biological function of an APO9, APO4, APO6, TNRL1 or TNRL3  
20 polypeptide, respectively, is retained. Further, various molecules can be attached to an APO8, APO9, APO4, APO6, TNRL1 or TNRL3 polypeptide, for example, other polypeptides, carbohydrates, lipids, or chemical moieties. Such modifications are included within the  
25 definition of each of the polypeptides of the invention.

Polypeptide fragments or segments to be screened for activity can be produced, for example, by recombinant methods or by chemical or proteolytic cleavage of the isolated polypeptide. Methods for  
30 chemical and proteolytic cleavage and for purification of the resultant polypeptide fragments are well known in the art as described above. (See, for example, Deutscher, Methods in Enzymology, Vol. 182, "Guide to Protein



Purification," San Diego: Academic Press, Inc. (1990), which is incorporated herein by reference).

A polypeptide fragment or segment of the invention can be screened, for example, for pro-apoptotic or anti-apoptotic activity. Pro-apoptotic activity is the ability either alone, or in combination with another molecule, to produce cell death accompanied by at least one of the morphological or biochemical alterations characteristic of apoptosis. Morphological alterations characteristic of apoptosis are well known in the art and include, for example, condensed and rounded cellular morphology; membrane blebbing; the formation of apoptotic bodies, which are membrane-bound bodies containing cytoplasmic and nuclear components; and condensation of the nucleus, with cytoplasmic organelles being relatively well maintained (Studzinski (Ed.), Cell Growth and Apoptosis, Oxford: Oxford University Press (1995), which is incorporated herein by reference). Biochemical alterations characteristic of apoptosis also are well known in the art. The classical biochemical alteration characteristic of apoptosis is the appearance of oligonucleosome-sized fragments of DNA, which produce a "ladder" upon agarose gel electrophoresis. This extensive fragmentation can be preceded by an earlier endonucleolytic cleavage of chromatin, producing DNA fragments of about 50 kb to 300 kb in size.

A variety of assays for determining whether a polypeptide fragment or segment has pro-apoptotic or anti-apoptotic activity are well known in the art. Such methods include light microscopy for determining the presence of one or more morphological characteristics of apoptosis, such as condensed or rounded morphology, shrinking and blebbing of the cytoplasm, preservation of

structure of cellular organelles including mitochondria, and condensation and margination of chromatin. As described in Example II, cells expressing fragments of hAPO8 were determined to be apoptotic by scoring for  
5 condensed and rounded morphology.

A polypeptide fragment or segment of the invention also can be assayed for pro-apoptotic or anti-apoptotic activity using terminal deoxytransferase-mediated (TdT) dUTP biotin nick  
10 end-labeling (TUNEL) (Gavriel et al., J. Cell Biol. 119:493 (1992), which is incorporated herein by reference; Gorczyca et al., Int. J. Oncol. 1:639 (1992); Studzinski, *supra*, 1995). ApopTag™ (ONCOR, Inc., Gaithersburg, MD) is a commercially available kit for  
15 identification of apoptotic cells using digoxigenin labeling. In addition, a polypeptide fragment or segment of the invention can be assayed for pro-apoptotic or anti-apoptotic activity by detecting nucleosomal DNA fragments using agarose gel electrophoresis (Studzinski,  
20 *supra*, 1995; Gong et al., Anal. Biochem. 218:314 (1994)).

DNA filter elution methodology also can be used to detect apoptosis-associated DNA fragmentation and to determine pro-apoptotic or anti-apoptotic activity (Studzinski, *supra*, 1995; Bertrand et al., Drug Devel.  
25 34:138 (1995), which is incorporated herein by reference). Pro-apoptotic or anti-apoptotic activity also can be detected and quantitated by determining an altered mitochondrial to nuclear DNA ratio as described in Tepper et al., Anal. Biochem. 203:127 (1992) and  
30 Tepper and Studzinski, J. Cell Biochem. 52:352 (1993), each of which is incorporated herein by reference. One skilled in the art understands that these, or other

assays for pro-apoptotic or anti-apoptotic activity, can be performed using methodology routine in the art.

A nucleic acid to be assayed can encode a polypeptide fragment or segment corresponding to a portion of a native polypeptide of the invention or can be modified to encode one or more amino acid substitutions, deletions or insertions. One or more point mutations can be introduced into the nucleic acid encoding the modified polypeptide, fragment or segment to be assayed using, for example, site-directed mutagenesis (see Wu (Ed.), Meth. In Enzymol. Vol. 217, San Diego: Academic Press (1993); Chapter 22 of Innis et al. (Ed.), PCR Protocols, San Diego: Academic Press, Inc. (1990), each of which is incorporated herein by reference). Such mutagenesis can be used to introduce a specific, desired amino acid substitution, deletion or insertion; alternatively, a nucleic acid sequence can be synthesized having random nucleotides at one or more predetermined positions to generate random amino acid substitutions. Scanning mutagenesis also can be useful in generating nucleic acid molecules encoding, for example, an APO8 polypeptide, fragment or segment that is modified throughout the entire sequence. Such a modified fragment or segment can be screened, for example, for the ability to bind an APO8 ligand; the ability to bind TRADD or RIP; the ability to induce or suppress apoptosis or the ability to activate NF- $\kappa$ B.

A polypeptide of the invention can be obtained by a variety of methods known within the art, including biochemical, recombinant and chemical synthesis methods. Biochemical methods for isolating a polypeptide of the invention, or active fragment thereof, include preparative gel electrophoresis, gel filtration, affinity

chromatography, ion exchange and reversed phase chromatography, chromatofocusing, isoelectric focusing and sucrose or glycerol density gradients (see, for example, Chapter 38 of Deutscher, Methods in Enzymology: Guide to Protein Purification, Vol. 182, Academic Press, Inc., San Diego (1990) and Chapter 8 of Balch et al., Methods in Enzymology, Vol. 257, Academic Press, Inc., San Diego (1995), each of which is incorporated herein by reference in its entirety). For example, as disclosed herein in Example I, human APO8 RNA is expressed in a variety of human tissues including spleen, thymus, prostate, testis, ovary, small intestine, colonic mucosa and peripheral blood lymphocyte. From these results, one skilled in the art knows that one of these tissues can be used as a source of material for isolating an hAPO8 polypeptide of the invention.

Preparative gel electrophoresis can be useful in preparing an isolated polypeptide, active fragment or active segment of the invention. For example, an APO8 polypeptide, or an active fragment or segment thereof, can be isolated by preparative polyacrylamide gel electrophoresis and elution by diffusion or electroelution (see, for example, Chapter 33 of Deutscher, *supra*, 1990). Continuous elution gel electrophoresis using a system such as the Model 491 Prep Cell (BioRad, Hercules, CA) can be used to purify a polypeptide or an active fragment or segment of the invention. If desired, continuous elution gel electrophoresis can be combined with further purification steps such as liquid phase preparative isoelectric focusing using, for example, the Rotofor system (BioRad).

Affinity chromatography is particularly useful in preparing an isolated polypeptide or an active

fragment or segment of the invention. For example, a polypeptide that interacts with an APO8 polypeptide can be useful as an affinity matrix for isolating an APO8 polypeptide or an active APO8 fragment or segment of the invention. As disclosed herein, APO8 interacts physically with TRADD and RIP (Example II), indicating that TRADD or RIP can be used as an affinity matrix for isolating an APO8 polypeptide. Death domain containing polypeptides or fragments also can be useful as an affinity matrix for isolating an APO8 polypeptide or an active APO8 fragment or segment of the invention.

Immunoaffinity chromatography can be particularly useful in isolating a polypeptide or an active fragment or segment of the invention. For example, immunoprecipitation or column chromatography with an antibody that selectively binds APO8 can be used to isolate an APO8 polypeptide or active fragment thereof. An anti-APO8 monoclonal or polyclonal antibody that selectively binds APO8 can be prepared using an immunogen such as the sequence shown as SEQ ID NO:2, or a synthetic peptide fragment thereof, as described further below. Methods of affinity chromatography are well known in the art and are described, for example, in Chapters 29, 30 and 38 of Deutscher, *supra*, 1990, which has been incorporated herein by reference.

Recombinant methods for producing a polypeptide through expression of a nucleic acid sequence in a suitable host cell also are well known in the art and are described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed, Vols 1 to 3, Cold Spring Harbor Laboratory Press, New York (1989), which is incorporated herein by reference. A nucleic acid for expression of an APO8 polypeptide is provided herein as

SEQ ID NO:1 and a nucleic acid for expression of an APO8RP polypeptide is provided herein as SEQ ID NO:3. A nucleic acid for expression of an APO9 polypeptide is provided herein as SEQ ID NO:5; nucleic acids for expression of APO4 polypeptides are provided herein as SEQ ID NOS:7, 9, 11, 13 and 15; and a nucleic acid for expression of an APO6 polypeptide is provided herein as SEQ ID NO:17. Nucleic acids for expression of a TNRL1 polypeptide also are provided as SEQ ID NOS:19, 21, 23 and 25; and nucleic acids for expression of a TNRL3 polypeptide are provided herein as SEQ ID NOS:27 and 29.

A recombinant polypeptide of the invention, or active fragment or segment thereof, also can be expressed as a fusion protein with a heterologous "tag" for convenient isolation from bacterial or mammalian host proteins. For example, histidine-tagged recombinant APO8 can be isolated by nickel-chelate chromatography. Similarly, a glutathione-S-transferase tag or an antigenic tag such as "FLAG," "AU" or a myc epitope tag also can be included in a recombinant polypeptide or active fragment of the invention (Sambrook et al., *supra*, 1989). The PinPoint™ expression system is a commercially available system for expression of a polypeptide or active fragment as a fusion protein with a heterologous biotinylated peptide.

A polypeptide or an active fragment or segment of the invention also can be produced by chemical synthesis, for example, by the solid phase peptide synthesis method of Merrifield et al., J. Am. Chem. Soc. 85:2149 (1964), which is incorporated herein by reference. Standard solution methods well known in the art also can be used to synthesize a polypeptide or an active fragment or segment useful in the invention (see,

for example, Bodanszky, Principles of Peptide Synthesis, Springer-Verlag, Berlin (1984) and Bodanszky, Peptide Chemistry, Springer-Verlag, Berlin (1993), each of which is incorporated herein by reference). A newly

5 synthesized polypeptide, fragment or segment can be purified, for example, by high performance liquid chromatography (HPLC) and can be characterized using mass spectrometry or amino acid sequence analysis.

Also provided herein are nucleic acid molecules  
10 encoding the tumor necrosis family receptors and ligands of the invention. These nucleic acid molecules are useful, for example, in producing recombinant polypeptides and as probes for diagnosing diseases mediated by the polypeptides of the invention, as  
15 described further below. A nucleic acid molecule of the invention can have a nucleotide sequence of, for example, about 15 to about 1500 nucleotides. In particular, a nucleic acid molecule of the invention can have a sequence of about 15, 18, 20, 25, 30, 35, 50, 100, 200,  
20 500 or more nucleotides.

The term "isolated," as used herein in reference to a nucleic acid molecule of the invention, means a nucleic acid molecule that is in a form that is relatively free from contaminating lipids, polypeptides,  
25 unrelated nucleic acids and other cellular material normally associated with a nucleic acid molecule in a cell.

Provided herein is an isolated nucleic acid molecule containing a nucleotide sequence encoding  
30 substantially the same amino acid sequence as AP08, or an active segment thereof, provided that the nucleic acid molecule does not consist of the identical nucleotide

sequence of an expressed sequence tag having GenBank accession number AA223122 or AA232440. An isolated nucleic acid molecule of the invention can have, for example, a nucleotide sequence encoding substantially the same amino acid sequence as hAPO8 (SEQ ID NO:2), or an active segment thereof, provided that the nucleic acid molecule does not consist of the identical nucleotide sequence of an expressed sequence tag having GenBank accession number AA223122 or AA232440. An exemplary nucleic acid molecule of the invention encodes human APO8 and is provided herein as SEQ ID NO:1 (see Figure 2). In one embodiment, the invention provides an isolated nucleic acid molecule containing a nucleotide sequence encoding a soluble APO8 active segment having an APO8 ligand binding domain.

The invention further provides an isolated nucleic acid molecule containing a nucleotide sequence encoding substantially the same amino acid sequence as APO9, or an active segment thereof, provided that the nucleic acid molecule does not consist of the identical nucleotide sequence of an expressed sequence tag having GenBank accession number AA031883, AA150849, T71406 or R10995. For example, the invention provides an isolated nucleic acid molecule of the invention having a nucleotide sequence encoding substantially the same amino acid sequence as hAPO9 (SEQ ID NO:6), or an active segment thereof, provided that the nucleic acid molecule does not consist of the identical nucleotide sequence of an expressed sequence tag having GenBank accession number AA031883, AA150849, T71406 or R10995. An exemplary nucleic acid molecule of the invention encodes human APO9 and is provided herein as SEQ ID NO:5 (see Figure 6). In one embodiment, the invention provides an isolated nucleic acid molecule containing a nucleotide sequence



encoding a soluble APO9 active segment having an APO9 ligand binding domain.

In addition, the invention provides an isolated nucleic acid molecule containing a nucleotide sequence encoding substantially the same amino acid sequence as an APO4 polypeptide, or an active segment thereof, provided that the nucleic acid molecule does not consist of the identical nucleotide sequence of an expressed sequence tag having GenBank accession number AA036247, AA003356, W55289, AA445805 or W56629. Such a nucleic acid molecule can have a nucleotide sequence encoding substantially the same amino acid sequence as mAPO4- $\alpha$ L (SEQ ID NO:8), mAPO4- $\alpha$ S (SEQ ID NO:10), hAPO4- $\alpha$  (SEQ ID NO:12), rAPO4- $\alpha$  (SEQ ID NO:14), mAPO4- $\beta$  (SEQ ID NO:16), or mAPO4- $\gamma$  (SEQ ID NO:32), or an active segment thereof, provided that the nucleic acid molecule does not consist of the identical nucleotide sequence of an expressed sequence tag having GenBank accession number AA036247, AA003356, W55289, AA445805 or W56629. Exemplary nucleic acid molecules encoding the APO4 polypeptides of the invention are provided herein. As shown in Figure 7A-E, SEQ ID NO:7 is a nucleotide sequence encoding murine APO4- $\alpha$ L; SEQ ID NO:9 is a nucleotide sequence encoding murine APO4- $\alpha$ S; SEQ ID NO:11 is a nucleotide sequence encoding human APO4- $\alpha$ ; and SEQ ID NO:13 is a nucleotide sequence encoding rat APO4- $\alpha$  and SEQ ID NO:31 is a nucleotide sequence encoding murine APO4- $\gamma$ . Figure 8 shows SEQ ID NO:15, which is a nucleotide sequence encoding murine APO4- $\beta$ . The invention also provides an isolated nucleic acid molecule containing a nucleotide sequence encoding a soluble active segment of an APO4 polypeptide having an APO4 ligand binding domain.

Also provided by the invention is an isolated nucleic acid molecule containing a nucleotide sequence encoding substantially the same amino acid sequence as APO6, or an active segment thereof, provided that the

5 nucleic acid molecule does not consist of the identical nucleotide sequence of an expressed sequence tag having GenBank accession number AA025673, AA025672, AA155701, AA155646, W67560 or AA158406. For example, the invention provides an isolated nucleic acid molecule of the

10 invention having a nucleotide sequence encoding substantially the same amino acid sequence as hAPO6 (SEQ ID NO:18), or an active segment thereof, provided that the nucleic acid molecule does not consist of the identical nucleotide sequence of an expressed sequence

15 tag having GenBank accession number AA025673, AA025672, AA155701, AA155646, W67560 or AA158406. Provided in Figure 9 is an exemplary nucleic acid molecule of the invention, SEQ ID NO:17, which encodes human APO6. In one embodiment, the invention provides an isolated

20 nucleic acid molecule containing a nucleotide sequence encoding a soluble APO6 active segment having an APO6 ligand binding domain.

The invention also provides an isolated nucleic acid molecule containing a nucleotide sequence encoding

25 substantially the same amino acid sequence as a TNRL1 polypeptide, or an active segment thereof, provided that the nucleic acid molecule does not consist of the identical nucleotide sequence of an expressed sequence tag having GenBank accession number AA166695, T87299,

30 R16882, AA254047, AA056924, AA057069, N91002, N79018 or AA497494 or TIGR sequence number M78231. The invention provides, for example, an isolated nucleic acid molecule having a nucleotide sequence encoding substantially the same amino acid sequence as hTNRL1- $\alpha$  (SEQ ID NO:20),

mTNRL1- $\alpha$  (SEQ ID NO:22), hTNRL1- $\beta$  (SEQ ID NO:24) or mTNRL1- $\beta$  (SEQ ID NO:26) or an active segment thereof, provided that the nucleic acid molecule does not consist of the identical nucleotide sequence, or a segment thereof, of an expressed sequence tag having GenBank accession number AA166695, T87299, R16882, AA254047, AA056924, AA057069, N91002, N79018 or AA497494 or TIGR sequence number M78231. Provided in Figures 11 and 12 are exemplary nucleic acid molecules of the invention:

10 SEQ ID NO:19 encodes human TNRL1- $\alpha$ ; SEQ ID NO:21 encodes murine TNRL1- $\alpha$ ; SEQ ID NO:23 encodes human TNRL1- $\beta$ ; and SEQ ID NO:25 encodes murine TNRL1- $\beta$ . The invention also provides an isolated nucleic acid molecule containing a nucleotide sequence encoding a soluble TNRL1 active

15 segment having a TNRL1 ligand binding domain.

The invention further provides an isolated nucleic acid molecule containing a nucleotide sequence encoding substantially the same amino acid sequence as TNRL3, or an active segment thereof, provided that the

20 nucleic acid molecule does not consist of the identical nucleotide sequence of an expressed sequence tag having GenBank accession number R55285, N35070, C00994 or AA221610. For example, the invention provides an isolated nucleic acid molecule of the invention having a

25 nucleotide sequence encoding substantially the same amino acid sequence as hTNRL3 (SEQ ID NO:28) or mTNRL3 (SEQ ID NO:30), or an active segment thereof, provided that the nucleic acid molecule does not consist of the identical nucleotide sequence of an expressed sequence tag having

30 GenBank accession number R55285, N35070, C00994 or AA221610. Provided in Figure 13 are exemplary nucleic acid molecules of the invention. SEQ ID NO:27 encodes human TNRL3, and SEQ ID NO:29 encodes murine TNRL3. The invention also provides an isolated nucleic acid molecule

containing a nucleotide sequence encoding a soluble TNRL3 active segment having a TNRL3 ligand binding domain.

The invention also provides selective binding agents, which are agents that exhibit selective binding  
5 for a receptor or ligand of the invention.

Provided herein are APO8 selective binding agents, which are agents that selectively bind an APO8 polypeptide or an active fragment thereof. Such an APO8 selective binding agent exhibits selective binding  
10 affinity for an APO8 polypeptide, such as a polypeptide having substantially the same amino acid sequence as hAPO8 (SEQ ID NO:2) or active fragment thereof. In addition to exhibiting selective binding affinity for APO8, such APO8 selective binding agents can also  
15 function to selectively enhance or inhibit the function of APO8. For example, an APO8 selective binding agent can function to enhance or inhibit binding of an APO8 polypeptide to its natural APO8 ligand, enhance or inhibit binding to TRADD or RIP, enhance or inhibit  
20 apoptotic activity, enhance or inhibit the capacity of APO8 to activate NF- $\kappa$ B, or enhance or inhibit the ability of an APO8 polypeptide to effect cell proliferation, differentiation or cytokine secretion.

The invention also provides APO9 selective  
25 binding agents, which are agents that selectively bind an APO9 polypeptide or active fragment thereof, such as a polypeptide having, for example, substantially the same amino acid sequence as hAPO9 (SEQ ID NO:6). Such APO9 selective binding agents exhibit selective binding  
30 affinity for APO9 and, in addition, can function to selectively enhance or inhibit the function of APO9. An APO9 selective binding agent can, for example, enhance or

inhibit APO9 binding to a ligand, enhance or inhibit the pro-apoptotic or anti-apoptotic activity of an APO9 polypeptide, or enhance or inhibit the ability of an APO9 polypeptide to effect cell proliferation, differentiation or cytokine secretion.

Further provided herein are APO4 selective binding agents, which are agents that selectively bind an APO4 polypeptide or active fragment thereof. An APO4 selective binding agent can exhibit selective binding affinity for an APO4 polypeptide having, for example, substantially the same amino acid sequence as mAPO4- $\alpha$ L (SEQ ID NO:8), mAPO4- $\alpha$ S (SEQ ID NO:10), hAPO4- $\alpha$  (SEQ ID NO:12), rAPO4- $\alpha$  (SEQ ID NO:14), mAPO4- $\beta$  (SEQ ID NO:16) or mAPO4- $\gamma$  (SEQ ID NO:32), or an active fragment thereof.

Such APO4 selective binding agents exhibit selective binding affinity for an APO4 polypeptide and, in addition, can selectively enhance or inhibit the function of an APO4 polypeptide. An APO4 selective binding agent can, for example, enhance or inhibit binding of an APO4 polypeptide to a ligand, enhance or inhibit pro-apoptotic or anti-apoptotic activity of an APO4 polypeptide, or enhance or inhibit the ability of an APO4 polypeptide to effect cell proliferation, differentiation or cytokine secretion.

APO6 selective binding agents also are provided by the present invention. Such APO6 selective binding agents are agents that selectively bind an APO6 polypeptide of the invention or active fragment thereof. An APO6 selective binding agent can exhibit selective binding affinity for an APO6 polypeptide having, for example, substantially the same amino acid sequence as hAPO6 (SEQ ID NO:18), or active fragment thereof. Such APO6 selective binding agents exhibit selective binding

affinity for an APO6 polypeptide and, in addition, can selectively enhance or inhibit the function of an APO6 polypeptide. For example, an APO6 selective binding agent can enhance or inhibit the binding of an APO6 polypeptide to a ligand, enhance or inhibit the pro-apoptotic or anti-apoptotic activity of an APO6 polypeptide, or enhance or inhibit the ability of an APO6 polypeptide to effect cell proliferation, differentiation or cytokine secretion.

10           The invention additionally provides binding agents that selectively bind a ligand of the invention. Provided herein are TNRL1 selective binding agents, which are agents that selectively bind a TNRL1 polypeptide or active fragment thereof. A TNRL1 selective binding agent  
15 can exhibit selective binding affinity for a TNRL1 polypeptide having, for example, substantially the same amino acid sequence as hTNRL1- $\alpha$  (SEQ ID NO:20), mTNRL1- $\alpha$  (SEQ ID NO:22), hTNRL1- $\beta$  (SEQ ID NO:24) or mTNRL1- $\beta$  (SEQ ID NO:26), or active fragments thereof. Such TNRL1  
20 selective binding agents exhibit selective binding affinity for a TNRL1 polypeptide and, in addition, can selectively enhance or inhibit the function of a TNRL1 polypeptide. For example, a TNRL1 selective binding agent can enhance or inhibit the binding of a TNRL1  
25 polypeptide to its cognate receptor.

          The invention further provides a TNRL3 selective binding agent, which is an agent that selectively binds a TNRL3 polypeptide or active fragment thereof. A TNRL3 selective binding agent can exhibit  
30 selective binding affinity for a TNRL3 polypeptide having, for example, substantially the same amino acid sequence as hTNRL3 (SEQ ID NO:28) or mTNRL3 (SEQ ID NO:30), or active fragments thereof. Such TNRL3

selective binding agents exhibit selective binding affinity for a TNRL3 polypeptide and, additionally, can selectively enhance or inhibit the function of a TNRL3 polypeptide. For example, a TNRL3 selective binding agent can enhance or inhibit the binding of a TNRL3 polypeptide to a cognate receptor.

The term "selective binding agent," as used herein, means an agent that exhibits selective binding to the indicated polypeptide or polypeptide family. As used herein, the term "agent" encompasses simple or complex organic molecules, peptides, peptidomimetics, polypeptides and antibodies as well as nucleic acids, carbohydrates or lipids. A selective binding agent is any such agent that binds with substantially higher affinity to the indicated polypeptide or nucleic acid than to an unrelated polypeptide or nucleic acid.

Selective binding agents include natural ligands as well as other agents that exhibit selective binding for the indicated polypeptide of the invention. Such agents include polyclonal or monoclonal antibodies as well as selective binding agents isolated, for example, from random bacteriophage libraries or combinatorial libraries. Particularly useful selective binding agents include activating antibodies that selectively bind an APO8, APO9, APO4, APO6, TNRL1 or TNRL3 polypeptide of the invention. Such activating antibodies can, for example, function to cross-link receptors and trigger receptor signaling in the absence of ligand. Particularly useful selective binding agents also include neutralizing antibodies, which can bind and dampen or inactivate the function of an APO8, APO9, APO4, APO6, TNRL1 or TNRL3 polypeptide. Particularly useful selective binding agents that selectively bind a TNRL1 or

TNRL3 polypeptide of the invention also include soluble or full-length cognate receptors, which bind their respective TNRL1 or TNRL3 polypeptide ligand.

The term "selective binding," as used in  
5 reference to a selective binding agent and an indicated polypeptide, means that the agent binds with substantially higher affinity to the indicated polypeptide, or fragment thereof, than to another polypeptide. For example, an APO8 selective binding  
10 agent, which selectively binds an APO8 polypeptide, binds with substantially higher affinity to an APO8 polypeptide, or fragment thereof, than to another member of the TNFR superfamily such as TNFR-1 or another death domain containing polypeptide such as FADD. Thus, for  
15 example, an agent that binds the death domains of TNFR-1, FAS/APO-1 and APO8 with similar affinity is not a selective binding agent as defined herein. However, an agent that has substantially higher affinity for an APO8 death domain than for the TNFR-1 and FAS/APO-1 death  
20 domains exhibits selective binding for APO8 and, therefore, is encompassed within the definition of an APO8 selective binding agent. Similarly, a TNRL1 selective binding agent, which as defined herein is an agent that selectively binds a TNRL1 polypeptide, binds  
25 with substantially higher affinity to a TNRL1 polypeptide than to another member of the TNF family such as TNF- $\alpha$ .

The invention also provides a method of identifying an APO8 selective binding agent by contacting  
an APO8 polypeptide, or fragment thereof, with an agent  
30 and determining selective binding of the agent to the APO8 polypeptide, where said the selective binding indicates that the agent is an APO8 selective binding agent.



A variety of methods for determining the selective binding of an agent to a polypeptide or fragment of the invention are well known in the art. Such methods include, for example, ELISA, RIA, 5 receptor/ligand binding assays and other affinity assays such as chromatographic methods and panning. These screening methods are well known in the art and are described, for example in Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1992); Ansubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD 10 (1989) and in Devlin, T.M., Textbook of Biochemistry with Clinical Correlations, Wiley-Liss, New York, NY (1992).

Screening assays for detecting selective 15 binding also include two-hybrid systems such as the yeast two hybrid system, which can be used to screen a panel of agents to detect selective binding to a polypeptide of the invention or fragment thereof (see Fields and Song, Nature 340:245-246 (1989), which is incorporated herein 20 by reference) or a two-hybrid system adapted for use in mammalian cells (see Fearon et al., Proc. Natl. Acad. Sci., USA 89:7958-7962 (1992), which is incorporated herein by reference).

Using one of the assays described above, or 25 another assay well known in the art, a large collection, or library, of random agents or agents of interest can be screened for selective binding activity. Polypeptide libraries and tagged chemical libraries including those comprising polypeptides, peptides and peptidomimetic 30 molecules can be screened. Polypeptide libraries also include those generated by phage display technology. Phage display technology includes the expression of polypeptide molecules on the surface of phage as well as

other methodologies by which a protein ligand is or can be associated with the nucleic acid which encodes it. Methods for production of phage display libraries, including vectors and methods of diversifying the population of peptides which are expressed, are well known in the art (see, for example, Smith and Scott, Methods Enzymol. 217:228-257 (1993); Scott and Smith, Science 249:386-390 (1990); and Huse, WO 91/07141 and WO 91/07149, each of which is incorporated herein by reference). These or other well known methods can be used to produce a phage display library which can be screened, for example, to identify a selective binding agent of the invention.

Each of the isolated receptor polypeptides provided herein are useful as immunogens for preparing antibodies. Thus, the invention provides an antibody that selectively binds an APO8 polypeptide, for example, hAPO8 (SEQ ID NO:2). Such an antibody is useful, for example, in purifying an APO8 polypeptide by immunoaffinity chromatography.

The invention further provides an antibody that selectively binds an APO9 polypeptide of the invention, for example, hAPO9 (SEQ ID NO:6). Similarly, the invention provides an antibody that selectively binds an APO4 polypeptide; such an antibody can selectively bind, for example, mAPO4- $\alpha$ L (SEQ ID NO:8), mAPO4- $\alpha$ S (SEQ ID NO:10), hAPO4- $\alpha$  (SEQ ID NO:12), rAPO4- $\alpha$  (SEQ ID NO:14), mAPO4- $\beta$  (SEQ ID NO:16) or mAPO4- $\gamma$  (SEQ ID NO:32). Further provided by the invention is an antibody that selectively binds an APO6 polypeptide, for example, hAPO6 (SEQ ID NO:18). Each of these antibodies are useful in purifying the polypeptide to which it selectively binds using immunoaffinity chromatography.

The isolated ligand polypeptides provided herein also are useful as immunogens for preparing antibodies. Thus, the invention provides antibodies that selectively bind a ligand of the invention. Provided  
5 herein is an antibody that selectively binds a TNRL1 polypeptide, for example, hTNRL1- $\alpha$  (SEQ ID NO:20), mTNRL1- $\alpha$  (SEQ ID NO:22), hTNRL1- $\beta$  (SEQ ID NO:24) or mTNRL1- $\beta$  (SEQ ID NO:26) or an active fragment thereof. Also provided herein is an antibody that selectively  
10 binds a TNRL3 polypeptide of the invention. Such an antibody can selectively bind, for example, hTNRL3 (SEQ ID NO:28) or mTNRL3 (SEQ ID NO:30).

As used herein, the term "antibody" is used in its broadest sense to include polyclonal and monoclonal  
15 antibodies, as well as polypeptide fragments of antibodies that retain a selective binding activity for a polypeptide of the invention of at least about  $1 \times 10^5$  M<sup>-1</sup>. One skilled in the art would know that antibody fragments such as Fab, F(ab')<sub>2</sub> and Fv fragments can retain  
20 selective binding activity for a polypeptide of the invention and, thus, are included within the definition of an antibody. In addition, the term antibody as used herein includes naturally occurring antibodies, as well as non-naturally occurring antibodies and fragments such  
25 as chimeric antibodies and humanized antibodies that have selective binding activity. Such non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, produced recombinantly or obtained, for example, by screening combinatorial libraries consisting  
30 of variable heavy chains and variable light chains as described by Borrebaeck (Ed.), Antibody Engineering (Second edition) New York: Oxford University Press (1995), which is incorporated herein by reference.

Methods for producing antibodies are routine in the art. A purified polypeptide of the invention, which can be prepared from natural sources or produced recombinantly as described above, or a fragment thereof, such as a synthetic peptide, can be used as an immunogen. Non-immunogenic fragments or synthetic peptides can be made immunogenic by coupling the hapten to a carrier molecule such as bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). In addition, various other carrier molecules and methods for coupling a hapten to a carrier molecule are well known in the art as described, for example, by Harlow and Lane, Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1988), which is incorporated herein by reference.

An antibody "having selective binding for" a polypeptide, or that "selectively binds" a polypeptide, binds with substantially higher affinity to that polypeptide than to another polypeptide.

The APO8 encoding nucleic acids and polypeptides of the invention can be used to diagnose, treat or reduce the severity of an APO8-mediated disease. For example, the APO8 encoding nucleic acids, polypeptides and active fragments and segments thereof can be used for diagnosis of an APO8-mediated disease or can be used to generate reagents useful for such diagnosis. Diagnosis can be performed, for example, by nucleic acid probe hybridization, or by amplification of APO8 encoding nucleotide sequences and subsequent electrophoretic analysis such as DNA sequencing. Diagnosis also can be performed, for example, using antibody or ligand based detection with an APO8 selective binding agent. Detection can be performed ex vivo, for example, by removing a cell or tissue sample from an

individual at risk of, suspected of having or exhibiting one or more symptoms of an APO8-mediated disease.

Altered APO8 expression or activity is indicative of an APO8-mediated disease. As used herein, the term

- 5 "APO8-mediated disease" means a disease, pathology, or other condition resulting from an abnormality in the expression or activity of an APO8 polypeptide. Included within the meaning of the term "APO8-mediated disease" are disorders of cell loss, disorders of cell
- 10 accumulation and disorders of differentiation, as described further below.

The present invention provides a method of treating or reducing the severity of an APO8-mediated disease in a subject by administering an APO8 polypeptide

15 or active fragment thereof or by administering a nucleic acid molecule encoding the APO8 polypeptide or fragment. An APO8 polypeptide or nucleic acid molecule useful in such a method can be or encode, for example, an amino acid sequence that is identical or substantially the same

20 as hAPO8 (SEQ ID NO:2), or an active fragment thereof. An APO8 antisense nucleic acid molecule, which has a nucleotide sequence that is identically or substantially complementary to an APO8 encoding nucleic acid or active fragment thereof, also can be used to treat or reduce the

25 severity of an APO8-mediated disease according to a method of the invention.

Also provided herein is a method of treating or reducing the severity of an APO8-mediated disease in a subject by administering an APO8 regulatory agent to the

30 subject. As used herein, an "APO8 regulatory agent" is an agent that inhibits or enhances a biological activity of an APO8 polypeptide. Such an APO8 regulatory agent can be, for example, an APO8 inhibitory agent such as a

dominant negative form of APO8, an APO8 selective binding agent that inhibits a biological activity of an APO8 polypeptide, or a cysteine protease inhibitor. Dominant negative forms of APO8 include, for example, soluble  
5 forms of APO8 having an APO8 ligand binding domain, as well as membrane bound forms of APO8 having an APO8 ligand binding domain but lacking a functional cytoplasmic tail, known as "decoy receptors." Examples of such "decoy receptor" APO8 inhibitory agents are  
10 provided herein as APO8ACP and APO8ADD (see Example II).

An APO8 regulatory agent also can be an agent that inhibits or enhances the activity or expression of FADD, FLICE, TRADD or RIP or that inhibits or enhances the activity or expression of NF- $\kappa$ B. One skilled in the  
15 art understands that such an APO8 regulatory agent can be an agent that selectively regulates a biological activity of an APO8 polypeptide or, alternatively, can be a non-selective agent that, in addition to regulating a biological activity of an APO8 polypeptide, also  
20 regulates the activity of, for example, other death domain containing receptors. As shown in Example II, the FADD dominant negative construct DN-FADD, the FLICE dominant negative construct (FL-C360S) and the cysteine protease inhibitors CrmA and z-VAD-fmk each inhibit APO8  
25 induced apoptosis. In addition, the TRADD dominant negative construct ND-TRADD inhibits APO8-mediated NF- $\kappa$ B activation, which can protect cells from apoptosis (Example II). Thus, each of these molecules are examples of APO8 regulatory agents as defined herein.

30 As described above, an agent can be a simple or complex organic molecule, peptide, peptidomimetic, polypeptide, antibody, nucleic acid, carbohydrate or lipid molecule.

The present invention also provides a method of treating or reducing the severity of an APO8RP-mediated disease in a subject by administering to the subject a FADD regulatory agent. Such a FADD regulatory agent is an agent, such as a simple or complex organic molecule, peptide, peptidomimetic, polypeptide, antibody, nucleic acid, carbohydrate or lipid molecule, that inhibits or enhances FADD activity or expression. As disclosed herein, hAPO8 (SEQ ID NO:2) and hAPO8RP (SEQ ID NO:4) induce apoptosis through the FADD adaptor molecule. The data shown in Figure 5B demonstrate that a FADD dominant negative construct (DN-FD) reduces APO8RP-mediated apoptosis. These results indicate that a FADD regulatory agent, such as a FADD dominant negative construct, can be used to reduce APO8RP-induced apoptosis and, thus, treat or reduce the severity of an APO8RP-mediated disease. An "APO8 related polypeptide-mediated disease," as used herein, is synonymous with "APO8RP-mediated disease" and means a disease, pathology, or other condition resulting from an abnormality in the expression or activity of an APO8RP polypeptide and can be, for example, a disorder of cell loss, disorder of cell accumulation or disorder of cell differentiation. An APO8RP-mediated disease also can be, for example, an autoimmune disorder.

Further provided by the present invention is a method of treating or reducing the severity of an APO8RP-mediated disease in a subject by administering to the subject a TRADD regulatory agent or a RIP regulatory agent. Such an agent enhances or inhibits the activity or expression of TRADD or RIP. As disclosed herein in Example II, both APO8 and APO8RP directly interact with the TRADD and RIP adaptor molecules. Example II further demonstrates that a TRADD dominant negative construct blocks NF- $\kappa$ B activation by APO8 and APO8RP. Thus, a

TRADD regulatory agent or a RIP regulatory agent, such as a TRADD dominant negative construct, can be used to treat or reduce the severity of an APO8RP-mediated disease.

The present invention also provides a method of  
5 treating or reducing the severity of an APO8RP-mediated disease in a subject by administering to the subject an NF- $\kappa$ B regulatory agent, which is an agent that enhances or inhibits the activity or expression of NF- $\kappa$ B. Activation of the NF- $\kappa$ B pathway is known to protect cells  
10 from apoptosis, and, as disclosed herein, expression of APO8 or APO8RP results in NF- $\kappa$ B activation (see Example II). Thus, an NF- $\kappa$ B regulatory agent can block, for example, apoptosis and, therefore, can be useful in treating or reducing the severity of an APO8RP-mediated  
15 disease that results from excessive cell death.

The APO9 encoding nucleic acids and polypeptides of the invention can be used to diagnose, treat or reduce the severity of an APO9-mediated disease. For example, the APO9 encoding nucleic acids,  
20 polypeptides and active fragments thereof can be used for diagnosis of an APO9-mediated disease or can be used to generate reagents useful for such diagnosis. Diagnosis can be performed, for example, by nucleic acid probe hybridization, or by amplification of APO9 encoding  
25 nucleotide sequences and subsequent electrophoretic analysis such as DNA sequencing. Diagnosis also can be performed using, for example, antibody or ligand based detection with an APO9 selective binding agent. Detection can be performed ex vivo, for example, by  
30 removing a cell or tissue sample from an individual at risk of, suspected of having or exhibiting one or more symptoms of an APO8-mediated disease. Altered APO9 expression or activity is indicative of an APO9-mediated



disease. As used herein, the term "APO9-mediated disease" means a disease, pathology, or other condition resulting from an abnormality in the expression or activity of an APO9 polypeptide. Included within the  
5 meaning of the term "APO9-mediated disease" are disorders of cell loss, disorders of cell accumulation and disorders of cell differentiation.

The present invention provides a method of treating or reducing the severity of an APO9-mediated  
10 disease in a subject by administering an APO9 polypeptide or active fragment thereof or by administering a nucleic acid molecule encoding the APO9 polypeptide or fragment. An APO9 polypeptide or nucleic acid molecule useful in such a method can be or encode, for example, an amino  
15 acid sequence identical or substantially the same as hAPO9 (SEQ ID NO:6), or an active fragment thereof. An APO9 antisense nucleic acid molecule, which has a nucleotide sequence that is identically or substantially complementary to an APO9 encoding nucleic acid or active  
20 fragment thereof, also can be used to treat or reduce the severity of an APO9-mediated disease according to a method of the invention.

Further provided herein is a method of treating or reducing the severity of an APO9-mediated disease in a  
25 subject by administering an APO9 regulatory agent to the subject. As used herein, an "APO9 regulatory agent" is an agent that inhibits or enhances a biological activity of an APO9 polypeptide. Such an APO9 regulatory agent can be, for example, an APO9 inhibitory agent such as a  
30 dominant negative form of APO9, an alternative spliced full-length form of APO9, or an APO9 selective binding agent that inhibits a biological activity of an APO9 polypeptide. Dominant negative forms of APO9 include,

for example, soluble forms of APO9 having an APO9 ligand binding domain, as well as membrane bound forms of APO9 having an APO9 ligand binding domain but lacking a functional cytoplasmic tail, known as "decoy receptors."

5 An APO9 regulatory agent can also be an agent that selectively binds an alternative spliced full-length form of APO9, thereby blocking or transmitting a signal through full-length APO9. One skilled in the art understands that such an APO9 regulatory agent can be an

10 agent that selectively regulates a biological activity of an APO9 polypeptide or, alternatively, can be a non-selective agent that, in addition to regulating a biological activity of an APO9 polypeptide, also regulates the activity of, for example, other TNF family

15 receptors.

The APO4 encoding nucleic acids and polypeptides of the invention can be used to diagnose, treat or reduce the severity of an APO4-mediated disease. The APO4 encoding nucleic acids, polypeptides and active

20 fragments thereof can be used for diagnosis of an APO4-mediated disease or can be used to generate reagents useful for such diagnosis. Diagnosis can be performed, for example, by nucleic acid probe hybridization, or by amplification of APO4 encoding nucleotide sequences and

25 subsequent electrophoretic analysis such as DNA sequencing. Diagnosis also can be performed, for example, using antibody or ligand based detection with an APO4 selective binding agent. Detection can be performed ex vivo, for example, by removing a cell or tissue sample

30 from an individual at risk of, suspected of having or exhibiting one or more symptoms of an APO4-mediated disease. Altered APO4 polypeptide expression or activity can be indicative of an APO4-mediated disease. As used herein, the term "APO4-mediated disease" means a disease,

pathology, or other condition resulting from an abnormality in the expression or activity of an APO4 polypeptide. Included within the meaning of the term "APO4-mediated disease" are disorders of cell loss, disorders of cell accumulation and disorders of cell differentiation.

As disclosed herein, APO4 was expressed highly in embryonic tissue at day 11, 15 and 17, indicating that APO4 can play a role in early development (see Example IV). APO4 expression in embryonic tissues also indicates that APO4 can play a role in developmental abnormalities or in gestation. Thus, APO4 can be used in the diagnosis or treatment of developmental or gestational abnormalities.

The present invention provides, for example, a method a diagnosing a developmental abnormality caused by the aberrant expression of APO4 during development by determining the level or pattern of expression of APO4 mRNA or protein in embryonic cells or tissue. The invention further provides a method of diagnosing a developmental abnormality caused by the aberrant expression of APO4 during development by detecting a mutation in an APO4 gene in a cell or tissue derived from embryos.

In adult tissues, APO4 expression was highest in adult prostate, with lower levels of expression seen in adult spleen, thymus, testis, uterus, small intestine, colon and peripheral blood leukocytes. APO4 also was highly expressed in a prostate carcinoma epithelial cell line, LNCaP (see Example IV). Since the glandular epithelial cells of the prostate represent the site of origin of prostate cancer and the cell type that

increases during prostate cancer growth, increased APO4 levels can be used as a marker diagnostic of the presence of prostate cancer. For example, as the levels of APO4 secreted by prostatic tissue increase with the increasing mass of the prostate epithelial cells, elevated levels of APO4 either in the serum or from a tissue biopsy of an individual suspected of having prostate cancer can be used to diagnose the existence of prostate cancer. In addition, altered APO4 levels can be assayed in an individual with prostate cancer as a method of staging the degree or severity of the cancer, thereby providing critical information for determining the most advantageous therapeutic strategy. Altered APO4 levels also can be useful for the diagnosis of local and distant metastatic spread of prostate cancer and for assessment of disease volume. Such a diagnostic indicator is particularly useful in planning radiation therapy for prostate cancer by defining the limits of the spread of disease.

Thus, the present invention provides a method of diagnosing prostate cancer in an individual by determining the level of APO4 in the individual. A method of the invention can be particularly useful in diagnosing prostate cancer in an individual at risk for this cancer, such as in men over the age of fifty or with a family history of prostate cancer.

Soluble APO4 can be a naturally occurring form secreted into the bloodstream. For example, murine APO4 form occurs naturally in soluble form and is secreted into the bloodstream. In one embodiment, the invention provides a method of diagnosing prostate cancer in an individual by determining the level of soluble APO4 in the individual. Such methods can be particularly useful

since a non-invasive blood test can be used in order to determine the level of soluble APO4.

A variety of methods can be used to assay for the level of APO4 according to a method of the invention  
5 for diagnosing prostate cancer. Such methods include assays for APO4 RNA levels, for example, reverse transcriptase polymerase chain reaction (RT-PCR) analysis. Such methods further include immunoassays for determining the level of APO4 polypeptide, for example,  
10 radioimmunoassays and enzyme-linked immunoassays. The level of APO4 in an individual suspected of having prostate cancer can be determined, for example, in a sample such as a serum sample from the individual. If desired, the level of APO4 also can be assayed *in situ*,  
15 for example, by administering an anti-APO4 antibody linked to a detectable moiety and subsequent detection of the moiety.

The invention also provides a method of identifying an effective pharmacological agent useful in  
20 the diagnosis or treatment of a disease associated with APO4 activity. The method includes the steps of contacting an APO4 polypeptide or active fragment thereof with an agent; and determining selective binding of the agent to the APO4 polypeptide or  
25 active fragment thereof, where the selective binding indicates that the agent is an effective pharmacological agent useful in the diagnosis or treatment of a disease associated with APO4 activity. An APO4 polypeptide or active fragment thereof useful in the invention can be,  
30 for example, an APO4 extracellular ligand binding domain. In one embodiment, the APO4 polypeptide or active fragment thereof is expressed in a cell or on the surface of a cell. In another embodiment, the APO4 polypeptide

or active fragment thereof is contacted with an agent *in vitro*.

Methods for determining selective binding are known in the art and are described hereinabove. For  
5 example, assays to determine selective binding include, two-hybrid systems, ELISA, RIA, receptor/ligand binding assays and other affinity assays such as chromatographic methods and panning.

The present invention also provides a method of  
10 screening for an APO4 agonist useful in treating prostate cancer. The method includes the steps of contacting a cell expressing an APO4 polypeptide or active fragment thereof with an agent; and assaying for increased APO4 activity, where increased APO4 activity indicates that  
15 the agent is an APO4 agonist useful in treating prostate cancer.

An APO4 activity can be, for example, APO4 binding to a ligand, activation of the JNK pathway or activation of NF- $\kappa$ B activity. APO4 activity also  
20 includes apoptotic activity in a cell in response to increased APO4 expression or contact with APO4. The stimulation or induction of apoptosis in the cell includes any increased level of apoptosis compared to the level observed prior to contact with the APO4 agonist.

Further provided herein is a method of  
25 screening for an APO4 antagonist. The method includes the steps of contacting a cell expressing an APO4 polypeptide or active fragment thereof with an agent; and assaying for decreased APO4 activity, where decreased  
30 APO4 activity indicates that the agent is an APO4 antagonist.

The invention also provides a method of identifying an effective pharmacological agent useful in the diagnosis or treatment of a disease associated with APO4 activity by forming a mixture including an APO4 polypeptide or active fragment thereof, an APO4 signal transducer molecule that specifically interacts with a cytoplasmic domain of the APO4 polypeptide or active fragment thereof, and an agent; and detecting the level of APO4 activity in the presence of the agent, where an alteration in the APO4 activity relative to control activity indicates that the agent is an effective pharmacological agent useful in the diagnosis or treatment of a disease associated with APO4 activity. An alteration in APO4 activity can be an increased or decreased activity. Examples of APO4 activity include, for example, activation of the JNK pathway, activation of NF- $\kappa$ B, apoptosis, cell proliferation or cell differentiation. In such a method of the invention, the APO4 activity can be measured, for example, *in vivo* or *in vitro*.

As discussed above, APO4 can be highly expressed in prostate cancer epithelial cells. Based on this expression, the present invention also provides a method of treating prostate cancer by administering to an individual having prostate cancer a conjugate including an APO4 selective binding agent linked to a therapeutic moiety. Administration of a conjugate including an APO4 selective binding agent, for example, an anti-APO4 monoclonal antibody, facilitates targeted delivery of a linked therapeutic moiety such as doxorubicin to prostate cancer epithelial cells.

As used herein, the term "APO4 selective binding agent" means a simple or complex organic

molecule, peptide, peptidomimetic, polypeptide, antibody, nucleic acid, carbohydrate or lipid that binds with substantially higher affinity to an APO4 polypeptide than to an unrelated polypeptide. Methods for identifying a selective binding agent are described hereinabove.

As disclosed herein, a therapeutic moiety can be, for example, a cancer chemotherapeutic agent linked to an APO4 selective binding agent to produce a conjugate containing an APO4 selective binding agent linked to a therapeutic moiety. Cytotoxic chemotherapy is the basis of the systemic treatment of disseminated malignant tumors. However, a major limitation of the currently used chemotherapeutic agents is that these drugs have the narrowest therapeutic index in all of medicine. As such, the dose of cancer chemotherapeutic agents generally is limited by undesirable toxicity to the patient being treated. Thus, the ability of an APO4 selective binding agent to target a drug to cancerous prostate tissue allows for a higher amount of chemotherapeutic agent to be delivered directly to the cancer with reduced side effects.

As used herein, the term "therapeutic moiety" means a physical, chemical, or biological material that is linked to an APO4 selective binding agent for the purpose of being targeted *in vivo* to an APO4 polypeptide. A therapeutic moiety can be a cancer chemotherapeutic agent such as doxorubicin, which, when linked to an APO4 selective binding agent, provides a conjugate useful for treating a cancer in a subject. In addition, a therapeutic moiety can be a drug delivery vehicle such as a chambered microdevice, a cell, a liposome or a virus, which can contain an agent such as a drug or a nucleic acid. An APO4 selective binding agent also can be linked



to a therapeutic moiety expressed by a virus, for example, the adenovirus penton base coat protein, thus providing a means to target a virus to cancerous prostate cells (Wickman et al., Gene Ther. 2:750-756 (1995);  
5 Weitzman et al., In: "Gene Therapy and Vector Systems" 2:17-25 (1997), each of which is incorporated herein by reference).

A therapeutic moiety also can be, for example, a radioactive moiety or can be a cytotoxic agent,  
10 including a toxin such as ricin or a drug such as a chemotherapeutic agent or can be a physical, chemical or biological material such as a liposome, microcapsule, micropump or other chambered microdevice, which can be used, for example, as a drug delivery system. Generally,  
15 such microdevices, should be nontoxic and, if desired, biodegradable. Various moieties including microcapsules, which can contain an agent, are well known in the art and commercially available (see, for example, "Remington's Pharmaceutical Sciences" 18th ed. (Mack Publishing Co.  
20 1990), chapters 89-91; Harlow and Lane, Antibodies: A laboratory manual (Cold Spring Harbor Laboratory Press 1988), each of which is incorporated herein by reference).

25 In one embodiment, an APO4 selective binding agent for treating prostate cancer is a monoclonal or polyclonal antibody. Use of antibody-conjugated immunotoxins and radioactive moieties for the treatment of cancer are well known in the art, as described, for  
30 example, by Geissler et al. Cancer Res., 52:2907-2915 (1992); Thrush et al., Ann Rev. Immunol., 14:49-71 (1996); and Trail et al., Science, 261:212-215 (1993). For example, the anthracyclin, doxorubicin, has been linked to antibodies and the antibody/doxorubicin

conjugated have been therapeutically effective in treating tumors (Sivan et al., Cancer Res. 55:2352-2356 (1995); Lau et al., Bioorg. Med. Chem. 3:1299-1304 (1995); Shih et al., Cancer Immunol. Immunother. 38:92-98 (1994); which are incorporated herein by reference). Similarly, other anthracyclins, including idarubicin and daunorubicin, have been chemically conjugated to antibodies, which have delivered effective doses of the therapeutic moiety to tumors (Rowland et al., Cancer Immunol. Immunother. 37:195-202 (1993); Aboud-Pirak et al., Biochem. Pharmacol. 38:641-648 (1989)). Thus, an anthracyclin, such as doxorubicin, idarubicin or daunorubicin, is a therapeutic moiety particularly useful in the methods of the invention.

15           A therapeutic moiety can be conjugated to a selective binding agent using a variety of methods. A covalent bond can be formed, for example, using glutaraldehyde, a heterobifunctional cross-linker or a homobifunctional cross-linker. Additional conjugation  
20 methods include carbodiimide conjugation methods (Bauminger and Wilchek, Meth. Enzymol. 70:151-159 (1980), which is incorporated herein by reference). Carbodiimides comprise a group of compounds that have the general formula  $R-N=C=N-R'$ , where R and R' can be  
25 aliphatic or aromatic, and are used for synthesis of peptide bonds. The preparative procedure is simple, relatively fast, and is carried out under mild conditions. Carbodiimide compounds attack carboxylic groups to change them into reactive sites for free amino  
30 groups. Carbodiimide conjugation has been used to conjugate a variety of compounds to carriers for the production of antibodies.

In addition to using carbodiimides for conjugation, the water soluble carbodiimide, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) also can be used for conjugating a therapeutic moiety to an APO4 selective binding agent. EDC can also be used to prepare active esters such as N-hydroxysuccinimide (NHS) ester. The NHS ester, which binds only to amino groups, then can be used to induce the formation of an amide bond with the single amino group of the doxorubicin. The use of EDC and NHS in combination is commonly used for conjugation in order to increase the yield of conjugate formation (Bauminger and Wichek, *supra*, 1980).

Other methods for conjugating a therapeutic moiety to an APO4 selective binding agent also can be used. For example, sodium periodate oxidation followed by reductive alkylation of appropriate reactants can be used, as can glutaraldehyde cross-linking. The cross-linking of proteins can additionally be accomplished by using reactive groups within the individual protein such as carbohydrate, disulfide, carboxyl or amino groups. Coupling can also be accomplished by oxidation or reduction of the native protein, or treatment with an enzyme, for example. However, it is recognized that, regardless of which method of producing a conjugate is selected, a determination must be made that the APO4 selective binding agent maintains its targeting ability and that the therapeutic moiety maintains its relevant function.

The yield of therapeutic moiety/selective binding agent conjugate formed is determined using routine methods. For example, HPLC or capillary electrophoresis or other qualitative or quantitative method can be used (see, for example, Liu et al., J.

Chromatogr. 735:357-366 (1996); Rose et al., J. Chromatogr. 425:419-412 (1988), each of which is incorporated herein by reference). In particular, the skilled artisan will recognize that the choice of a method for determining yield of a conjugation reaction depends, in part, on the physical and chemical characteristics of the specific therapeutic moiety and selective binding agent. Following conjugation, the reaction products are desalted to remove any free peptide and free drug.

A conjugate made up of an APO4 selective binding agent linked to a therapeutic moiety can be administered to an individual having prostate cancer, or, if desired, to an individual suspected of having prostate cancer or an individual at risk of developing prostate cancer. Administration can be accomplished, for example, by intravenous, intraperitoneal or subcutaneous injection. A conjugate made up of an APO4 selective binding agent linked to a therapeutic moiety can be administered by conventional methods using a dosage sufficient to reduce the growth or severity of the prostate cancer. Such dosages can be readily determined by those skilled in the art and include a variety of different regimes, including single high dose administration or repeated small dose administration or a combination of both. The dosing will depend on the progression of the disease and overall health of the individual and can be determined by those skilled in the art.

The present invention also provides a method of treating or reducing the severity of an APO4-mediated disease in a subject by administering an APO4 polypeptide or active fragment thereof or by administering a nucleic acid molecule encoding the APO4 polypeptide or fragment.

An APO4 polypeptide or nucleic acid molecule useful in such a method can be or encode, for example, an amino acid sequence identical or substantially the same as mAPO4- $\alpha$ L (SEQ ID NO:8) or an active fragment thereof, 5 mAPO4- $\alpha$ S (SEQ ID NO:10) or an active fragment thereof, hAPO4- $\alpha$  (SEQ ID NO:12) or an active fragment thereof, rAPO4- $\alpha$  (SEQ ID NO:14) or an active fragment thereof or mAPO4- $\beta$  (SEQ ID NO:16) or an active fragment thereof, or mAPO4- $\gamma$  (SEQ ID NO:32) or an active fragment thereof. An 10 APO4 antisense nucleic acid molecule, which has a nucleotide sequence that is identically or substantially complementary to an APO4 encoding nucleic acid or active fragment thereof, also can be used to treat or reduce the severity of an APO4-mediated disease according to a 15 method of the invention.

The present invention also provides a method of treating or reducing the severity of an APO4-mediated disease in a subject such as, for example, prostate cancer, by administering an APO4 regulatory agent to the 20 subject. As used herein, an "APO4 regulatory agent" is an agent that inhibits or enhances a biological activity of an APO4 polypeptide. Such an APO4 regulatory agent can be, for example, an inhibitory agent capable of inhibiting the activity of APO4 or an APO4-mediated 25 activity. For example, in the case of prostate cancer, individuals with this disease can be treated with inhibitors of a JNK pathway to reduce the severity of the disease.

An APO4 regulatory agent can also be an APO4 30 inhibitory agent such as a dominant negative form of APO4, or an APO4 selective binding agent that inhibits a biological activity of an APO4 polypeptide. Dominant negative forms of APO4 include, for example, soluble

forms of APO4 having an APO4 ligand binding domain such as mAPO4- $\beta$ , as well as membrane bound forms of APO4 having an APO4 ligand binding domain but lacking a functional cytoplasmic tail such as mAPO4- $\alpha$ S, known as  
5 "decoy receptors." One skilled in the art understands that such an APO4 regulatory agent can be an agent that selectively regulates a biological activity of an APO4 polypeptide or, alternatively, can be a non-selective agent that, in addition to regulating a biological  
10 activity of an APO4 polypeptide, also regulates the activity of, for example, other TNF family receptors.

As disclosed herein, amino acids 194 to 355 are important for activation of the JNK pathway and apoptosis. Since the mAPO4 $\alpha$ -short and mAPO4- $\gamma$  forms lack  
15 the above domains, these and similar isoforms of APO4 can lack the ability to induce the JNK pathway or cell death. However, since these isoforms of APO4 possess a complete or almost complete ligand-binding extracellular domain, they can still compete with the full-length form of APO4  
20 for binding to the ligand, thereby blocking signal transduction mediated by the full-length receptor. As such, mAPO4 $\alpha$ -short, mAPO4- $\gamma$ , their species homologs and isoforms, and natural or synthetic compounds mimicking their ligand-binding ability but lacking the complete  
25 cytoplasmic domain or the domain encoding the amino acids 194 to 355 (or homologous domains in other species) can be useful therapeutic tools for the treatment of diseases resulting from the dysregulation of APO4 signal transduction pathway. Such agents also can serve as lead  
30 compounds for the development of therapeutic compounds useful in the diagnosis and treatment of diseases resulting from the dysregulation of APO4 function.

The APO6 encoding nucleic acids and polypeptides of the invention can be used to diagnose, treat or reduce the severity of an APO6-mediated disease. For example, the APO6 encoding nucleic acids, 5 polypeptides and active fragments thereof can be used for diagnosis of an APO6-mediated disease or can be used to generate reagents useful for such diagnosis. Diagnosis can be performed, for example, by nucleic acid probe hybridization, or by amplification of APO6 encoding 10 nucleotide sequences and subsequent electrophoretic analysis such as DNA sequencing. Diagnosis also can be performed, for example using antibody or ligand based detection with an APO6 selective binding agent. Detection can be performed *ex vivo*, for example, by 15 removing a cell or tissue sample from an individual at risk of, suspected of having or exhibiting one or more symptoms of an APO6-mediated disease. Altered APO6 expression or activity is indicative of an APO6-mediated disease. As used herein, the term "APO6-mediated 20 disease" means a disease, pathology, or other condition resulting from an abnormality in the expression or activity of an APO6 polypeptide. Included within the meaning of the term "APO6-mediated disease" are disorders of cell loss, disorders of cell accumulation and 25 disorders of cell differentiation.

The invention provides a method of treating or reducing the severity of an APO6-mediated disease in a subject by administering an APO6 polypeptide or active fragment thereof or by administering a nucleic acid 30 molecule encoding the APO6 polypeptide or fragment. An APO6 polypeptide or nucleic acid molecule useful in such a method can be or encode, for example, an amino acid sequence identical or substantially the same as hAPO6 (SEQ ID NO:18), or an active fragment thereof. An APO6

antisense nucleic acid molecule, which has a nucleotide sequence that is identically or substantially complementary to an APO6 encoding nucleic acid or active fragment thereof, also can be used to treat or reduce the severity of an APO6-mediated disease according to a method of the invention.

In addition, the invention provides a method of treating or reducing the severity of an APO6-mediated disease in a subject by administering an APO6 regulatory agent to the subject. An "APO6 regulatory agent," as used herein, is an agent that inhibits or enhances a biological activity of an APO6 polypeptide. Such an APO6 regulatory agent can be, for example, an APO6 inhibitory agent such as a dominant negative form of APO6, an alternatively spliced full-length form of APO6 polypeptide or an APO6 selective binding agent that inhibits a biological activity of an APO6 polypeptide. An APO6 regulatory agent also can be an agent that selectively binds an alternatively spliced full-length form of APO6, thereby blocking or transmitting a signal through full-length APO6. One skilled in the art understands that an APO6 regulatory agent can be an agent that selectively regulates a biological activity of an APO6 polypeptide or, alternatively, can be a non-selective agent that, in addition to regulating a biological activity of an APO6 polypeptide, also regulates the activity of, for example, other TNF family receptors.

The TNRL1 encoding nucleic acids and polypeptides of the invention can be used to diagnose, treat or reduce the severity of a TNRL1-mediated disease. For example, the TNRL1 encoding nucleic acids, polypeptides and active fragments thereof can be used for



diagnosis of a TNRL1-mediated disease or can be used to generate reagents useful for such diagnosis. Diagnosis can be performed, for example, by nucleic acid probe hybridization, or by amplification of TNRL1 encoding  
5 nucleotide sequences and subsequent electrophoretic analysis such as DNA sequencing. Diagnosis also can be performed using, for example, antibody or ligand based detection with a TNRL1 selective binding agent. Detection can be performed *ex vivo*, for example, by  
10 removing a cell or tissue sample from an individual at risk of, suspected of having or exhibiting one or more symptoms of a TNRL1-mediated disease. Altered TNRL1 expression or activity is indicative of a TNRL1-mediated disease. As used herein, the term "TNRL1-mediated  
15 disease" means a disease, pathology, or other condition resulting from an abnormality in the expression or activity of a TNRL1 polypeptide. Included within the meaning of the term "TNRL1-mediated disease" are disorders of cell loss, disorders of cell accumulation  
20 and disorders of cell differentiation.

The invention also provides a method of treating or reducing the severity of a TNRL1-mediated disease in a subject by administering a TNRL1 polypeptide or active fragment thereof or by administering a nucleic  
25 acid molecule encoding the TNRL1 polypeptide or fragment. A TNRL1 polypeptide or nucleic acid molecule useful in the method can be or encode, for example, an amino acid sequence identical or substantially the same as hTNRL1- $\alpha$  (SEQ ID NO:20) or an active fragment thereof, mTNRL1- $\alpha$   
30 (SEQ ID NO:22) or an active fragment thereof, hTNRL1- $\beta$  (SEQ ID NO:24) or an active fragment thereof, or mTNRL1- $\beta$  (SEQ ID NO:26) or an active fragment thereof. A TNRL1 antisense nucleic acid molecule, which has a nucleotide sequence that is identically or substantially

complementary to a TNRL1 encoding nucleic acid or active fragment thereof, also can be used to treat or reduce the severity of a TNRL1-mediated disease.

In addition, the invention provides a method of  
5 treating or reducing the severity of a TNRL1-mediated disease in a subject by administering a TNRL1 regulatory agent to the subject. A "TNRL1 regulatory agent," as used herein, is an agent that inhibits or enhances a biological activity of a TNRL1 polypeptide. A TNRL1  
10 regulatory agent can be, for example, a TNRL1 stimulatory agent such as a soluble form of TNRL1 having a TNRL1 receptor binding domain. A TNRL1 regulatory agent also can be, for example, a TNRL1 selective binding agent that inhibits a biological activity of a TNRL1 polypeptide.  
15 Such a TNRL1 selective binding agent can be, for example, a small peptide, organic molecule or other agent which competes with TNRL1 for binding to a TNRL1 receptor but which, when bound, does not lead to receptor aggregation or signal transduction. One skilled in the art  
20 understands that a TNRL1 regulatory agent can be an agent that selectively regulates a biological activity of a TNRL1 polypeptide or, alternatively, can be a non-selective agent that, in addition to regulating a biological activity of a TNRL1 polypeptide, also  
25 regulates the activity of, for example, other TNF family ligands.

The TNRL3 encoding nucleic acids and polypeptides of the invention also can be used to diagnose, treat or reduce the severity of a  
30 TNRL3-mediated disease. For example, the TNRL3 encoding nucleic acids, polypeptides and active fragments thereof can be used for diagnosis of a TNRL3-mediated disease or can be used to generate reagents useful for such

diagnosis. Diagnosis can be performed, for example, by nucleic acid probe hybridization, or by amplification of TNRL3 encoding nucleotide sequences and subsequent electrophoretic analysis such as DNA sequencing.

- 5 Diagnosis also can be performed, for example, using antibody or ligand based detection with a TNRL3 selective binding agent. Detection can be performed *ex vivo*, for example, by removing a cell or tissue sample from an individual at risk of, suspected of having or exhibiting
- 10 one or more symptoms of a TNRL3-mediated disease. Altered TNRL3 expression or activity is indicative of a TNRL3-mediated disease. As used herein, the term "TNRL3-mediated disease" means a disease, pathology, or other condition resulting from an abnormality in the
- 15 expression or activity of a TNRL3 polypeptide. Included within the meaning of the term "TNRL3-mediated disease" are disorders of cell loss, disorders of cell accumulation and disorders of cell differentiation.

- The invention also provides a method of
- 20 treating or reducing the severity of a TNRL3-mediated disease in a subject by administering a TNRL3 polypeptide or active fragment thereof or by administering a nucleic acid molecule encoding the TNRL3 polypeptide or fragment. A TNRL3 polypeptide or nucleic acid molecule useful in
- 25 the method can be or encode, for example, an amino acid sequence identical or substantially the same as hTNRL3 (SEQ ID NO:28) or an active fragment thereof, or mTNRL3 (SEQ ID NO:30) or an active fragment thereof. A TNRL3 antisense nucleic acid molecule, which has a nucleotide
- 30 sequence that is identically or substantially complementary to a TNRL3 encoding nucleic acid or active fragment thereof, also can be used to treat or reduce the severity of a TNRL3-mediated disease.

In addition, the invention provides a method of treating or reducing the severity of a TNRL3-mediated disease in a subject by administering a TNRL3 regulatory agent to the subject. A "TNRL3 regulatory agent," as  
5 used herein, is an agent that inhibits or enhances a biological activity of a TNRL3 polypeptide. A TNRL3 regulatory agent can be, for example, a TNRL3 stimulatory agent such as a soluble form of TNRL3 having a TNRL3 receptor binding domain. A TNRL3 regulatory agent also  
10 can be, for example, a TNRL3 selective binding agent that inhibits a biological activity of a TNRL3 polypeptide. Such a TNRL3 selective binding agent can be, for example, a small peptide, organic molecule or other agent which competes with TNRL3 for binding to a TNRL3 receptor but  
15 which, when bound, does not lead to receptor aggregation or signal transduction. One skilled in the art understands that such a TNRL3 regulatory agent can be an agent that selectively regulates a biological activity of a TNRL3 polypeptide or, alternatively, can be a  
20 non-selective agent that, in addition to regulating a biological activity of a TNRL3 polypeptide, also regulates the activity of, for example, other TNF family ligands.

The present invention also provides a method of  
25 treating or reducing the severity of a disorder of cell loss. Examples of such pathologies, which can result from excessive programmed cell death, include AIDS and degenerative disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis,  
30 retinitis pigmentosa, and cerebellar degeneration. Disorders of cell loss caused by excessive programmed cell death also include myelodysplastic syndromes such as aplastic anemia and ischemic injuries such as myocardial infarction, stroke and reperfusion injury. Any such

pathology is encompassed by the term "disorder of cell loss," which, as used herein, means a disease, pathology or other condition characterized by excessive cell death or differentiation or inadequate cellular proliferation  
5 resulting in an abnormally reduced number of cells.

Thus, the invention provides a method of treating or reducing the severity of a disorder of cell loss in a subject by administering an agent that selectively decreases APO8 apoptotic activity, thereby  
10 inhibiting apoptosis in the subject. The invention also provides a method of treating or reducing the severity of a disorder of cell loss in a subject by administering an agent that selectively decreases apoptotic activity, where the apoptotic activity is selected from the group  
15 selected from APO9 apoptotic activity, APO4 apoptotic activity or APO6 apoptotic activity. Such methods can be used to treat, for example, acquired immunodeficiency syndrome, which is characterized by an increased level of apoptosis in an infected T cell as compared to a normal T  
20 cell. The methods of the invention for treating or reducing the severity of a disorder of cell loss in a subject also can be used to treat neurodegenerative disorders such as Alzheimer's disease or Parkinson's disease, the disorders of cell loss described above or  
25 another disorder of cell loss known in the art.

As used herein, an agent that "selectively decreases APO8 apoptotic activity" produces a substantially greater reduction in the apoptotic activity of an APO8 polypeptide relative to any reduction in the  
30 apoptotic activity of another polypeptide, for example, another pro-apoptotic TNF receptor such as TNFR-1. Similarly, an agent that selectively decreases APO9, APO4 or APO6 apoptotic activity produces a substantially

greater reduction in the apoptotic activity of an APO9 polypeptide, an APO4 polypeptide, or an APO6 polypeptide, respectively, relative to any reduction in the apoptotic activity of an unrelated polypeptide.

5           The present invention also provides a method of treating or reducing the severity of a disorder of increased cell accumulation. Disorders of increased cell accumulation include cancers such as lymphomas, carcinomas, and hormone dependent tumors such as breast, prostate and ovarian tumors. Additionally, autoimmune  
10       diseases, such as myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus and immune-mediated glomerulonephritis, and viral infections such as herpesvirus, poxvirus and adenovirus can be a  
15       disorder of increased cell accumulation. Pathological conditions involving smooth or cardiac muscle cells, such as hepatic necrosis vasculitis, angiogenesis, atherosclerosis and myocarditis, also can result from increased cell accumulation. Any such pathology is  
20       encompassed within the term "disorder of increased cell accumulation," which, as used herein, means a disease, pathology or other condition characterized by diminished cell death or differentiation or excess cell proliferation resulting in an abnormally high number of  
25       cells.

          Provided herein is a method of treating or reducing the severity of a disorder of cell accumulation in a subject by administering an APO8 polypeptide or active fragment thereof, or a nucleic acid molecule  
30       encoding the APO8 polypeptide or active fragment, to the subject. The present invention also provides a method of treating or reducing the severity of a disorder of cell accumulation in a subject by administering an APO9

polypeptide or active fragment thereof, or a nucleic acid molecule encoding the APO9 polypeptide or fragment, to the subject. Further provided herein is a method of treating or reducing the severity of a disorder of cell accumulation in a subject by administering an APO4 polypeptide or active fragment thereof, or a nucleic acid molecule encoding the APO4 polypeptide or fragment, to the subject. The invention also provides a method of treating or reducing the severity of a disorder of cell accumulation in a subject by administering an APO6 polypeptide or active fragment thereof, or a nucleic acid molecule encoding the APO6 polypeptide or fragment, to the subject.

The TNRL1 and TNRL3 polypeptides of the invention also can be useful in treating or reducing the severity of the disorder of cell accumulation. The present invention provides a method of treating or reducing the severity of a disorder of cell accumulation in a subject by administering a TNRL1 polypeptide or active fragment thereof, or a nucleic acid molecule encoding the TNRL1 polypeptide or fragment, to the subject. Also provided herein is a method of treating or reducing the severity of a disorder of cell accumulation in a subject by administering a TNRL3 polypeptide or active fragment thereof, or a nucleic acid molecule encoding the TNRL3 polypeptide or fragment, to the subject.

Further provided herein is a method of treating or reducing the severity of a disorder of cell accumulation in a subject by administering an agent that selectively increases APO8 apoptotic activity, thereby enhancing apoptosis in the subject. The invention also provides a method of treating or reducing the severity of

a disorder of cell accumulation in a subject by administering an agent that selectively increases apoptotic activity, where the apoptotic activity is selected from the group consisting of APO9 apoptotic activity, APO4 apoptotic activity or APO6 apoptotic activity. The present invention further provides a method of treating or reducing the severity of a disorder of cell accumulation in a subject by administering an agent that selectively increases apoptotic activity, where the apoptotic activity is selected from the group consisting of TNRL1 apoptotic activity and TNRL3 apoptotic activity. The methods of the invention for treating or reducing the severity of a disorder of cell accumulation can be used to treat, for example, cancers such as breast, prostate and ovarian tumors, lymphomas and carcinomas as well as the disorders of cell accumulation described above or another disorder of cell accumulation known in the art.

As used herein, an agent that "selectively increases APO8 apoptotic activity" means an agent that produces a substantially greater enhancement of the apoptotic activity of an APO8 polypeptide relative to any enhancement of the apoptotic activity of another polypeptide, for example, another pro-apoptotic TNF receptor such as CD27. Similarly, an agent that selectively increases APO9, APO4, or APO6 apoptotic activity produces a substantially greater enhancement of the apoptotic activity of an APO9 polypeptide, an APO4 polypeptide, or an APO6 polypeptide, respectively, relative to any enhancement of the apoptotic activity of an unrelated polypeptide. In addition, an agent that selectively increases TNRL1 or TNRL3 apoptotic activity produces a substantially greater enhancement of the apoptotic activity of a TNRL1 polypeptide or TNRL3



polypeptide, respectively, relative to any enhancement of an unrelated polypeptide such as TNF- $\alpha$ .

The following examples are intended to illustrate but not limit the present invention.

5

**EXAMPLE I****Identification and Characterization of human APO8 and APO8 related polypeptide**

This example describes the identification and characterization of nucleic acid sequences encoding  
10 full-length human APO8 and the APO8 related polypeptide APO8RP.

***Isolation and characterization of the hAPO8 cDNA***

APO8 is a human cDNA related to IMAGE consortium clones 650744 and 664665, which were derived  
15 from a Stratagene NT neuronal library. These clones were identified by searching the EST database (dbEST) for sequences with homology to the extracellular domain of human TNFR-1 protein using the TBLASTN algorithm 5' and 3' RACE was performed on human fetal brain Marathon-ready  
20 mRNA (Clontech, Palo Alto, CA) according to the manufacturer's instructions. 3' RACE was performed with primer SEQ ID NO:34

(5'-CTGTTGGATCCAGCTGAGTCTGCTCTGATCACCCAAC-3') and AP1 primer SEQ ID NO:38 (5'-CCATCCTAATACGACTCATATAGGGC-3').

25 The subsequent round of nested PCR was performed with primer SEQ ID NO:35 (5'-GGACACCATATCTCAGAAGACGGTAGAG-3') AP2 primer SEQ ID NO:36 (5'-ACTCATATAGGGCTCGAGCGGC-3').

5' RACE was performed with primer SEQ ID NO:37

(5'-TATAGTCCTGTCCATATTTGCAGGAGATG-3') and the AP1 primer

30 SEQ ID NO:38. The subsequent round of nested PCR was

performed with primer SEQ ID NO:38  
(5'-CTCTACCGTCTTCTGAGATATGGTGTCC-3') and the AP2 primer  
SEQ ID NO:36. RACE fragments were cloned into the PCR2.1  
vector using the Original TA Cloning kit (Invitrogen,  
5 Carlsbad, CA). Inserts from eight or more individual  
clones were PCR amplified using flanking vector primers  
Vn26 (SEQ ID NO:39; 5'-TTTCCCAGTCACGACGTTGTA-3') and Vn27  
(SEQ ID NO:40; 5'-GTGAGCGGATAACAATTCAC-3') and purified  
using the Wizard PCR kit (Promega, Madison, WI). The  
10 inserts were sequenced on an ABI 373 automated  
fluorescent sequencer with dye terminators using purified  
PCR product or plasmid DNA as template and primers SEQ ID  
NOS:39 and 40 as the sequencing primers. Percentage  
identity and similarity scores were obtained using the  
15 Gap program (Genetic Computer Group, Madison, WI).

The isolated full-length APO8 cDNA nucleotide  
sequence, provided as SEQ ID NO:1, encodes a polypeptide  
of 411 amino acids with characteristics of a cell surface  
receptor, including an N-terminal signal peptide of 51  
20 amino acids and a transmembrane region of 27 amino acids  
(residues 185 to 212). The context of the initiating  
methionine (CCGCCATGG) conforms to the Kozak consensus  
sequence, and an in-frame stop codon ten amino acids  
upstream of this methionine confirmed that it is the true  
25 start site. The extracellular domain (residues 52  
to 184) of hAPO8 contains the cysteine-rich  
pseudo-repeats that are a hallmark of the TNF receptor  
family and exhibits a high degree of amino acid sequence  
homology to the TRAIL receptor (DR4) (58% identity and  
30 70% similarity; Pan et al., *supra*, 1997, which is  
incorporated herein by reference). To a lesser extent,  
the extracellular domain of hAPO8 is homologous to TNFR-1  
(27% amino acid identity and 46% similarity), FAS/APO-1  
(25% amino acid identity and 45% similarity), DR3 (21%

amino acid identity and 40% similarity) and other members of the TNFR family (see Table 1). Based on this homology, the APO8 polypeptide is classified as a new member of the TNFR family.

5                   hAPO8 has a cytoplasmic tail of 212 amino acids (residues 213 to 411) with a death domain near the C-terminus. As shown in Figure 4B, the APO8 death domain exhibits significant sequence homology to the death domains of DR4, TNFR-1, FAS/APO-1 and DR3. Furthermore,  
10 several amino acids that are essential for transmission of the apoptotic signal by TNFR-1 and FAS/APO-1 also are conserved in the death domain of APO8. This includes leucine residue 334, which corresponds to the site of the *lpr* mutation in the murine FAS receptor (see Figure 4B).

15                   Expression of hAPO8 was studied by Northern analysis. A major transcript of about 4.4 kb was seen in all tissues tested, including spleen, thymus, prostate, testis, ovary, small intestine, colonic mucosa and peripheral blood lymphocyte (PBL), with the highest level  
20 of expression in PBL. A more slowly migrating minor transcript, which may represent the product of alternative splicing, was present in all tissues assayed. These results demonstrate that RNA encoding the human APO8 polypeptide is widely expressed.

25                   Northern analysis was performed using a multiple human tissue RNA blot (#7759-1) from Clontech. The blot was hybridized with a <sup>32</sup>P-labeled APO8 cDNA according to the manufacturer's instructions.

**Characterization of the APO8 related polypeptide (APO8RP)  
cDNA**

The APO8RP nucleotide sequence, shown in Figure 3A, encodes a polypeptide of 410 amino acids.

5 Alignment of the amino acid sequences of human APO8 (SEQ ID NO:2) and human APO8RP (SEQ ID NO:4) revealed that hAPO8RP exhibits substantial homology to hAPO8 throughout the entire polypeptide sequence. The hAPO8 and hAPO8RP predicted signal peptides, transmembrane regions and

10 death domains are shown in Figure 4A. In particular, the hAPO8RP signal peptide sequence (residues 1 to 51) is homologous to the hAPO8 signal peptide (residues 1 to 51), indicating that the N-terminal portion of the hAPO8RP signal is Met-Gly-Gln-His. Hydrophobicity plots

15 of the hAPO8 and hAPO8RP sequences support the conclusion that the hAPO8 signal peptide corresponds to residues 1 to 51 shown in Figure 4A and that the APO8RP signal peptide corresponds to residues 1 to 51 shown in Figure 4A. Furthermore, two artificial neural networks

20 (Nielsen et al., Protein Eng. 10:1-6 (1997), which is incorporated by reference herein), trained at recognizing eukaryotic signal peptides and their cleavage sites, identified cleavable signal peptides between amino acids 1 to 51 of APO8 and between amino acids 1 to 51 of

25 hAPO8RP, respectively. The results with hAPO8RP contrast with those of Pan et al., *supra*, 1997, which describe a related protein containing an additional 58 N-terminal residues.

Hydrophobicity plots were generated by using

30 the Pepplot program (Genetic Computer Group). Artificial neural networks analysis for recognizing the signal peptides and their cleavage sites was performed using the

Signal V1.1 World Wide Web Server (<http://www.cbs.dtu.dk/service>)

## EXAMPLE II

### APO8 and DR4 regulate NF- $\kappa$ B expression and induce FADD-dependent apoptosis

5           This example demonstrates that APO8 and APO8RP induce cell death through the cytoplasmic protein FADD. In addition, the APO8 and APO8RP polypeptides activate NF- $\kappa$ B expression.

#### ***APO8 induces apoptosis***

10           The ability of hAPO8 to induce apoptosis was assayed in the human breast carcinoma cell line MCF-7, the human embryonic kidney cell 293T subclone and the baby hamster kidney BHK cell line. Transient transfection of full-length hAPO8 induced rapid apoptosis  
15 in all three cell lines tested. In contrast, expression of an APO8 deletion mutant lacking the C-terminal 192 amino acids ("APO8 $\Delta$ CP") or an APO8 deletion mutant lacking the C-terminal 134 amino acids, which includes the death domain, ("APO8 $\Delta$ DD") failed to induce apoptosis.  
20 Exemplary results in MCF-7 cells are shown in Figure 5A. These data demonstrate that the C-terminal 134 amino acids of hAPO8 including its death domain are essential for transmitting the apoptotic signal. Furthermore, a mutant construct containing a leucine to asparagine  
25 substitution at residue 334 ("APO8-L334N") also failed to induce apoptosis (Figure 4A). Leucine 334 corresponds to the site of the *lpr* mutation and is essential for apoptotic signaling in TNFR-1, FAS/APO-1 and DR3. These results indicate that, like TNFR-1, FAS/APO-1 and DR3,  
30 leucine residue 334 is required for apoptotic activity of hAPO8.

***APO8 and APO8RP induced apoptosis is mediated by  
FADD/MORT1***

The adaptor molecule FADD/MORT1 mediates apoptosis by the death domain containing receptors

5 TNFR-1, FAS/APO-1 and DR3 either directly or through an intermediate adaptor molecule TRADD. For example, dominant negative FADD can effectively block the apoptosis mediated by these death receptors. A dominant negative FADD construct consisting of the FADD death

10 domain was tested for the ability to modulate APO8 and APO8RP mediated apoptosis in 293T cells. Increasing amounts of dominant negative FADD led to progressive inhibition of apoptosis mediated by DR3, which has previously been shown to mediate cell death through FADD.

15 As shown in Figure 5B, progressive inhibition of apoptosis was also observed for the hAPO8 and hAPO8RP receptors, with almost complete inhibition of apoptosis at a receptor to dominant negative FADD DNA ratio of 1:10. Dominant negative FADD also inhibited APO8

20 mediated apoptosis in MCF-7 cells (Figure 5C). These results demonstrate that both hAPO8 and hAPO8RP induced apoptosis is dependent upon FADD/MORT. Thus, a variety of death domain containing receptors (TNFR-1, FAS/APO-1, DR3, hAPO8 and hAPO8RP) induce apoptosis through the

25 FADD/MORT adaptor molecule.

Apoptotic signaling by the TNF receptors TNFR-1 and DR3 involves FADD-mediated recruitment of the ICE protease FLICE/MACH1 (Caspase 8) to the aggregated death receptor complex. To test whether hAPO8 induced

30 apoptosis also involves recruitment of FLICE/MACH1, the ability of a dominant negative FLICE mutant to block APO8-induced apoptosis was tested. This FLICE mutant contains a cysteine to serine substitution at the

catalytic site and is designated "FLICE-C360S." As shown in Figure 5C, this FLICE-C360S mutant was able to effectively block apoptosis mediated by APO8. In view of previous results demonstrating that FLICE interacts with FADD, these data provide further evidence that APO8-induced apoptosis relies on a FADD-dependent pathway.

Several caspase inhibitors, z-VAD-fmk and CrmA, have previously been shown to block apoptosis of TNF death receptors. The ability of these caspase inhibitors to effect APO8 mediated apoptosis was assayed, and the results are shown in Figure 5C. These results demonstrate that z-VAD-fmk and CrmA each inhibit APO8-induced apoptosis, indicating that APO8 causes cell death through a caspase-dependent pathway.

Myc and 6X-His epitope tagged APO8 constructs were prepared by amplifying amino acids 51 to 411 of APO8 using *pfu* polymerase (Stratagene, La Jolla, CA) with a 5' primer containing a BamHI site and a 3' primer containing a SalI site. The amplified APO8 fragment was subsequently ligated to a modified pSecTag A vector (Invitrogen) containing a Myc or an MRG-6XHis epitope tag downstream of a murine Ig  $\kappa$ -chain signal peptide. The APO8-L334N construct, which has a leucine to asparagine mutation at residue 334, was generated by mutagenesis of the 6X-His-APO8 plasmid with primers SEQ ID NO:41 (5'-CGCTCATGAGGAAGTTGGGCAACATGGACAATGAGATAAAG-3') and SEQ ID NO:42 (5'-CTTTATCTCATTGTCCATGTTGCCCAACTTCCTCATGAGCG-3') using the Quickchange kit (Stratagene) according to the manufacturer's instructions. Deletion construct APO8 $\Delta$ CP lacks the 192 C-terminal residues of full-length APO8 and was constructed by creating a PCR generated XbaI site in the wild type APO8 sequence. Deletion construct APO8 $\Delta$ DD

lacks the C-terminal 134 residues of APO8 and was prepared using a naturally occurring SmaI site in the APO8 sequence. The sequences of each of the above constructs were confirmed by automated fluorescent  
5 sequencing.

Epitope-tagged versions of APO8RP (amino acids 52 to 410), DR3 (amino acids 27 to 418) and FAS/APO1 (amino acids 19 to 335) were constructed as described above for the APO8 expression vector except that the 5'  
10 primer for amplifying Fas/APO1 contained an EcoRI site and the resulting PCR product was cloned into the EcoRI and SalI sites of the modified pSecTag A vector.

The dominant negative FADD construct (DN-FADD) encodes amino acids 80 to 208 of human FADD in pCDNA3  
15 (Invitrogen) and was prepared by Michael Wright of the University of Washington. The FLICE-C360S mutant, which contains a cysteine to serine substitution at residue 360, was prepared with primers SEQ ID NO:43 (5'-GTGTTTTTTTATTCAGGCTAGTCAGGGGGATAACTACCAGAA-3') and SEQ  
20 ID NO:44 (TTCTGGTAGTTATCCCCCTGACTAGCCTGAATAAAAAACAC-3') using Stratagene's Quickchange kit. The N-terminal TRADD deletion mutant ND-TRADD-HA, which lacks the N-terminal 102 amino acids, and RIP-HA tagged constructs were prepared using custom primers designed to generate a  
25 C-terminal HA-tag. The sequence of each of the above constructs was confirmed by automated fluorescent sequencing.

For transient transfection assays,  $0.8-1 \times 10^5$  MCF-7 or BHK cells were cotransfected with 1  $\mu$ g of  
30 various test plasmids and 200 ng of a lacZ expression plasmid in a 24-well plate using 3  $\mu$ l of Superfect (Qiagen, Santa Clarita, CA) in DMEM supplemented with 10%



FCS essentially according to the manufacturer's instructions. After 3 hr, 0.5 ml of fresh DMEM supplemented with 10% FCS was added. Twenty-four to thirty-six hours later, cells were fixed with 0.05% glutaraldehyde in PBS and stained with 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactosidase (X-GAL). For transient transfection of 293T cells,  $1 \times 10^5$  cells were transfected by calcium phosphate precipitation in a 24-well plate essentially as described in Sambrook et al., *supra*, 1989. The data shown in Figure 5A represent the mean  $\pm$  the standard deviation determined from three independent experiments performed in duplicate. The percentage of apoptotic cells was calculated as the percentage of cells showing  $\beta$ -galactosidase activity and apoptotic morphology as indicated by a round and condensed shape as compared to the total number of blue staining cells.

For the dominant negative FADD experiments shown in Figure 5B, 150 ng of each receptor (APO8, APO8RP or DR3) was transfected into 293T cells with 150 ng, 750 ng or 1500 ng of DN-FADD DNA. The total amount of DNA in each transfection was held constant by adding control vector plasmid DNA. The results shown in Figure 5B are representative of two independent experiments performed in duplicate.

For the inhibition experiments shown in Figure 5C, MCF-7 cells were transfected with the Myc-APO8 expression construct and a control empty expression vector or an expression vector encoding DN-FADD, FLICE-C360S or CrmA. For experiments with the protease inhibitor z-VAD-fmk, cells transfected with Myc-APO8 and the control vector were treated with 20  $\mu$ M z-VAD-fmk twelve hours after transfection. Cells were transfected

and scored for apoptotic morphology as described above. The data shown in Figure 5C are representative of three independent experiments performed in duplicate.

***APO8 and APO8RP activate NF- $\kappa$ B by a TRADD dependent***

***5 pathway***

Activation of TNFR-1 and DR3 has been shown to induce NF- $\kappa$ B expression, and NF- $\kappa$ B activation can block apoptosis. To test the possibility that APO8 can regulate NF- $\kappa$ B expression, APO8 expression constructs  
10 were cotransfected into 293T cells with a NF- $\kappa$ B luciferase reporter containing four copies of an NF- $\kappa$ B binding site. As shown in Figure 5D, overexpression of APO8 produced significant activation of NF- $\kappa$ B in 293T cells, while C-terminal deletion mutants APO8 $\Delta$ CP and  
15 APO8 $\Delta$ DD and the APO8-L334N point mutant did not activate NF- $\kappa$ B. Similarly, overexpression of APO8RP activated NF- $\kappa$ B as compared to control expression vector (see Figure 5D). These results show that APO8 activates NF- $\kappa$ B expression and that the APO8 death domain is required for  
20 this activation. In addition, these results show that APO8RP, in contrast to the DR4 receptor described in Pan et al., *supra*, 1997, also activates NF- $\kappa$ B expression.

NF- $\kappa$ B activation experiments were performed as follows using a NF- $\kappa$ B luciferase reporter with four NF- $\kappa$ B  
25 binding sites and a minimal thymidine kinase promoter (Berberich et al., *J. Immunol.* 153:4357-4366 (1994), which is incorporated herein by reference). 293T cells were cotransfected in duplicate as described above with 0.5  $\mu$ g of Myc-tagged or 6XHIS-tagged receptor expression  
30 construct, 0.5  $\mu$ g NF- $\kappa$ B reporter construct and 0.2  $\mu$ g lacZ expression construct. After eighteen hours, cells in one well were fixed and stained with X-GAL to

determine the relative transfection efficiency. Cell extracts were prepared from the duplicate well and analyzed for luciferase activity using the Luciferase Assay system (Promega, Madison, WI) following the manufacturer's instructions. Shown in Figure 5D is the mean +/- standard deviation calculated from three independent representative experiments.

***Dominant negative TRADD can block NF- $\kappa$ B activation by APO8, APO8RP, and DR3***

As described above, the death domain of APO8 is required for APO8-mediated apoptosis and for NF- $\kappa$ B activation. TNFR-1 and DR3 mediated apoptosis and NF- $\kappa$ B activation also are mediated through the TNFR-1 and DR3 death domains, and may be a result of death domain recruitment of TRADD (Kitson et al., Nature 384:372-375 (1996); Tartaglia et al., Cell 74:845-853 (1993), each of which is incorporated herein by reference). TRADD can activate the apoptotic pathway through FADD and can activate the NF- $\kappa$ B pathway through RIP and TRAF2 (Hsu et al., Cell 84:299-308 (1996); Liu et al., Cell 87:565-576, each of which is incorporated herein by reference).

A TRADD mutant deleted for the N-terminal 102 residues (ND-TRADD) lacks a complete TRAF2-binding domain but has a complete RIP/FADD-binding death domain (Liu et al., *supra*, 1996). This TRADD mutant may function as a dominant negative by competing with endogenous full-length TRADD for binding to receptor death domains but failing to effectively recruit TRAF2. The ability of dominant negative TRADD (ND-TRADD) to block NF- $\kappa$ B activation by APO8, APO8RP and DR3 was tested in 293T cells.

Briefly, 293T cells were cotransfected in duplicate with an appropriate receptor and ND-TRADD along with NF- $\kappa$ B (0.5  $\mu$ g) and lacZ (0.2  $\mu$ g) reporter constructs. The receptor-to-ND-TRADD ratio was 1:5 (0.15  $\mu$ g to 0.75  $\mu$ g). The total amount of plasmid was kept constant by adding vector DNA without insert. Eighteen hours post transfection, luciferase activity was measured from one of the duplicate wells using the luciferase assay reagent (Promega) and following the manufacturer's instructions. The cells in the other well were fixed with glutaraldehyde and stained with X-gal to obtain the relative transfection efficiency. Results (mean  $\pm$  SD) are from at least four independent experiments.

The results showed that ND-TRADD effectively blocked NF- $\kappa$ B activation by all three death domain receptors. Weak NF- $\kappa$ B activation was observed with ND-TRADD transfected alone in 293T cells, possibly as a result of the ability of ND-TRADD to recruit RIP and, indirectly, TRAF2 through death domain-death domain interactions (Liu et al., *supra*, 1996). In sum, these results indicate that APO8 and APO8RP resemble DR3 and TNFR-1 in activating NF- $\kappa$ B through a TRADD-dependent pathway.

***AP08 and APO8RP interact directly with TRADD and RIP but not with FADD***

Coprecipitation experiments were conducted to assay whether APO8 or APO8RP interacts directly with the FADD, TRADD or RIP adaptor molecules. Under conditions which supported the interaction of His epitope tagged FAS/AP01 with FADD, both His tagged APO8 and APO8RP failed to coprecipitate AUI-tagged FADD (AUI-FADD). In contrast, HA-tagged ND-TRADD or RIP were coprecipitated

with APO8 or APO8RP. Furthermore, both APO8 and APO8RP co-immunoprecipitated FADD in the presence of ND-TRADD. Thus, these results show that both APO8 and APO8RP, like DR3 and TNFR-1, directly bind TRADD and RIP and indirectly bind FADD through TRADD. The results with APO8RP are contrary to the results reported in Pan et al., *supra*, 1997, with the DR4 receptor. In sum, FADD appears to be the common mediator of apoptosis by all known death domain-containing receptors.

Coimmunoprecipitation experiments between receptors and various adaptor molecules were performed as follows. 293T cells ( $2 \times 10^6$ ) were plated in a 10 mm plate and cotransfected the following day with 5  $\mu$ g of various epitope tagged receptor plasmids or control vector lacking receptor sequence; 5  $\mu$ g of various adaptor plasmids; 2  $\mu$ g of Crm-A plasmid; and 0.5  $\mu$ g of a Green Fluorescent Protein (GFP) encoding plasmid (pEGFP-N1, Clontech) by calcium phosphate coprecipitation. The following day, cells were examined under a fluorescent microscope to ensure equal transfection efficiency as determined by the expression of the GFP. Twenty-four to thirty-six hours post-transfection, cells were lysed in 1 ml of lysis buffer containing 1% Triton X-100, 20 mM sodium phosphate (pH 7.4), 150 mM NaCl and 1 EDTA-free protease inhibitor tablet per 10 ml (Boehringer Mannheim, Indianapolis, IN), and the cell lysate cleared by centrifugation.

For immunoprecipitation, pre-cleared cells lysate (600  $\mu$ l) was incubated with 2  $\mu$ g of anti-Myc monoclonal 9E10 (American Type Culture Collection, Rockville, MD) for 2 hr at 4°C. The lysate was subsequently incubated for 1 hour with 10  $\mu$ l of Protein A/G ultralink beads (Pierce, Rockford, IL) pre-coated

with 1% BSA to reduce nonspecific binding. Beads were washed twice with lysis buffer, followed by two washes in buffer containing 1% Triton X-100, 20 mM sodium phosphate (pH 7.4) and 500 mM NaCl and once with a buffer  
5 containing 20 mM Tris-HCl (pH 7.4). Bound proteins were eluted by adding 70  $\mu$ l of 0.1 M glycine (pH 3.5) and subsequently neutralized with 10  $\mu$ l of 1 M Tris-HCl (pH 8.0). Samples were separated by SDS-PAGE, transferred to a nitrocellulose membrane and analyzed by Western blot  
10 analysis. For immunoprecipitation of MRG-6XHis tagged receptors, a cocktail of three monoclonal antibodies (MRG-4XHis, Penta-His and Tetra-His; Qiagen) was used. For precipitation using Nickel-sepharose, cell lysates were incubated for 1 hour with 20  $\mu$ l of Ni-sepharose beads  
15 pre-coated with 1% BSA in a buffer containing 1 % Triton X-100, 20 mM sodium phosphate (pH 7.4), 500 mM NaCl and EDTA-free protease inhibitor cocktail. Beads were washed extensively with the above buffer supplemented with 20 mM imidazole, and the bound protein subsequently eluted and  
20 analyzed by SDS-PAGE and Western blot analysis as described above.

***NF- $\kappa$ B expression protects against APO8-mediated apoptosis***

293T cells were transfected with APO8  
25 expression vector in the presence or absence of an NF- $\kappa$ B expression vector. Thirty-six hours later, cells were fixed and stained and morphology observed. Apoptotic morphology was observed in about 55% of APO8-transfected cells in the absence of NF- $\kappa$ B, while only about 30% of  
30 APO8-transfected cells were apoptotic when co-transfected with NF- $\kappa$ B. These results indicate that NF- $\kappa$ B protects against APO8-mediated cell killing.

Cell transfections were performed as described above using  $1 \times 10^5$  293T cells and 150 ng APO8 expression vector, 750 ng NF- $\kappa$ B expression vector or control empty vector, and 200 ng lacZ encoding plasmid in 24 well plates. After thirty-six hours, cells were fixed and stained and the percent apoptotic cells determined as described above.

***Myc-APO8RP is expressed on the cell surface and binds TRAIL ligand***

The cytotoxic ligand TRAIL has been shown to bind the DR4 receptor based on the ability of a soluble DR4 construct to coimmunoprecipitate TRAIL and to block TRAIL-induced apoptosis in MCF-7 cells. Direct binding of APO8RP to TRAIL was assayed by preparing a stable BHK cell line expressing Myc-epitope tagged APO8RP. Cell-surface expression of APO8RP was confirmed by immunofluorescence staining with an anti-Myc antibody using FACS analysis. Subsequently, the ability of FLAG-epitope tagged TRAIL (FLAG-TRAIL) to bind the APO8RP transformant was tested using immunofluorescence staining with an anti-FLAG antibody. The results demonstrated that FLAG-TRAIL binds Myc-APO8RP. These results demonstrate that APO8RP, like DR4, binds the TRAIL ligand.

Epitope tagged TRAIL protein was prepared as follows. A PCR fragment encoding amino acids 96 to 281 of TRAIL was cloned into a modified pET28(b) vector (Novagen Madison, WI), which has a FLAG epitope downstream of the His epitope, and the sequence confirmed by automated fluorescent sequencing. The His-FLAG-TRAIL protein was purified by Nickel-affinity chromatography according to the manufacturer's instructions.

Stable cell lines were generated by cotransfecting  $2 \times 10^5$  BHK cells with 1.5  $\mu$ g of a Myc-epitope tagged APO8RP expression vector or control vector lacking the receptor coding sequence and 300 ng of an expression vector encoding human DHFR gene using Superfect (Qiagen) according to the manufacture's instructions. Stable transformants were selected in 1  $\mu$ M methotrexate (Sigma, St. Louis, MO) in DMEM supplemented with 5% dialyzed fetal calf serum. After 10 to 12 days colonies were pooled to generate a mass culture.

Expression of the Myc-APO8RP construct was analyzed by FACS after indirect immunofluorescence labeling using the anti-Myc epitope antibody mAb 9E10 obtained from American Type Culture Collection or a control monoclonal antibody, followed by R-phycoerythrin (R-PE) labeled goat anti-mouse antibody (Fisher). Binding of FLAG-TRAIL (2  $\mu$ g) to the Myc-APO8RP expressing stable cell lines was detected similarly using the anti-FLAG M2 antibody (IBI Kodak, New Haven, CT) as the primary antibody and R-PE-labeled goat anti-mouse antibody as the secondary antibody.

### EXAMPLE III

#### Identification and Characterization of APO9

This example describes the identification and characterization of alternatively spliced forms of APO9.

APO9 is a human cDNA related to IMAGE consortium clones 470799, 504745, 110226 and 129137, which are clones with homology to human Fas antigen. The partial amino acid sequence of hAPO9S encodes a signal peptide at the 5' end and a hydrophobic transmembrane region at the 3' end as shown in Figure 6. In addition,



the hAPO9S sequence has a stop codon immediately after the transmembrane region. Thus, the hAPO9S cDNA can represent an alternatively spliced non-functional receptor isoform that competes with the full-length  
5 receptor for ligand binding.

In its extracellular domain, the hAPO9S amino acid sequence demonstrates significant homology to the extracellular domains of several members of the TNFR family. The greatest degree of homology is seen with the  
10 DR4 receptor, with which it shares 57% amino acid sequence identity and 71% amino acid sequence similarity (see Figure 1 and Table 1). Based on this homology, the APO9S cDNA is classified as a new member of the TNFR family.

15

#### EXAMPLE IV

##### Identification and Characterization of APO4 polypeptides

This example describes the identification and characterization of nucleic acid sequences encoding the  
20 short and long isoforms of murine, rat and human APO4- $\alpha$  and murine APO4- $\beta$ . In addition, the ability of hAPO4 to induce cell death through activation of the JNK pathway and the ability of hAPO4 to activate NF- $\kappa$ B expression is demonstrated.

##### 25 *Characterization of murine APO4- $\alpha$ and mAPO4- $\gamma$*

mAPO4 are murine cDNAs related to IMAGE consortium EST clones 472300 and 427152, which are mouse embryo-derived sequences with homology to the human DR3 receptor. These clones were identified by searching the  
30 EST database (dbEST) for homology to the extracellular domain of human DR3 using the TBLASTN algorithm.

The mAPO4- $\alpha$ S cDNA is represented by IMAGE consortium EST clone 472300 and has an open reading frame of 214 amino acids (Figure 7B), including an amino-terminal signal-peptide; cysteine-rich pseudo-repeats with significant homology to other members of TNFR family (20-24% sequence identity and 35-46% sequence similarity); a highly hydrophobic stretch of amino-acids representing the transmembrane region; and a short cytoplasmic tail.

10 The mAPO4- $\gamma$  cDNA is represented by the IMAGE consortium EST clone 427152 and has an open leading frame of 150 amino acids. The amino acid sequence of mAPO4- $\gamma$  is identical to the mAPO4- $\alpha$  form with the N-terminal 149 amino acids containing the signal peptide and the  
15 cysteine-rich pseudo repeats representing the majority of the ligand binding domain. However, mAPO4- $\gamma$  has a stop codon after amino acid 150 and thus represents a soluble receptor lacking a transmembrane domain.

No polyadenylation signal was observed at the  
20 3' end of mAPO4- $\alpha$ S, indicating that the stop codon present in the 3' end can be the result of alternative splicing. 3' Rapid Amplification of cDNA Ends (RACE) was used on murine spleen marathon-ready cDNA to isolate the full length cDNA. The full length cDNA has an open  
25 reading frame of 416 amino acids and a unique cytoplasmic tail with no significant homology to other members of TNF receptor family (Figure 7A). Thus, mAPO4- $\alpha$  is a type I membrane protein, having short and long forms. The long mAPO4- $\alpha$  form can have an important role in the regulation  
30 of the immune system, while the short form of the receptor is a decoy receptor which can compete with the long (full-length) form for ligand binding, thereby

modulating signal-transduction through the full-length receptor.

The full-length mAPO4- $\alpha$  (mAPO4- $\alpha$ L) sequence was obtained using 3' RACE and murine spleen Marathon-ready cDNA (Clontech) according to the manufacturer's instructions. Primer SEQ ID NO:45 (5'-CCCACCTCCTCCCTACGAACCACACTG-3') was used with AP1 primer SEQ ID NO:34 in a first round of PCR. Primer SEQ ID NO:46 (5'-GGCTGCTCGCCCTGCTCATCCTGTGTGT-3') and AP2 primer SEQ ID NO:36 were used in a subsequent round of nested PCR. RACE fragments were cloned into the PCR2.1 vector using the Original TA Cloning kit (Invitrogen). Inserts from eight or more individual clones were PCR amplified using flanking vector primers Vn26 (SEQ ID NO:39; 5'-TTTCCCAGTCACGACGTTGTA-3') and Vn27 (SEQ ID NO:40), and the amplified fragments purified using the Wizard PCR Preps kit (Promega). The inserts were sequenced on an ABI 373 automated fluorescent sequencer with dye terminators using the purified PCR products or plasmid DNA as template with the Vn26 (SEQ ID NO:39) and Vn27 (SEQ ID NO:40) primers as sequencing primers.

***mAPO4- $\alpha$ L is a cell surface receptor***

To demonstrate that mAPO4- $\alpha$ L is a cell surface receptor, Myc-AU1 tagged mAPO4- $\alpha$ L was expressed in BHK cells. Cell surface expression was confirmed by immunofluorescence labeling with the Myc monoclonal antibody 9E10 (American Type Culture Collection). These results show that mAPO4- $\alpha$ L is a cell surface receptor.

The Myc-AU1 tagged mAPO4- $\alpha$ L construct was prepared by PCR amplifying the protein coding region of the mature APO4- $\alpha$ L polypeptide with a 5' primer containing a BamHI site and encoding the AU1 tag and a 3'

primer containing a XhoI site using *pfu* polymerase (Stratagene). The 5' primer was SEQ ID NO:47 (5'-GGATCCAGACACATACCGCTACATTGCATGTAAAGTGAGTTGCGAAACC-3', and the 3' primer was SEQ ID NO:48 (5'-GAAGCTCGAGGCTGAAAGTATGGAAGTGCTG-3'). The resulting amplified product was digested with BamHI and XhoI and ligated to a BamHI/XhoI digested pSecTag A vector modified to include a Myc tag as described above.

#### ***Characterization of human APO4- $\alpha$***

10 Human APO4- $\alpha$  (hAPO4- $\alpha$ ) is encoded by a cDNA sequence related to IMAGE consortium clone 340844, which was identified by searching the EST database (dbEST) for sequence homology to the cytoplasmic tail of full-length mAPO4- $\alpha$  protein using the TBLASTN algorithm. The  
15 full-length nucleotide sequence encoding hAPO4- $\alpha$  is shown in Figure 7A. This hAPO4- $\alpha$  nucleotide sequence (Figure 7C) encodes a hAPO4- $\alpha$  polypeptide of 423 amino acids having 68.4% amino acid identity and 79.2% amino acid sequence similarity with mAPO4- $\alpha$ .

20 The full-length hAPO4- $\alpha$  sequence was obtained using 5' RACE and human fetal spleen Marathon-ready cDNA (Clontech) according to the manufacturer's instructions. Primer SEQ ID NO:49 (5'-TAGCTGGCTTCTCATAGTTAGTGC-3') and AP1 primer SEQ ID NO:34 were used for the first round of  
25 PCR. Primer SEQ ID NO:50 (5'-CCTGAGTTGATGCTGATTCTACCA-3') and AP2 primer SEQ ID NO:36 were used for a subsequent round of nested PCR. Inserts from eight or more individual clones were PCR amplified and sequenced essentially as described above.

***Characterization of rat APO4- $\alpha$*** 

Rat APO4- $\alpha$  (mAPO4- $\alpha$ ) is another APO4 polypeptide; the rAPO4- $\alpha$  cDNA is related to IMAGE consortium clone 319945 which was identified by searching  
5 the EST database (dbEST) for sequences with homology to the cytoplasmic tail of mAPO4- $\alpha$  protein using the TBLASTN algorithm. The partial cDNA sequence, shown in Figure 7D, lacks the 5' region. The partial rAPO4- $\alpha$  nucleotide sequence shares 95% amino acid sequence identity and  
10 about 81% nucleotide sequence identity with the cytoplasmic domain of mAPO4- $\alpha$ .

***Characterization of murine APO4- $\beta$*** 

Murine APO4- $\beta$  (mAPO4- $\beta$ ) is another APO4 polypeptide; the mAPO4- $\beta$  cDNA is related to IMAGE  
15 consortium clone 835418, derived from a Knowles Solter mouse blastocyst library. The IMAGE consortium clone was identified as described above. The partial cDNA sequence, shown in Figure 8, represents the carboxy-terminal 54 residues of the polypeptide. The  
20 encoded polypeptide fragment bears about 77% amino acid sequence identity and about 81% amino acid similarity with mAPO4- $\alpha$ . The mAPO4- $\beta$  fragment also bears about 74% amino acid identity and about 80% amino acid similarity with rAPO4- $\alpha$ .

***APO4 Expression in Adult and Embryonic Tissues***

Expression of APO4 in adult human tissues was studied by northern analysis using a multiple tissue northern blot obtained from Clontech (7759-1) following the manufacturer's instructions. The protein coding region of hAPO4 cDNA was radiolabeled with P<sup>32</sup> and used as a probe. High level APO4 expression was seen in the prostate gland, with very low expression seen in other tissues including spleen, thymus, testis, uterus, small intestine, colon and peripheral blood leukocytes.

The prostate gland consists primarily of fibroblast-like stromal cells and glandular epithelial cells, with the latter being the site of origin of prostatic carcinoma. Reverse-transcriptase/polymerase chain reaction (RT-PCR) was used to test the expression of hAPO4 in a prostate carcinoma derived epithelial cell line, LNCaP (ATCC, Bethesda, MD). Total RNA isolated from LNCaP cells was used for the first strand cDNA preparation using random hexamer primers and Superscript II Reverse Transcriptase (Life Technologies). The RT-PCR procedure was performed following the manufacturer's instruction with forward primer SEQ ID NO:57 (5'-GTCATGTAAAGTGAAGTGTG-3') and reverse primer SEQ ID NO:58 (5'-GAGCCGTTGTACTGAATGTCCTG-3'). A specific band corresponding to hAPO4 was detected in RNA from LNCaP cells, indicating that APO4 is expressed in epithelial derived prostate cancer cell lines. Essentially similar results were obtained in another prostate cancer cell line, P65.

APO4 expression during embryonic development was assayed by northern analysis of a multiple tissue

northern blot obtained from Clontech (7763-1), which contained polyA RNA from day 7, 11, 15 and 17 mouse embryos. The protein coding region of mAPO4 cDNA was radiolabeled with P<sup>32</sup> and used as a probe. A strong  
5 signal was detected in samples containing RNA from day 11, 15 and 17 embryos, indicating that APO4 is expressed during early embryonic development.

*hAPO4 induces apoptosis*

The ability of hAPO4 to induce apoptosis was  
10 assayed following transient transfection into the human embryonic kidney 293T cell line. Plasmids encoding various inhibitors were cotransfected to test for their ability to modulate hAPO4 mediated apoptosis in 293T cells.

15 A mammalian expression construct encoding human APO4 was constructed by amplifying the sequence encoding amino acids 23 to 423 of hAPO4 with a 5' primer containing a Bgl II site and a 3' primer containing a stop codon followed by a Sal I site, as described  
20 previously for the APO8 construct. Following digestion of the PCR product with Bgl II and Sal I, the resulting product was inserted into a modified pSecTag A vector as described previously.

Expression of the APO4 polypeptide described  
25 above was confirmed by transfecting the above construct into 293T cells using calcium phosphate transfection. After 24 hours, cell lysates were prepared, the proteins resolved by SDS-PAGE, and MYC-tagged hAPO4 detected by western blot analysis using rabbit polyclonal antibody  
30 against the MYC epitope tag (Santa Cruz Biotechnology, Inc., Santa Cruz, California) following the

manufacturer's instructions. A single band of approximately 55 kDa was detected in cells transfected with the MYC-APO4 construct.

Constructs encoding various inhibitor plasmids were prepared as follows. A K13-ORF (GenBank U90534) was prepared by PCR amplification of the desired coding sequence from a human genomic DNA sample containing KSHV/HHV8 (human herpesvirus 8) genomic DNA (obtained from Dr. Tim Rose; University of Washington, Seattle, WA). Primers for PCR amplification were based on the published sequence of K13-ORF with additional 5' sequence for subsequent restriction digestion and cloning of the amplified insert. Constructs encoding p35 were prepared by using a baculovirus vector pFastBac HTa (Life Technologies, Inc.) as the template. DN-I $\kappa$ B $\alpha$  or I $\kappa$ B $\alpha$ - $\Delta$ N (missing the N-terminal 36 amino acids) and I $\kappa$ B $\alpha$ -S32/36A (Brockman et al., Mol. Cell. Biol., 15: 2809-18, 1995); NF $\kappa$ B driven luciferase reporter construct (Berberch et al., J. Immunol., 153:4357-66, 1994); an active site mutant of full-length rat MEKK1 (MEKK1-D1369A) (Xu et al., Proc. Natl. Acad. Sci. USA, 93:5291-5295) and the JNK binding domain of JIP-1 have been described previously (Dickens et al., Science 277:693-696, 1997). DN-mTRAF2, which encodes a TRAF2 polypeptide lacking the first 87 amino acids, was generated by amplifying the DNA encoding amino acids 88 to 501 of mTRAF2 using the IMAGE consortium EST clone 439083 as a template and incorporating a start site (i.e. methionine residue) at the N-terminus.

Cell transfection was performed using calcium phosphate coprecipitation (Sambrook et al., *supra*, 1989). Briefly, 293T cells ( $1.2 \times 10^5$  cells) were cotransfected with 100 ng/well hAPO4 expression plasmid or control



plasmid along with lacZ reporter plasmid and 750 ng/well empty vector or one of various inhibitor plasmids (p35, Caspase 8 C360S, dominant-negative FADD (DN-FADD), MRIT $\alpha$ 1, K13-ORF, DN-I $\kappa$ B $\alpha$ , JNK binding domain (JBD) of JIP-1, BCLxL or the p65 subunit of NF- $\kappa$ B) and lacZ reporter plasmid and were assayed for hAPO4-induced apoptosis. Thirty-six hours after transfection, cells were fixed and stained with X-gal, and the percentage apoptotic cells determined as described previously.

The results shown in Figure 14A indicate that hAPO4 induces cell death and that the hAPO4-induced apoptosis is activated independently of the FADD-Caspase pathway. In particular, several inhibitors of the FADD-Caspase pathway (caspase 8 C360S, DN-FADD, p35, K13-ORF and MRIT $\alpha$ 1), when cotransfected with hAPO4, failed to block APO4-mediated cell death. These results demonstrate that, unlike a variety of receptors of the TNF family, APO4 can mediate apoptosis independently of the FADD-caspase pathway.

#### ***hAPO4 activates the Jun N-terminal kinase (JNK) pathway***

Activation of the JNK pathway by hAPO4 was measured using the PathDetect c-Jun Trans-Reporting system (Stratagene, La Jolla, CA). Briefly,  $1.2 \times 10^5$  293T EBNA cells were cotransfected in duplicate with 250 ng/well of hAPO4 expression vector and 750 ng/well of empty vector or inhibitor plasmid (JBD of JIP-1, MEKK1-D1269A, or DN-TRAF2). A fusion-transactivator plasmid containing the GAL4 DNA-binding domain fused to the c-Jun transcription factor (pFA-cJun, 50 ng), a reporter plasmid encoding the luciferase gene downstream of the GAL4 Upstream Activating sequence (pFR-luc,

500 ng) and a  $\beta$ -galactosidase (pRSV/LacZ) reporter construct (75 ng) were also included in the cotransfection. Forty hours after transfection, cell extracts were prepared and luciferase and  $\beta$ -galactosidase activities measured. The luciferase activity was normalized relative to the  $\beta$ -galactosidase activity to control for differences in transfection efficiency.

As shown in Figure 14B, expression of hAPO4 produced significant activation of c-jun. Furthermore, cotransfection of hAPO4 with JBD-JIP, and to a lesser extent with MEKK1-D1369A or DN-TRAF2, prevented APO4-mediated activation of the JNK pathway. These results indicate that APO4-induced apoptosis can be mediated through activation of the JNK pathway and MEKK1.

#### 15 ***hAPO4 induces NF- $\kappa$ B***

To test the possibility that APO4 can regulate NF- $\kappa$ B expression, hAPO4 expression constructs were cotransfected into 293T cells with a NF- $\kappa$ B luciferase reporter. Transfection and NF- $\kappa$ B activation experiments were performed as described previously. Inhibitor plasmids (DN-TRAF2 or I $\kappa$ B $\alpha$ -S32/36A) were also cotransfected to determine whether inhibition of the TRAF2 or JNK pathway affects NF- $\kappa$ B activation by hAPO4. As shown in Figure 14C, hAPO4 induced NF- $\kappa$ B expression, and this activation was not blocked by dominant-negative TRAF2. Also as shown in Figure 14C, hAPO4 failed to activate NF- $\kappa$ B in the presence of I $\kappa$ B-S32/36A, an I $\kappa$ B mutant that resists degradation in response to activators of NF- $\kappa$ B. These results demonstrate that APO4 can function, at least in part, through activation of NF- $\kappa$ B. Given the multiple roles of NF- $\kappa$ B and the high level of APO4 expression in embryonic development, these results

indicate that APO4 can stimulate growth in certain contexts, in addition to its pro-apoptotic role described above.

#### ***Deletion analysis of APO4***

5           To determine the domains of APO4 which are responsible for JNK activation and apoptosis, deletion analysis was carried out using the following constructs: pSecTag-MYC-APO4 encoding amino acid 23 to 423; pCDNA3.1 HisA-APO4.CP encoding the cytoplasmic domain of APO4  
10 (amino acids 194 to 423); pSecTag-MYC-APO4-C377 encoding amino acids 23 to 377; pSecTag-MYC-APO4-C355 encoding amino acids 23 to 355; pSecTag-MYC-APO4-C286 encoding amino acids 23 to 286; pSecTag-MYC-APO4-C172 encoding the extracellular domain (amino acids 23 to 172).

15           These constructs were prepared by PCR amplification of the nucleic acid fragment encoding the designated amino acids using custom primers with appropriate restriction enzyme containing sites and by using human APO4 cDNA as template. The desired PCR  
20 fragment was subsequently cloned into the modified pSecTag vector described previously or the pCDNA3.1 HisA vector (Invitrogen).

          The constructs were subsequently tested for  
25 their ability to activate the JNK pathway in 293EBNA cells as described above. The results indicated that, while the full-length APO4 and its cytoplasmic domain were able to activate the JNK pathway, the construct encoding the extracellular domain failed to do so.  
30 Furthermore, the pSecTag MYC-APO4-C286 failed to significantly activate the JNK pathway although the

pSecTag MYC-APO4-C377 and C355 constructs could do so.  
could.

The above constructs were also tested for their ability to induce cell death in the 293T cells using the  
5 assay described before. While the full-length APO4 polypeptide, its cytoplasmic domain, C377, and C355 constructs were able to effectively induce cell death, the C286 and the C172 constructs were inactive. These results indicate that the C-terminal 68 amino acids are  
10 not essential for the APO4-induced activation of the JNK pathway or apoptosis and that these activities reside among the amino acids 194 to 355.

#### EXAMPLE V

##### 15 Identification and Characterization of APO6

This example describes the identification and characterization of a nucleic acid sequence encoding human APO6.

Human APO6 (hAPO6) is a cDNA related to IMAGE  
20 consortium clones 366305, 592256, 343204 and 591875, which have some similarity with the extracellular domain of human TNFR-2. These clones were identified by searching the EST database (dbEST) for sequences with homology to the extracellular domain of human TNFR-2  
25 protein using the TBLASTN algorithm. The partial nucleotide sequence, lacking both 5' and 3' sequence, is shown in Figure 9. The partial hAPO6 sequence shows significant homology to the extracellular domains of TNFR-2, TNFR-1, and other members of the TNFR family  
30 (about 16-33% amino acid sequence identity and about 30-50% amino acid sequence similarity) (Figure 1 and Table

1). Based on this homology, hAPO6 is classified as a new member of the TNFR family.

#### EXAMPLE VI

##### Identification and Characterization of Tumor Necrosis

5

##### Factor Related Ligands

This example describes the identification and characterization of nucleic acid sequences encoding human and murine TNRL1- $\alpha$  and TNRL1- $\beta$ . This example also demonstrates that human TNRL1- $\alpha$  is a cytotoxic ligand.

#### 10 *Characterization of human TNRL1- $\alpha$*

Human tumor necrosis factor related ligand 1- $\alpha$  (hTNRL1- $\alpha$ ) is encoded by a cDNA clone related to IMAGE consortium clones 593690, 115371 and 129696, which are clones with homology to human TNF- $\alpha$ . The full length  
15 cDNA encodes a predicted protein of 285 amino acids with significant sequence homology to TNF- $\alpha$  as well as other members of the TNF family (Figures 10 and 11A).

The 5' end of the human TNRL- $\alpha$  sequence was  
20 obtained using 5' RACE on Marathon Ready cDNA derived from human leukocytes (Clontech) as described previously. The first round of RACE was performed using AP1 primer SEQ ID NO:34 as the forward primer and SEQ ID NO:59 (5'-GTTGGTGTTCCTACTGTCTGCAATCAG-3') as the reverse primer.  
25 The race products were diluted 1:50 in water and used for a second round of RACE using forward primer SEQ ID NO:36 and SEQ ID NO:60 (5'-GTTCTGACTGGAGTTGCCTTCTCCTG-3') reverse primer. As in other members of the TNRL family, the 5' sequence encodes a membrane-anchoring domain.  
30 This factor, hTNRL1- $\alpha$ , is designated a new member of the

TNF family which can play an important role in the modulation of the immune and nervous systems.

***Human TNRL1- $\alpha$  is a cytotoxic ligand***

His-FLAG epitope-tagged extracellular portions  
5 of hTNRL1- $\alpha$ , hTNRL3 or cytotoxic TRAIL ligand were produced in bacteria. Western analysis of bacterial lysates with an anti-FLAG antibody demonstrated that hTNRL1- $\alpha$ , hTNRL3 and TRAIL extracellular polypeptide portions were produced. BJAB cells were treated with  
10 ligand, and cell survival measured after twenty-four hours using the MTT assay in wells pre-coated with anti-FLAG monoclonal antibody. The relative survival of BJAB cells treated with hTNRL1- $\alpha$ , hTNRL3 or TRAIL was significantly reduced as compared to control cells.  
15 These results indicate that hTNRL1- $\alpha$ , like TRAIL, is a cytotoxic ligand.

Epitope tagged hTNRL1- $\alpha$ , hTNRL3 and TRAIL polypeptide fragments were prepared in a modified pET28(b) vector (Novagen Madison, WI), which has a FLAG  
20 epitope downstream of the His epitope, and the sequences confirmed by automated fluorescent sequencing. The His-FLAG-tagged polypeptide fragments were expressed in bacteria and purified by nickel-affinity chromatography (Qiagen) according to the manufacturer's instructions.

25

For cell survival assays, a 96-well plate was pre-treated by incubation with 100  $\mu$ l/well 10  $\mu$ g/ $\mu$ l anti-FLAG monoclonal antibody for two hours at 37°C. BJAB cells were plated at  $2 \times 10^4$  cells/well and treated  
30 with 5  $\mu$ l purified ligand. Cell survival was measured after 24 hours using the MTT assay (SIGMA) according to the manufacturer's instructions.

**Characterization of murine TNRL1- $\alpha$** 

Murine tumor necrosis factor related ligand 1- $\alpha$  (mTNRL1- $\alpha$ ) is encoded by a cDNA related to IMAGE consortium clones 722549, 803594 and 791670. These  
5 clones were identified by searching the dbEST database (NCBI) for sequences with homology to hTNRL1- $\alpha$  polypeptide (SEQ ID NO:20) using the TBLASTN algorithm. Murine TNRL1- $\alpha$  sequence was obtained using 5' RACE on murine spleen Marathon-ready cDNA (Clontech) according to  
10 the manufacturer's instructions. Primer SEQ ID NO:51 (5'-GTCTCCGTTGCGTGAAATCTGTGC-3') and AP1 primer SEQ ID NO:34 were used for the first round of PCR. Primer SEQ ID NO:52 (5'-AGGAATTGTTGGGAGTGTGTTTGG-3') and AP2 primer  
15 SEQ ID NO:36 were used for a subsequent round of nested PCR. The RACE products were cloned into vector PCR2.1 using the TA cloning kit (Invitrogen) and sequenced on an automated fluorescent sequencer (ABI 373) essentially as described before.

The available mTNRL1- $\alpha$  sequence is shown in  
20 Figure 11B. The predicted mTNRL1- $\alpha$  sequence is highly homologous to hTNRL1- $\alpha$  at both the nucleotide and protein levels and indicates a type II membrane protein with a putative N-terminal cytoplasmic domain (amino acids 1-46, a transmembrane domain (amino acids 47-74) and a large  
25 extracellular receptor binding domain (amino acids 75-290).

**Characterization of human TNRL1- $\beta$** 

Human tumor necrosis factor related ligand 1- $\beta$  (hTNRL1- $\beta$ ) is encoded by a cDNA related to IMAGE consortium clones 306307, 489038 and 306064, identified  
5 as described above, and which exhibit homology to TNRL1- $\alpha$ . The hTNRL1- $\beta$  sequence, shown in Figure 12A, encodes a predicted polypeptide of 250 amino acids with sequence homology to TNRL1- $\alpha$  and TNF- $\alpha$  as well as other members of TNF family (see Figure 10). The sequence  
10 indicates a type II membrane protein with a putative N-terminal cytoplasmic domain (amino acids 1-25), a transmembrane hydrophobic domain (26-50) and a large extracellular receptor binding domain (amino acids 51-250).

**15 Characterization of murine TNRL1- $\beta$** 

Murine tumor necrosis factor related ligand 1- $\beta$  (mTNRL1- $\beta$ ) is encoded by a cDNA related to IMAGE consortium clone 876879. This clone was identified by searching the dbEST database (NCBI) for sequences with  
20 homology to hTNRL1- $\beta$  polypeptide (SEQ ID NO:24) using the TBLASTN algorithm. The full-length mTNRL1- $\beta$  cDNA sequence is shown in Figure 12B. The sequence indicates a type II membrane protein with a putative N-terminal cytoplasmic domain (amino acids 1-16), a transmembrane  
25 hydrophobic domain (amino acids 17-42) and a large extracellular receptor binding domain (amino acids 43-241).



**EXAMPLE VII****Identification and Characterization of TNRL3**

This example describes the identification and characterization of nucleic acid sequences encoding human and murine TNRL3. This example also demonstrates that human TNRL3 is a cytotoxic ligand.

***Characterization of human TNRL3***

Human tumor necrosis factor related ligand 3 (hTNRL3) is related to IMAGE consortium clones 154742 and 271670 and Genbank clone C00994. These sequences were identified by searching the dbEST database (NCBI) for sequences with homology to human TRAIL ligand protein using the TBLASTN algorithm. 5' RACE with human fetal spleen marathon ready cDNA (Clontech) was performed according to the manufacturer's instructions to obtain additional 5' sequence. Primer SEQ ID NO:53 (5'-CGAAGTAGGTGAGGAAGGGGGCAG-3') and AP1 primer SEQ ID NO:34 were used for the first round of PCR. Primer SEQ ID NO:54 (5'-GTAGACAGCCTTCCCCTCATCAAA-3') and AP2 primer SEQ ID NO:36 were used for a subsequent round of nested PCR.

The partial hTNRL3 sequence shown in Figure 13A lacks sequence at the 5' end of the molecule and encodes the ligand-binding extracellular domain. The missing 5' sequence can encode a membrane anchoring sequence. The partial sequence shown in Figure 13A exhibits homology to TRAIL (TNF Related Apoptosis Inducing Ligand) and other members of the TNF family (see Figure 10).

***Human TNRL3 is a cytotoxic ligand***

BJAB cells were treated with epitope-tagged extracellular portions of hTNRL1- $\alpha$ , hTNRL3 or TRAIL, and cell survival measured after twenty-four hours using the  
5 MTT assay as described above. The relative survival of BJAB cells treated with epitope-tagged hTNRL1- $\alpha$ , hTNRL3 or TRAIL extracellular fragments was significantly reduced as compared to control cells. These results indicate that hTNRL3 functions as a cytotoxic ligand.

**10 *Characterization of murine TNRL3***

Murine tumor necrosis factor related ligand 3 (TNRL3) is encoded by a cDNA related to IMAGE consortium clone 696209. This clone was identified by searching the dbEST database for sequences with homology to hTNRL3  
15 protein (SEQ ID NO:28) using the TBLASTN algorithm. The available sequence of clone 696209 is incomplete at the 5' end. Additional murine TNRL3 sequence was obtained using 5' RACE on murine spleen Marathon-ready cDNA (Clontech) according to the manufacturer's instructions.  
20 Primer SEQ ID NO:55 (5'-CACACCGTTCACCAGCAAGTCCAG-3') and AP1 primer SEQ ID NO:34 were used for the first round of PCR. Primer SEQ ID NO:56 (5'-GGTAGACAGCCTTCCCTCATCAA-3') and AP2 primer SEQ ID NO:36 were used for a subsequent round of nested PCR.  
25 The RACE products were cloned into vector PCR2.1 using the TA cloning kit (Invitrogen) and sequenced on an automated fluorescent sequencer (ABI 373).

The partial mTNRL3 sequence, lacking the 5' end, is shown in Figure 13B. The mTNRL3 cDNA encodes a  
30 polypeptide with significant sequence homology to hTNRL3.

All journal article, reference, and patent citations provided above, in parentheses or otherwise, whether previously stated or not, are incorporated herein by reference.

5           Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various  
10 modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

What is claimed is:

1. An isolated APO4 polypeptide, comprising substantially the same amino acid sequence as an APO4 polypeptide, or an active fragment thereof.
- 5           2. The isolated polypeptide of claim 1, comprising substantially the same amino acid sequence as an amino acid sequence selected from the group consisting of mAPO4- $\alpha$ L (SEQ ID NO:8) or an active fragment thereof, mAPO4- $\alpha$ S (SEQ ID NO:10) or an active fragment thereof,  
10 hAPO4- $\alpha$  (SEQ ID NO:12) or an active fragment thereof, and rAPO4- $\alpha$  (SEQ ID NO:14) or an active fragment thereof.
3. The isolated polypeptide of claim 1, comprising substantially the same amino acid sequence as mAPO4- $\beta$  (SEQ ID NO:16).
- 15           4. The isolated polypeptide of claim 1, wherein said active fragment comprises a soluble form of an APO4 polypeptide having an APO4 polypeptide ligand binding domain.
5. An isolated nucleic acid molecule,  
20 comprising a nucleotide sequence encoding substantially the APO4 polypeptide of claim 1, or an active segment thereof.
6. An APO4 selective binding agent, said agent comprising the activity of selectively binding to  
25 the APO4 polypeptide of claim 1.

7. A method of diagnosing prostate cancer in an individual, comprising determining the level of APO4 in said individual.

8. A method of treating prostate cancer,  
5 comprising administering to an individual having prostate cancer a conjugate comprising an APO4 selective binding agent linked to a therapeutic moiety.

9. A method of identifying an effective pharmacological agent useful in the diagnosis or  
10 treatment of a disease associated with APO4 activity, comprising the steps of:

- a) contacting an APO4 polypeptide or active fragment thereof with an agent, and
- b) determining selective binding of said  
15 agent to said APO4 polypeptide or active fragment thereof,

wherein said selective binding indicates that said agent is an effective pharmacological agent useful in the diagnosis or treatment of a disease associated  
20 with APO4 activity.

10. The method of claim 9, wherein said APO4 polypeptide or active fragment thereof is an APO4 extracellular ligand binding domain.

11. The method of claim 9, wherein said APO4  
25 polypeptide or active fragment thereof is expressed in a cell or on the surface of a cell.

12. The method of claim 9, wherein said APO4 polypeptide or active fragment thereof is contacted with an agent *in vitro*.

13. A method of screening for an APO4 agonist  
5 useful in treating prostate cancer, comprising the steps of:

- a) contacting a cell expressing an APO4 polypeptide or active fragment thereof with an agent;
  - 10 b) assaying for increased APO4 activity,
- wherein increased APO4 activity indicates that said agent is an APO4 agonist useful in treating prostate cancer.

14. A method of screening for an APO4  
15 antagonist, comprising the steps of:

- a) contacting a cell expressing an APO4 polypeptide or active fragment thereof with an agent;
  - b) assaying for decreased APO4 activity,
- 20 wherein decreased APO4 activity indicates that said agent is an APO4 antagonist.

15. A method of identifying an effective pharmacological agent useful in the diagnosis or treatment of a disease associated with APO4 activity, comprising the steps of:

- 5           a) forming a mixture comprising an APO4 polypeptide or active fragment thereof, an APO4 signal transducer molecule that specifically interacts with a cytoplasmic domain of said APO4 polypeptide or active  
10           fragment thereof, and an agent;
- b) detecting the level of APO4 activity in the presence of said agent,

          wherein an alteration in said APO4 activity relative to control activity indicates that said agent is an  
15       effective pharmacological agent useful in the diagnosis or treatment of a disease associated with APO4 activity.

16. A method of claim 15, wherein said APO4 activity is measured *in vivo*.

17. A method of claim 15, wherein said APO4  
20       activity is measured *in vitro*.

18. An isolated APO8 polypeptide, comprising substantially the same amino acid sequence as APO8, or an active fragment thereof.

19. The isolated polypeptide of claim 18,  
25       comprising substantially the same amino acid sequence as hAPO8 (SEQ ID NO:2), or an active fragment thereof.

20. The isolated polypeptide of claim 18,  
wherein said active fragment comprises a soluble form of  
APO8 having an APO8 ligand binding domain.

21. An isolated nucleic acid molecule,  
5 comprising a nucleotide sequence encoding substantially  
the APO8 polypeptide of claim 18, or an active segment  
thereof.

22. An APO8 selective binding agent, said  
agent comprising the activity of selectively binding to  
10 the APO8 polypeptide of claim 18.

23. An isolated APO9 polypeptide, comprising  
substantially the same amino acid sequence as APO9, or an  
active fragment thereof.

24. The isolated polypeptide of claim 23,  
15 comprising substantially the same amino acid sequence as  
hAPO9 (SEQ ID NO:6), or an active fragment thereof.

25. The isolated polypeptide of claim 23,  
wherein said active fragment comprises a soluble form of  
APO9 having an APO9 ligand binding domain.

20 26. An isolated nucleic acid molecule,  
comprising a nucleotide sequence encoding substantially  
the APO9 polypeptide of claim 23, or an active segment  
thereof.

27. An APO9 selective binding agent, said  
25 agent comprising the activity of selectively binding to  
the APO9 polypeptide of claim 23.



28. An isolated APO6 polypeptide, comprising substantially the same amino acid sequence as APO6, or an active fragment thereof.

29. The isolated APO6 polypeptide of claim 28,  
5 comprising substantially the same amino acid sequence as hAPO6 (SEQ ID NO:18), or an active fragment thereof.

30. The isolated polypeptide of claim 28, wherein said active fragment comprises a soluble form of APO6 having an APO6 ligand binding domain.

10 31. An isolated nucleic acid molecule, comprising a nucleotide sequence encoding substantially the APO6 polypeptide of claim 28, or an active segment thereof.

32. An APO6 selective binding agent, said  
15 agent comprising the activity of selectively binding to the APO6 polypeptide of claim 28.

33. An isolated tumor necrosis factor related ligand 1 (TNRL1) polypeptide, comprising substantially the same amino acid sequence as TNRL1, or an active  
20 fragment thereof.

34. The isolated TNRL1 polypeptide of claim 33, comprising substantially the same amino acid sequence as an amino acid sequence selected from the group consisting of hTNRL1- $\alpha$  (SEQ ID NO:20), or an active  
25 fragment thereof, and mTNRL1- $\alpha$  (SEQ ID NO:22), or an active fragment thereof.

35. The isolated TNRL1 polypeptide of claim 33, comprising substantially the same amino acid sequence as an amino acid sequence selected from the group consisting of hTNRL1- $\beta$  (SEQ ID NO:24), or an active  
5 fragment thereof, and mTNRL1- $\beta$  (SEQ ID NO:26), or an active fragment thereof.

36. The isolated polypeptide of claim 33, wherein said active fragment comprises a soluble form of TNRL1 having a TNRL1 receptor binding domain.

10

37. An isolated nucleic acid molecule, comprising a nucleotide sequence encoding substantially the TNRL1 polypeptide of claim 33, or an active segment thereof.

15 38. A TNRL1 selective binding agent, said agent comprising the activity of selectively binding to the TNRL1 polypeptide of claim 33.

39. An isolated TNRL3 polypeptide, comprising substantially the same amino acid sequence as TNRL3, or  
20 an active fragment thereof.

40. The isolated TNRL3 polypeptide of claim 39, comprising substantially the same amino acid sequence as an amino acid sequence selected from the group consisting of hTNRL3 (SEQ ID NO:28), or an active  
25 fragment thereof, and mTNRL3 (SEQ ID NO:30), or an active fragment thereof.

41. The isolated polypeptide of claim 39, wherein said active fragment comprises a soluble form of TNRL3 having a TNRL3 receptor binding domain.

42. An isolated nucleic acid molecule,  
comprising a nucleotide sequence encoding substantially  
the TNRL3 polypeptide of claim 39, or an active segment  
5 thereof.

43. A TNRL3 selective binding agent, said  
agent comprising the activity of selectively binding to  
the TNRL3 polypeptide of claim 39.

[illegible]

1 / 23

hAP04- $\alpha$	81	frdrsgncvp	CnqCgPGmeL	sKECgfygE	DaqCvaCr1h	rFkeDWGfQk	.....CkpC1	dCavvnRfak	160
hAP06	.....	.....	.....	.....	.....	.....	.....	nv1cgeReeE	anCSaTsdaI
hAP08	gL.....	.....	.....	.....	.....	.....	.....	rCDsg...eve	araChaThnN
AP08RP	EL.....	.....	.....	.....	.....	.....	.....	rCkSd...eeE	ISpCTITTRNT
hAP09	Ee.....	.....	.....	.....	.....	.....	.....	vCkSd...gkh	rSpCTITTRNT
CD40	qY1lnsq..C	.....	.....	.....	.....	.....	.....	dpn1gLRvqq	kSSCTmTRDT
Fas	gLH.hdgQfC	hkpCpPgErk	vsDC..TEft	EteC1pCgEs	Dep...dCvpc	qegkeYtdka	ethChqhKyc	hK9tsetdIT	..k9tsetdIT
DR3	DFHkklglfC	CrqCPaGhYL	KapC..TEpc	gns..tClVC	padtflawen	esgsftasen	hfnSeCaRCq	eInCTrTqNT	einCTrTqNT
TNFR1	iHpQnnnsiC	CtKChkGtYL	vnDC..pgpg	qdt..dCrEC	esgsftasen	TYtqlwnwvp	h1.rhCLsCs	IenCSavadt	IenCSavadt
TNFR2	EYydQtaQmC	CSKCSpGqHa	Kvfc..Tkts	DtVcdsCeDs	TYtqlwnwvp	esgsftasen	h1.rhCLsCs	ISsCtVdRdT	ISsCtVdRdT

**FIG. 1A**

2/23

161	hAP04- $\alpha$	cgdcIPGFYR	ktklvgfqdm	eCvpCgdbpp	pYe...phCas	kvnlvklast	assprdtala	AviCsa...	240
	hAP06	acrcrtGFFa	h...edSpEMCR	fCLEhasCPP	GagviapgiP	sgntaqCpSp	pgtFSasss	seEqCqPhrNC	faiglainvp
	hAP08	VCQCeegtFR	e.dnSaEMCR	K...CrtgCPr	GmvkvvgdCTP	wSDIeCVhKE	sg...	...	...
	AP08RP	aCQCKPGtFR	n.dnSaEMCR	K...CstgCPr	GmvkvkdCTP	wSDIeCVhKE	sgnghN...	AEetmntSpG	tpapaaeEtm
	hAP09	VCQCKeGtFR	n.enSpEMCR	K...Csr.CPS	GevqvsncTs	wSDIaCveef	ganatvetpA	fEkChPwtSC	etkdLvqqqa
	CD40	ICtCeegWhc	t...SEa.Ce	scvIhRscSP	GFgVklqIaTg	VSDtIcEpcP	VGfFSNVSSA	...	...
	Fas	KCrCKPnFFq	nstvCE...	...hCdbCtk	cehgIikect	ItsntkckeE	GsrS...	gDgCVscpts	tiGscperca
	DR3	rCgCKPgWfV	ecqvSqcvs	spFYCapCId	cg.alhrhr	lIcsrrrdtdc	gtcLpgfyeh	eneCVscSNC	kks...lEct
	TNFR1	VCgCrknqYR	hy...ws	enLF...qCfn	csIcIngtyh	IScqeKantv	ctchagffir	tdICrPhqIC	n...vvaip
	TNFR2	ICtCrPgWYC	alskdEg.CR	iCapIRKCrP	GFgVarpgTe	tSDVvCkPca	pgtFSNttSS	...	...
241	hAP04- $\alpha$	gssShdtict	sctgfPiStr	vPGAeEcEra	VidfvaFqdi	sikrLSgccS	prgpegWGpt	PrAaarpss	309
	hAP06	...	...	...	...	...	...	...	...
	hAP08	...	...	...	...	...	...	...	...
	AP08RP	nTspgtPapa	aeETmttSpG	tpapaaeEtm	ttspgtPapa	aeETmttSpG	tpasshYisc	t...	...
	hAP09	GtnktDVvcg	pqD...rl...	...	...	...	...	...	...
	CD40	...	...	...	...	...	...	...	...
	Fas	avcgwRQmfW	V...	...	...	...	...	...	...
	DR3	kIc.lpQIen	vkgtedsG...	...	...	...	...	...	...
	TNFR1	GnaSRdaVct	sts..Ptrsm	apGAVhIpbq	vstrsqhtap	tpEp.StaPs	tsfilpmGPs	ppAegstg.	...
	TNFR2	...	...	...	...	...	...	...	...

FIG. 1B

3/ 23

1 CGGAGAACCCGCAATCTCTGCGCCACAAAATACACGACGATGCCGATCTACTTTAA 60  
61 GGGCTGAAACCCACGGGCTGAGAGACTATAAGAGCGTTCCCTACCGCCATGGAACAACG 120  
M E Q R 4  
121 GGGACAGAACGCCCCGGCCGCTTCGGGGGCCCGGAAAAGGCACGGCCCCAGGACCCAGGGA 180  
5 G Q N A P A A S G A R K R H G P G P R E 24  
181 GGCGCGGGGAGCCAGGCTGGGCTCCGGGTCCTCCCAAGACCCTTGTGCTCGTTGTGCGCCG 240  
25 A R G A R P G L R V P K T L V L V V A A 44  
241 GGTCTGCTGTTGGTCTCAGCTGAGTCTGCTCTGATCACCAACAAGACCTAGCTCCCA 300  
45 V L L L V S A E S A L I T Q Q D L A P Q 64  
301 GCAGAGAGTGGCCCCACAACAAAGAGGTCCAGCCCCTCAGAGGGATTGTGTCCACCTGG 360  
65 Q R V A P Q Q K R S S P S E G L C P P G 84  
361 ACACCATATCTCAGAAGACGGTAGAGATTGCATCTCTGCAATATGGACAGGACTATAG 420  
85 H H I S E D G R D C I S C K Y G Q D Y S 104  
421 CACTCACTGGAATGACCTCCTTTCTGCTTGCCTGCACAGGTGTGATTGAGGTGAAGT 480  
105 T H W N D L L F C L R C T R C D S G E V 124  
481 GGAGCTAAGTCCCTGCACCAGCAGGAGACAGTGTGTGAGTGCAGGAAGGACCTT 540  
125 E L S P C T T T R N T V C Q C E E G T F 144  
541 CCGGGAAGAAGATTCTCTGAGATGTGCCGGAAGTGCCGCACAGGGTGTCCAGAGGGAT 600  
145 R E E D S P E M C R K C R T G C P R G M 164  
601 GGTCAAGGTGCGGTGATTGTACACCTGGAGTGACATCGAATGTGTCCACAAAGAATCAGG 660  
165 V K V G D C T P W S D I E C V H K E S G 184  
661 CATCATAGGAGTCACAGTTGCAGCCGTAGTCTTGATTGTGGCTGTGTTGTTGCAA 720  
185 I I I G V T V A A V V L I V A V F V C K 204  
721 GTCTTTACTGTGGAAGAAAGTCTTCTTACCTGAAAGGCATCTGCTCAGGTGGTGGTGG 780  
205 S L L W K K V L P Y L K G I C S G G G G 224  
781 GGACCTGAGCGTGTGGACAGAAGCTCACACGACCTGGGGCTGAGGACAATGTCTCAA 840  
225 D P E R V D R S S Q R P G A E D N V L N 244  
841 TGAGATCGTGAGTATCTTGACGCCACCCAGGTCCTGAGCAGGAAATGGAAGTCCAGGA 900  
245 E I V S I L Q P T Q V P E Q E M E V Q E 264  
901 GCCAGCAGAGCCAACAGGTGTCAACATGTTGTCCCCGGGGAGTCAGAGCATCTGTGGA 960  
265 P A E P T G V N M L S P G E S E H L L E 284  
961 ACCGGCAAGCTGAAAGGTCTCAGAGGAGGAGGCTGCTGGTTCCAGCAAATGAAGGTGA 1020  
285 P A E A E R S Q R R R L L V P A N E G D 304  
1021 TCCCACTGAGACTCTGAGACAGTGTCTCGATGACTTTGCAGACTTGGTGCCCTTTGACTC 1080  
305 P T E T L R Q C F D D F A D L V P F D S 324  
1081 CTGGGAGCCGCTCATGAGGAAGTTGGGCTCATGGACAATGAGATAAAGGTGGCTAAAGC 1140  
325 W E P L M R K L G L M D N E I K V A K A 344  
1141 TGAGGCAGCGGGCCACAGGGACACCTTGTACACGATGCTGATAAAGTGGGTCAACAAAC 1200  
345 E A A G H R D T L Y T M L I K W V N K T 364  
1201 CGGGCAGATGCCCTGTTCACACCCTGTGGATGCCCTGGAGACGCTGGGAGAGAGACT 1260  
365 G R D A S V H T L L D A L E T L G E R L 384  
1261 TGCCAAGCAGAAGATTGAGGACCACTTGTGAGCTCTGGAAAGTTTCATGTATCTAGAAGG 1320  
385 A K Q K I E D H L L S S G K F M Y L E G 404  
1321 TAATGCAGACTCTGCCATGTCCTAAGTGTGATTCTCTTCAGGAAGTCAGACCTTCCTGG 1380  
405 N A D S A M S \* 424  
1381 TTTACCTTTTTCTGGAAAAAGCCCAACTGGACTCCAGTCAGTAGGAAAGTGCCACAATT 1440  
1441 GTCACATGACCGGTACTGGAAGAACTCTCCCATCCAACATCACCCAGTGGATGGAACAT 1500  
1501 CCTGTAACCTTTTCACTGCACTTGGCATTATTTTATAAGCTGAATGTGATAATAAGGACA 1560  
1561 CTATGGAAATGTCTGGATCATTCCGTTTGGTACTTTGAGATTGGTTTGGGATGTCA 1620  
1621 TTGTTTTCACAGCACTTTTTATCCTAATGTAAATGCTTTATTTATTTTGGGGTACA 1680  
1681 TTGTAAGATCCATCTACACAGTCGTAACAAAAA 1717

FIG. 2

4/23

1	ATGGCGCCACCACCAGCTAGAGTACATCTAGGTGCGTTCCTGGCAGTGACTCCGAATCCC	60
61	GGGAGCGCAGCGAGTGGGACAGAGGCAGCCGCGGCCACCCAGCAAAGTGTGGGGCTCT	120
121	TCCGCGGGGAGGATTGAACCACGAGGCAGGGGCGGAGGAGCGCTCCCTACCTCCATGGGA	180
-17		
181	CAGCACGGACCCAGTGCCCGGGCCCGGGCAGGGCGCGCCCAAGGACCCAGGCCGCGCGG	240
3	Q H G P S A R A R A G R A P G P R P A R	22
241	GAAGCCAGCCCTCGGCTCCGGGTCCACAAGACCTTCAAGTTTGTCTGTCGTCGGGGTCTG	300
23	E A S P R L R V H K T F K F V V V G V L	42
301	CTGCAGGTCGTACCTAGCTCAGCTGCAACCATCAAACCTTCATGATCAATCAATTGGCACA	360
43	L Q V V P S S A A T I K L H D Q S I G T	62
361	CAGCAATGGGAACATAGCCCTTTGGGAGAGTTGTGTCCACCAGGATCTCATAGATCAGAA	420
63	Q Q W E H S P L G E L C P P G S H R S E	82
421	CGTCTGGAGCCTGTAACCGGTGCACAGAGGGTGTGGGTACACCAATGCTTCCAACAAT	480
83	R P G A C N R C T E G V G Y T N A S N N	102
481	TTGTTTGTGCTCCCATGTACAGCTTGTAAATCAGATGAAGAAGAGAGAAGTCCCTGC	540
103	L F A C L P C T A C K S D E E E R S P C	122
541	ACCACGACCAGGAACACAGCATGTCAAGTGCACAAACAGGAACCTTCCGGAATGACAATTCT	600
123	T T T R N T A C Q C K P G T F R N D N S	142
601	GCTGAGATGTCCGGAAGTGCAGCAGAGGGTGCACAGAGGGATGGTCAAGGTCAAGGAT	660
143	A E M C R K C S T G C P R G M V K V K D	162
661	TGTACGCCCTGGAGTGACATCGAGTGTGTCCACAAAGAATCAGGCAATGGACATAATATA	720
163	C T P W S D I E C V H K E S G N G H N I	182
721	TGGGTGATTTGGTTGTGACTTTGGTTGTTCCTGCTGTTGGTGGCTGTGCTGATTGTC	780
183	W V I L V V T L V V P L L L V A V L I V	202
781	TGTTGTTGCATCGGCTCAGGTTGTGGAGGGGACCCCAAGTGCATGGACAGGGTGTGTTTC	840
203	C C C I G S G C G G D P K C M D R V C F	222
841	TGGCGCTTGGGTCTCCTACGAGGGCCTGGGGCTGAGGACAATGCTCACAACGAGATTCTG	900
223	W R L G L L R G P G A E D N A H N E I L	242
901	AGCAACGCAGACTCGCTGTCCACTTTCGTCTCTGAGCAGCAAATGGAAAGCCAGGAGCCG	960
243	S N A D S L S T F V S E Q Q M E S Q E P	262
961	GCAGATTTGACAGGTGTCACTGTACAGTCCCCAGGGGAGGCACAGTGTCTGCTGGGACCG	1020
263	A D L T G V T V Q S P G E A Q C L L G P	282
1021	GCAGAAGCTGAAGGGTCTCAGAGGAGGAGGCTGCTGGTTCCAGCAAATGGTGTGACCCC	1080
283	A E A E G S Q R R R L L V P A N G A D P	302
1081	ACTGAGACTCTGATGCTGTTCTTTGACAAGTTTGCAAACATCGTGCCCTTTGACTCCTGG	1140
303	T E T L M L F F D K F A N I V P F D S W	322
1141	GACCAGCTCATGAGGCAGCTGGACCTACGAAAAATGAGATCGATGTGGTCAGAGCTGGT	1200
323	D Q L M R Q L D L T K N E I D V V R A G	342
1201	ACAGCAGGCCAGGGGATGCCTTGTATGCAATGTGATGAAATGGGTCAACAAAACCTGGA	1260
343	T A G P G D A L Y A M L M K W V N K T G	362
1261	CGGAACGCCTCGATCCACACCCTGCTGGATGCCTTGGAGAGGATGGAAGAGAGACATGCA	1320
363	R N A S I H T L L D A L E R M E E R H A	382
1321	AAAGAGAAGATTCAAGACCTCTTGGTGGACTCTGGAAAGTTCATCTACTTAGAAGATGGC	1380
383	K E K I Q D L L V D S G K F I Y L E D G	402
1381	ACAGGCTCTGCCGTGTCTTGGAGTGA	1407
403	T G S A V S L E *	411

FIG. 3

5 / 23

<-----SIGNAL PEPTIDE----->  
 1 MEQRGQNAIPASGARKRHGPGPREARGRPGLRVPKTLVLVVAIVLIVSAESALITQQDLAPQQRVAPQCKRSPSEGL  
 1 MGEHGPSARARAG---RAPGPRPARASPRLRVAKIFKRVVAGVLLQWVPSAATIKLHDQS---LGIQQMEHSPGLGEL  
 <-----SIGNAL PEPTIDE----->  
 81 CPPGHIISEDGRDCISCKYGDYSTHWNDFCLRCIRCDSGEVELSPCTITRNIVCQCEEGTFRFEDSPCMCRKORTGC  
 74 CPPGSHRSERPGACNRCITEGVGYHVASNNLFACLPCTACKSDHEEFERSPCITTRNTACQCKPGTFRNBNSAEMCRKCSIGC  
 <-----T.M. REGION----->  
 161 PRGMVKVGDCTPWSDIECVHKESGIIIGVTVAAMVEIVAVFVCKSLIMKKVLPYLYKGLCSGGGGGDPFERNDRSS---Q  
 154 PRGMVKVKDCTPWSDIECVHKESGI---NGHNTIMVITLWTELVVPLLLVAVLITVCCCJGSGGGGDPKQMDRVCFWRRLGLL  
 <-----T.M. REGION----->  
 235 R-PGAEDNVLINEIVS---ILOPTQVPECEMEMEQEPAEITGVNMLSPGESEHLIEPAEAERSQRRRLVLPANEGDPTETLRQ  
 229 RGPGAEDNAHNEIISNADSLSTFVSEQQMESQEPADITGVIVQSPGEAQCLLGPAAEGSQRRRLVLPANGADPTETLML  
 <-----DEATH DOMAIN----->  
 312 QFDDFADEVPFDSWEPIMRKILGLIMDNEIKVAKAEAGHRTILYIMLIKWNKVTGRDASVHTLLDALEITEGERLAKOKIED  
 309 FEDKFEANTIVPDSWDQLMRQLDITKNEIDVMRAGTAGPGDALYAMLIKWNKVTGRNASHTLLDALEITEERHAKKEKIQD  
 <-----DEATH DOMAIN----->  
 392 HLESSGKFMYLEGNADSNMS--  
 389 LLMDSGKHHYLEDTGTSAMSE

FIG. 4A

hAP08 (316) FADIEVPFDSWEPIMRKILGLIMDNEIKVAKAEAGHRTILYIMLIKWNKVTGRDASVHTLLDALEITEGERLAKOKIED  
 DR4 (348) FADIEVPFDSWDQLMRQLDITKNEIDVMRAGTAGPGDALYAMLIKWNKVTGRNASHHTLLDALEITEERHAKKEKIQD  
 DR3 (338) WVDVAPRRMKEFEVRLGLREAEIEAVEVEITGR-FRDQQYEMILKEIR---QQQ-PAGLGAVYALERMGLDGCVEDIERS  
 TNFR1 (362) WVENVPPLRMKEFEVRLGLSDHEIDRLLELNGRCLEHQAQYSLATMRRRTPRNEATLELEGRVLRDMDLLGCLEDIEE  
 Fas (236) ILAGVMTLSQVKGFEVRKNGVNEAKLIDELKNDINVDQDTAEQKQVQLIRNMFHGLHGL-KEAYDILLIKDKLKKANLCTLAKEKIQD

FIG. 4B



6 / 23




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D

7/23

1 CACGCGCACGAACTCAGCCAACGATTTCGATAGATTTTGGGAGTTTGACCAGAGATGC 60  
61 AAGGGGTGAAGGAGCGCTTCTACCGTTAGGAACTCTGGGGACAGAGCGCCCCGGCCGCC 120  
121 TGATGGCCGAGGCAGGGTGCACCCAGGACCCAGGACGGCGTCGGGAACCATACCATGGC 180  
-17  
181 CCGGATCCCCAAGACCCTAAAGTTCGTGTCGTGTCATCGTCGCGGTCCTGCTGCCAGTCCT 240  
3 R I P K T L K F V V V I V A V L L P V L 22  
241 AGCTTACTCTGCCACCACTGCCCGGAGGAGGAGTTCCCAGCAGACAGTGGCCCCACA 300  
23 A Y S A T T A R Q E E V P Q Q T V A P Q 42  
301 GCAACAGAGGCACAGCTTCAAGGGGGAGGAGTGTCCAGCAGGATCTCATAGATCAGAACA 360  
43 Q Q R H S F K G E E C P A G S H R S E H 62  
361 TACTGGAGCCTGTAACCCGTGCACAGAGGGTGTGGATTACACCAACGCTTCCAACAATGA 420  
63 T G A C N P C T E G V D Y T N A S N N E 82  
421 ACCTTCTTGCTTCCCATGTACAGTTTGTAAATCAGATCAAAAACATAAAAGTTCCTGCAC 480  
83 P S C F P C T V C K S D Q K H K S S C T 102  
481 CATGACCAGAGACACAGTGTGTAGTGTAAAGAAGGCACCTTCCGGAATGAAAACCTCCCC 540  
103 M T R D T V C Q C K E G T F R N E N S P 122  
541 AGAGATGTGCCGGAAGTGTAGCAGGTGCCCTAGTGGGGAAGTCCAAGTCAGTAATTGTAC 600  
123 E M C R K C S R C P S G E V Q V S N C T 142  
601 GTCTGGGATGATATCCAGTGTGTGAAGAATTTGGTGCCAATGCCACTGTGGAAACCCC 660  
143 S W D D I Q C V E E F G A N A T V E T P 162  
661 AGCTGCTGAAGAGACAATGAACACCAGCCCGGGGACTCCTGCCCAGCTGCTGAAGAGAC 720  
163 A A E E T M N T S P G T P A P A A E E T 182  
721 AATGAACACCAGCCAGGGACTCCTGCCCAGCTGCTGAAGAGACAATGACCACCAGCCC 780  
183 M N T S P G T P A P A A E E T M T T S P 202  
781 GGGGACTCCTGCCCAGCTGCTGAAGAGACAATGACCACCAGCCCGGGGACTCCTGCCCC 840  
203 G T P A P A A E E T M T T S P G T P A P 222  
841 AGCTGCTGAAGAGACAATGACCACCAGCCCGGGGACTCCTGCCTCTTCTATTACCTCTC 900  
223 A A E E T M T T S P G T P A S S H Y L S 242  
901 ATGCACCATCGTAGGGATCATAGTTCTAATTGTGCTTCTGATTGTGTTTGTGTTGAAAGAC 960  
243 C T I V G I I V L I V L L I V F V \* 262  
961 TTCACTGTGGAAGAAATTCCTTACCTGAAAGGTTACGTTACGCGCTGGCTGAAGG 1020  
1021 CGGGGGGCGCTGGACACTCTCTGCCCTGCCCTCCTCTGCTGTGTTCCACAGACAGAAAC 1080  
1081 GCCTGCCCCCTGCCCAAGTCTGGTGTCTCCAGCCTGGCTCTATCTTCTCCTTGTGATC 1140  
1141 GTCCCATCCCCACATCCCGTGCACCCCCAGGACCCTGGTCTCATCAGTCCCTCTCCTGG 1200  
1201 AGCTGGGGGTCCACACATCTCCAGCCAAGTCCAAGAGGGCAGGGCCAGTTCTCCCATC 1260  
1261 TTCAGGCCCAGCCAGGCAGGGGGCAGTCGGCTCCTCAACTGGGTGACAAGGGTGAGGATG 1320  
1321 AGAAGTGGTCACGGGATTTATTCAGCCTTGGTCAGAGCAGAAAAA 1365

FIG. 6

8 / 23

```

1  CCAGCCTCAAAGTGCAGTCCGGCGCCGGGGCAGGACAAGGGGAAGGAATAAACACGTT 60
61  TGGTGAGAGCCATGGCACTCAAGGTCCTACCTCTACACAGGACGGTGCTCTCGCTGCCA 120
-2  M A L K V L P L H R T V L F A A I 17
121  TTCTCTTCTACTCCACCTGGCATGTAAAGTGAGTTGCGAAACCGGAGATTGCAGGCAGC 180
18  L F L L H L A C K V S C E T G D C R Q Q 37
181  AGGAATTCAGGATCGATCTGGAAGTGTGCTCTGCAACAGTGCAGGACCTGGCATGG 240
38  E F K D R S G N C V L C K Q C G P G M E 57
241  AGTTGTCCAAGGAATGTGGCTTCGGCTATGGGGAGGATGCACAGTGTGTGCCCTGCAGGC 300
58  L S K E C G F G Y G E D A Q C V P C R P 77
301  CGCACCGGTTCAAGGAAGACTGGGGTTTCCAGAAGTGAAGCCATGTGCGGACTGTGCGC 360
78  H R F K E D W G F Q K C K P C A D C A L 97
361  TGGTGAACCGCTTTCAGAGGGCCAACTGCTCACACACCAAGTGTGCTGTGCGGGGACT 420
98  V N R F Q R A N C S H T S D A V C G D C 117
421  GCCTGCCAGGATTTTACCGGAAGACCAAACTGGTTGGTTTCAAGACATCGAGTGTGTGC 480
118  L P G F Y R K T K L V G F Q D M E C V P 137
481  CCTGCGGAGACCCACCTCCTCCTACGAACCACTGTACCAGCAAGGTGAACCTTGTGA 540
138  C G D P P P P Y E P H C T S K V N L V K 157
541  AGATCTCTCCACCGTCTCCAGCCCTCGGGACACGGCGCTGGCTGCCGTATCTGCAGTG 600
158  I S S T V S S P R D T A L A A V I C S A 177
601  CTCTGGCCACGGTGCTGCTCGCCCTGCTCATCCTGTGTGTCTACTGCAAGAGGCAGT 660
178  L A T V L L A L L I L C V I Y C K R Q F 197
661  TCATGGAGAAGAAACCCAGCTGGTCTCTGCGGTACAGGACATTAGTACAATGGCTCTG 720
198  M E K K P S W S L R S Q D I Q Y N G S E 217
721  AGCTGTATGCTTTGACCAAGCTCGGCTCCGCCACTGTGCCCATAGACATGCTGTCACT 780
218  L S C F D Q P R L R H C A H R A C C Q Y 237
781  ATCACCGGGACTCAGCCCCAATGTATGGGCTGTTACCTGATTCCGCTCTTGTGTGTG 840
238  H R D S A P M Y G P V H L I P S L C C E 257
841  AAGAGGCCCCGAGCTCTGCCGAGCTGTGCTTGGCTGTGGGCTGCGTTCTCCCACTACCC 900
258  E A R S S A R A V L G C G L R S P T T L 277
901  TCCAGGAGAGAAACCCGGCTTCTGTGGGGAACACGATGCCAGCCTTCTTTGGGTCTGTTT 960
278  Q E R N P A S V G N T M P A F F G S V S 297
961  CCCGTTCCATCTGCGCGGAGTTTCTGATGCTGGCTCTGTATGCAGAATCCTCTGGGCG 1020
298  R S I C A E F S D A W P L M Q N P L G G 317
1021  GTGACAGCTCTCTGTGACTCTTATCCTGAACACTGAGAGAAGATACCAATTCCCTCA 1080
318  D S S L C D S Y P E L T G E D T N S L N 337
1081  ATCCCGAAAACGAAAGCACAGCATCTCTGGATTCCAGTGGCGGCCAGGATCTGGCTGGGA 1140
338  P E N E S T A S L D S S G G Q D L A G T 357
1141  CAGCTGCTCTAGAGTCTTCTGGGAATGTTTCAGAACTACTGACTCACCTAGACATGGTG 1200
358  A A L E S S G N V S E S T D S P R H G D 377
1201  AACTGGTACAGTCTGGGAGCAGACGCTAGCTCAGGATGCTCAAAGGACTCCAAGCCAAG 1260
378  T G T V W E Q T L A Q D A Q R T P S Q G 397
1261  GAGGCTGGGAAGACAGGGAACCTGAATCTAGCCATGCCACAGCCTTCCAGGATGCCT 1320
398  G W E D R E N L N L A M P T A F Q D A * 417
1321  GAAGGCCATCTTCTGACGTGGAGGTGTGGGTCTGGACACGCTGTGATGAGGCCTACAG 1380
1381  ACTGAGCAGTCTTGGTGTCTGGAAGCAAAAATAAATCTGAACCAAACTGACAACATTTCC 1440
1441  ATCCTTTCAGCCACTAGCTACTGAGCCAGACAGCTGTAAGCTGAAACCCAGCAAGAAG 1500
1501  CAAGGAGAGACTTGAAGTGTAGCGGCTTGGGACATGTGCTTCTTCCCTAAGCGAAAACC 1560
1561  TTAGCTGGGGCAATTTGAAGGACCCATGGGTGGAATGTGCTGCTGTGAACCTTGTGGGC 1620
1621  ACAGCAGGACCCAGCCTGGCTCTTCTATGTCCACGGTGAATGTGTTTCAAGAC 1678

```

FIG. 7A

9 / 23

1 CCAGCCTCAAAGTGCAGTCCGGCGCCGCGGGGCAGGACAAGGGGAAGGAATAAACACGTT 60  
61 TGGTGAGAGCCATGGCACTCAAGGTCCTACCTCTACACAGGACGGTGCTCTTCGCTGCCA 120  
-2 M A L K V L P L H R T V L F A A I 17  
121 TTCTCTTCTACTCCACCTGGCATGTAAAGTGAGTTGCGAAACCGGAGATTGCAGGCAGC 180  
18 L F L L L H L A C K V S C E T G D C R Q Q 37  
181 AGGAATTCAAGGATCGATCTGGAACTGTGTCTCTGCAAACAGTGCAGGACCTGGCATGG 240  
37 E F K D R S G N C V L C K Q C G P G M E 57  
241 AGTTGTCCAAGGAATGTGGCTTCGGCTATGGGGAGGATGCACAGTGTGTGCCCTGCAGGC 300  
58 L S K E C G F G Y G E D A Q C V P C R P 77  
301 CGCACCGGTTCAAGGAAGACTGGGGTTTCCAGAAGTGTAAAGCCATGTGCGGACTGTCCGC 360  
78 H R F K E D Q G F Q K C K P C A D C A L 97  
361 TGGTGAACCGCTTTCAGAGGGCCAACTGCTCACACACAGTGATGCTGTCTGCGGGGACT 420  
98 V N R F Q R A N C S H T S D A V C G D C 117  
421 GCCTGCCAGGATTTTACCGGAAGACCAAACTGGTTGGTTTTCAAGACATGGAGTGTGTGC 480  
118 L P G F Y R K T K L V G F Q D M E C V P 137  
481 CCTGCGGAGACCCACCTCCTCCTACGAACCACTGTACCAGCAAGGTGAACCTTGTGA 540  
138 C G D P P P P Y E P H C T S K V N L V K 157  
541 AGATCTCCTCCACCGTCTCCAGCCCTCGGGACACGGCGCTGGCTGCCGTCTCTGCAGTG 600  
158 I S S T V S S P R D T A L A A V I C S A 177  
601 CTCTGGCCACGGTGCTGCTCGCCCTGCTCATCTGTGTGTCTACTGCAAGAGGCAGT 660  
178 L A T V L L A L L I L C V I Y C K R Q F 197  
661 TCATGGAGAAGAAACCCAGCTGTAAGTCCCATCCCTCTGTCTCACTGTGAAGTGAGCTT 720  
198 M E K K P S C K L P S L C L T V K \* 217  
721 GTTAGCATTGTCAACCAAGAGTTCTCAAGACACCTGGCTGAGACCTAAGACCTTTAGAGC 780  
781 ATCAACAGCTACTTAGAATACAAGATGCAGGAAAACGAGCCTCTTCAGGAATCTCAGGGC 840  
841 CTCCTAGGGATGCTGGCAAGGCTGTGATGTCTCAAGGCTACCAAGGA 886

FIG. 7B

10/23

1 GGACCTGCAGCCTCCAGGTGGCTGGGAAGAACTCTCCAACAATAAATACATTTGATAAG 60  
61 AAAGATGGCTTTAAAGTGCTACTAGAACAAAGAGAAAACGTTTTCTACTCTTTTAGTATT 120  
0 M A L K V L L E Q E K T F F T L L V L 19  
121 ACTAGGCTATTTGTCATGTAAAGTGACTTGTGAATCAGGAGACTGTAGACAGCAAGAATT 180  
20 L G Y L S C K V T C E S G D C R Q Q E F 39  
181 CAGGGATCGGTCTGGAAACTGTGTTCCCTGCAACCAAGTGTGGGCCAGGCATGGAGTTGTC 240  
40 R D R S G N C V P C N Q C G P G M E L S 59  
241 TAAGGAATGTGGCTTCGGCTATGGGGAGGATGCACAGTGTGTGGCGTGCCGGCTGCACAG 300  
60 K E C G F G Y G E D A Q C V A C R L H R 79  
301 GTTCAAGGAGGACTGGGGCTTCAGAAATGCAAGCCCTGTCTGGACTGCGCAGTGGTGAA 360  
80 F K E D W G F Q K C K P C L D C A V V N 99  
361 CCGCTTTAGAAAGGCAAAATTGTTAGCCACCAAGTGTGATGCCATCTGCGGGGACTGCTTGCC 420  
100 R F Q K A N C S A T S D A I C G D C L P 119  
421 AGGATTTTATAGGAAGACGAACTTGTGGCTTCAAGACATGGAGTGTGTGCTTGTGG 480  
120 G F Y R K T K L V G F Q D M E C V P C G 139  
481 AGACCCTCCTCCTTACGAACCGCACTGTGCCAGCAAGGTCAACCTGGAAGATCGC 540  
140 D P P P P Y E P H C A S K V N L V K I A 159  
541 GTCCACGGCTCCAGCCACGGGACACGGCGCTGGCTGCCGTTATCTGCAGCGCTCTGGC 600  
160 S T A S S P R D T A L A A V I C S A L A 179  
601 CACCGTCTGCTGGCCCTGCTCATCTCTGTGTCATCTATTGTAAGAGACAGTTTATGGA 660  
180 T V L L A L L I L C V I Y C K R Q F M E 199  
661 AAAGAAACCCAGCTGGTCTCTGCGGTACAGGACATTCAGTACAACGAGactGAGCTGC 720  
200 K K P S W S L R S Q D I Q Y N E T E L S 219  
721 GTGTTTTGACAGACCTCAGCTCCACGAATATGCCACAGAGCCTGCTGCCAGTGCCGCCG 780  
220 C F D R P Q L H E Y A H R A C C Q C R R 239  
781 TGACTCAGTGACACCTGCGGGCCGGTGCCTTGTCTCCATCCATGTGCTGTGAGGAGGC 840  
240 D S V Q T C G P V R L L P S M C C E E A 259  
841 CTGCAGCCCCAACCCGGCGACTCTTGTTGTGGGGTGATTCTGCAGCCAGTCTTCAGGC 900  
260 C S P N P A T L G C G V H S A A S L Q A 279  
901 AAGAAACGCAGGCCAGCCGGGGAGATGGTGCCGACTTTCTTCGGATCCCTCACGCAGTC 960  
280 R N A G P A G E M V P T F F G S L T Q S 299  
961 CATCTGTGGCGAGTTTTTACAGTGCCTGGCCTCTGATGCAGAATCCCATGGGTGGTGACAA 1020  
300 I C G E F S D A W P L M Q N P M G G D N 319  
1021 CATCTCTTTTGTGACTCTTATCCTGAACCTCACTGGAGAAGACATTCACTCTCAATCC 1080  
320 I S F C D S Y P E L T G E D I H S L N P 339  
1081 AGAACTTGAAGCTCAACGCTTTGGATTCAAATAGCAGTCAAGATTTGGTTGGTGGGGC 1140  
340 E L E S S T S L D S N S S Q D L V G G A 359  
1141 TGTCCAGTCCAGTCTCATTCTGAAACTTTACAGCAGCTACTGATTTATCTAGATATAA 1200  
360 V P V Q S H S E N F T A A T D L S R Y N 379  
1201 CAACACACTGGTAGAATCAGCATCAACTCAGGATGCACTAATATGAGAAGCCAGCTAGA 1260  
380 N T L V E S A S T Q D A L T M R S Q L D 399  
1261 TCAGGAGAGTGGCGCTGTATCCACCCAGCCACTCAGACGTCCTCCAGGTAAGGCAGCG 1320  
400 Q E S G A V I H P A T Q T S L Q V R Q R 419  
1321 ACTGGGTTCCCTGTGAACACAGCACTGACTTACAGTAGATCAGAATCTGTTCCAGCAT 1380  
420 L G S L \* 439  
1381 AAGATTTGGGGGAACCTGGATGAGTTTTTTTTTTCATCTTTAATAATTTCTTATATGT 1440  
1441 TGTAGAGTATGTTTTAAATAAATTTCAAGTATTTTTTAAAAAATTT 1489

FIG. 7C

11 / 23

1 TGGCCTCTGATGCAGAAATCCTCTGGGTGGTGACAGCTCTCTGTGACTCTTATCTCTGAA  
 61 W P L M Q N P L G G D S S L C D S Y P E  
 121 CTCACCTGGAGAAGATATCAATTCCTCAATCCGAAATGAAAGCTCAACATCTGTGGAT  
 41 L T G E D I N S L N P E N E S S T S V D  
 181 TCCAATGGTGGTCAGGATCTGGCTGGGCGAGCTGCTCCAGATTCTTCTGGAGATTTTCAA  
 61 S N G G Q D L A G A A P D S S G D F Q  
 241 GAAAATACTGACTCACCTAGATATGTGACGCCGATACGGTCTGGGAGCAAAACCCTAGCT  
 81 E N T D S P R Y G D A D T V W E Q T L A  
 301 CAGGATGCTCAAAGGACTCCAAGCAGAGAGGGCTGGGAGCCAGTGAAACCTGAATCTA  
 101 Q D A Q R T P S R E G W E A S E N L N L  
 361 GCCACGTCCACAGCCTTCCAGGATGCCCTGAAGGCCATCTTCTGACATGGAGGTGTGGGT  
 421 A T S T A F Q D A  
 481 CTGGCACGCCCTCIGGTGAGTCTTACAGACTGAGCAGTCTTGACCTTCTACGGTGCTG  
 541 AAGGAAAATAAATCTGAAGCAAACTGGCAGCACTTCCATACCTTTCAGCCACGAGCTTCT  
 601 GAGCCAGACCAAGCTGTAGCTGAACCCAGCAAGCAAGGAGAGACCGTAGCGGCC  
 661 TCGGACCTGACCTGCTTCCCTAAACAAGAACCTTAGCTGGGGCCAAATTTGAAGGACCAT  
 721 GATGGAATGTGCTGCTGCTGAGATTGTGGCACGCGCAGGCGCCAGCTGGCTCCTTCTTA  
 781 CGTTCATGGTGAATGTGGTTTCAACAAGAACCAAGATATAACTTTCATAGACTTCTCTT  
 841 TAAACATTACCCACTACCTGGGAAAAGCTTACGAGATGACTTCTTAGATTTAGGCA  
 901 GACTCTGGGGTTCTGTGAAAAGGCTTCTATCANCAAAATNTTCTCCCATTG  
 961 GTTNAAGGGNCTNCTTACCCCTGAAATGTTATTTGGTGAAATTTAANTGGCT  
 1021 GCCCTTATNCCCTTCTTGGNCTCCCTGTGGGTTTNCNCCCTTACNCGGAA  
 1081 AAGAAGCCCGGTCTTNAAGGTTGGTTTAAATTTGTTTNCNCAATTTTCCCGTTAAG  
 1133 GGAAGGAAGATTAAAGGGGAAAGGGCTCCCTTTTAAATTTNCCCTNNTCCCAATTTCC  
 TNAACCTGNNTTTTAAACNTCCCGTTAATTTGGAANC TTTTATTCCGC

FIG. 7D

12/23

## Nucleotide and amino acid sequence of mAPO4-γ

1	GC	G	T	T	G	G	C	G	G	A	A	G	T	G	C	T	A	C	C	A	G	C	T	G	C	G	G	A	A	G	C	G	T	G	G	A	A	G	C	A	C	T	G	G		60	
61	C	G	A	G	T	A	G	C	A	C	A	G	T	T	G	G	T	G	A	G	C	C	A	T	G	G	C	A	C	T	G	C	A	T	G	C	A	C	T	A	C	A		120			
-10																																									9						
121	C	A	G	G	A	C	G	G	T	G	C	T	T	C	G	C	A	T	T	C	T	C	T	A	C	C	A	C	T	G	G	C	A	T	G	T	A	A	G	T	G	A		180			
10	R	T	V	L	F	A	A	I	L	F	L	L	H	L	A	C	K	V	S	C																							29				
181	C	G	A	A	C	C	G	G	A	T	T	G	C	A	G	C	A	G	G	A	T	T	C	A	A	G	G	A	T	T	C	A	A	G	A	A	A	C	T	G	T	C	C	T	G		240
30	E	T	G	D	C	R	Q	Q	E	F	K	D	R	S	G	N	C	V	L	C																							49				
241	C	A	A	C	A	G	T	G	C	G	A	C	T	G	G	C	A	T	G	G	A	T	T	C	A	A	G	G	A	T	T	C	A	A	G	A	A	T	T	C	G	G	T	A		300	
50	K	Q	C	G	P	G	M	E	L	S	K	E	C	G	F	G	Y	G	E	D																							69				
301	T	G	C	A	G	T	G	T	G	C	C	C	T	G	C	A	G	C	C	G	G	T	T	C	A	A	G	G	A	A	G	A	A	C	T	G	G	G	T	T	C	C	A		360		
70	A	Q	C	V	P	C	R	P	H	R	F	K	E	D	W	G	F	Q	K	C																							89				
361	T	A	A	G	C	A	T	G	T	G	C	G	T	G	T	G	A	C	C	G	T	T	T	C	A	G	A	G	G	C	C	A	A	C	T	G	C	T	C	A	C	A	C		420		
90	K	P	C	A	D	C	A	L	V	N	R	F	Q	R	A	N	C	S	H	T																								109			
421	C	A	G	T	A	T	T	C	C	A	G	A	T	T	T	T	C	C	G	A	A	G	A	C	C	A	A	C	T	G	T	G													480		
110	S	D	A	V	C	G	D	C	L	P	G	F	Y	R	K	T	K	L	V	G																							129				
481	T	T	T	C	A	G	A	C	A	T	G	T	G	T	G	C	C	T	G	C	G	A	C	C	C	C	T	C	C	T	C	C	T	C	C	T	A	C	G	A	C	C		540			
130	F	Q	D	M	E	C	V	P	C	G	D	P	P	P	P	P	Y	E	P	H	C																						149				
541	T	G	A	G	T	G	T	G	C	C	A	A	G	T	G	C	A	G	A	C	C	T	T	T	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A		591			
150	E	*																																								166					

FIG. 7E

13/ 23

## Nucleotide and amino acid sequence of mAP04-β

1	CCACGCGTCCGATCCTGAAC	60
1	H A S D P E L T G E D T N S L N P E N E	20
61	AAGCGCAGCATCTCTGGATTCCAGTGGCGCCAGGATCTGGCTGGACAGCTGCTCTAGA	120
21	S A A S L D S S G G Q D L A G T A A L E	40
121	GTCTTCTGGGAATGTTTCAGAACTCTACTGACTCACCTAGACATGGTGACACTGGTACAGT	180
41	S S G N V S E S T D S P R H G D T G T V	60
181	CTGGGAGCAGACGCTAGCTCAGGATGCTCAAGGACTCCCAAGCCAAAGGAGGCTGGGAAGA	240
61	W E Q T L A Q D A Q R T P S Q G G W E D	80
241	CAGGAAACCTGAATCTAGCCATGCCACAGCCCTTCCAGGATGCCCTGAAGGCCATCTTC	300
81	R E N L N L A M P T A F Q D A *	95
301	CTGACGTGGAGGTGTGGGTCTGGACAAGCCTGTGATGAGGCCCTACAGACTGAGCAGTCTT	360
361	GGTGTCTGGAGCAAAAATAAATCTGAACCAAACTG	396

FIG. 8



14 / 23

## PARTIAL NUCLEOTIDE AND AMINO ACIDS SEQUENCE OF hAPO6

1	TGGAGCGCTCCGCTACTGCAACGTCCTCTGCGGGAGCGTGAGGAGGACGGCGCTT	60
1	E R C R Y C N V L C G E R E E A R A C	20
61	GCCACGCCACCAACCGTGCGCTGCGCTGCCGACCGGCTTCTTCGCGCACGCTGGTT	120
21	H A T H N R A C R C R T G F F A H A G F	40
121	TCTGCTTGGAGCAGCATCGTGTCCACCTGGTGCGGGGTGATGCGCGGACCCCA	180
41	C L E H A S C P P G A G V I A P G T P S	60
181	GCCAGAACCGCAGTGCCAGCGTGCGCCCCCAGGCACCTTCTCAGCCAGCTCCAGCT	240
61	Q N T Q C Q P C P P G T F S A S S S	80
241	CAGAGCAGTGCCAGCCCCACCGCAACTGCACGGCCCTGGGCCCTCAATGTGCCAG	300
81	E Q C Q P H R N C T A L G L A L N V P G	100
301	GCTCTTCTCCCATGACACCCCTGTGACCCAGCTGCACCTGGCTTCCCTCAGCACGAGG	360
101	S S S H D T L C T S C T G F P L S T R V	120
361	TACCAGGAGCTGAGGAGTGTGAGCGTGCCGTGTCATCGACTTGTGGCTTTCAGGACATCT	420
121	P G A E E C E R A V I D F V A F Q D I S	140
421	CCATCAAGAGGCTGCAGCGGCTGCTGAGGCCCTCGAGGCCCCCGAGGGCTGGGTCCGA	480
141	I K R L Q R L L Q A L E A P E G W G P T	160
481	CACCAAGGCGGCGCGCGGCTTGCAGCTGAGCTGCGTGGCGGCTCACGGAGCTCC	540
161	P R A G R A A L Q L K L R R R L T E L L	180
541	TGGGGCGCAGGACGGGGCGCTGTGCTGGCGGTGCTGCAGGCGCTGCGGTGGCCAGGA	600
181	G A Q D G A L L V R L L Q A L R V A R M	200
601	TGCCCCGGCTGGAGCGGAGCGTCCGTGAGCGCTTCCCTGTCGACTGATCCTGGCCCC	660
201	P G L E R S V R E R F L P V H *	220
661	CTCTTATTTATCTACATCTTGGCACCCCACTTGCACTGAAAGAGCGCTTTTTTTAAAT	720
721	AGAAGAAATGAGGTTTCTTAAAAAATAAAAAAAAAAAAAA 767	

FIG. 9



16 / 23

hLT- $\alpha$	118	KATSPKAT...SSPEYLAHEVQLFSSQYPEHVPL	SSQKVVY.....PGLQEPWHSYHGAHFGITGGDQLSTHT
hTNF- $\alpha$	143	GGCP.....STHMLTHTRSFVSYTKVNL	SAIKSPCQRETPEGTEAKPEWHEPIMLGAVFQLEKGRLSAEI
hFasL	200	QSC.....NNEPLSHKVMYRNKMPQDLVM	EGKMMSY.....CHTGGMMARRSSVILGAVENLTSADHLIYWNV
hLT- $\beta$	144	RAPPGGDPPGGRSMYLRSSLEMYRAGGAGPGTPEILL	LEGAEIVIPVLDPAARRQGYGGLMYTISVGFGLVQLRGRERVYNI
hCD40L	180	REASSQAPFHA.....SLCLKSPGRFERILLRAANTHSS	AKPCG.....QSSIHLLGGVFEIQQGASVFMNV
hTRAIL	193	EEIKENTKDKQW.....QYIYKYTSYDPDILLMKSARNSCWSKDAEYG	LYSIHQGGTFFELKENDRTFVSV
hTNRL3	131	GRAVYLKLDLIVDGVIALRQLEEFSAHA	ASSLGPQLRLQVSGILLALRPGSSIRRT
hTNRL3	134	GRAVYLKLDLIVDGVIALRQLEEFSAHA	ASSLGPQLRLQVSGILLALRPGSSIRRT
hTNRL1- $\beta$	174	VITIMGOVYSR.....EGQGRQETLERCIRSM	PSHPDRAVNSCYSGVHLHGGDILSV
hTNRL1- $\beta$	165	VITIMGOVYSR.....EGQGRQETLERCIRSM	PSHPDRAVNSCYSGVHLHGGDILSV
hTNRL1- $\alpha$	144	KTYAMGHLITGRKKVMVFGEISLIVLERCIGNM	PE..TLPNNSCYSGVHLHGGDILSV
hTNRL1- $\alpha$	209	PTFAMGCHVIAQRKKVMVFGEISLIVLERCIGNM	PK..TLPNNSCYSGVHLHGGDILSV
hLT- $\alpha$	186	DGIPHVLVSPTL...VEEGAFH	
hTNF- $\alpha$	213	NLPNYLDFEESG.QVWFGITAIL	
hFasL	262	SELSLVNFEESL...QIFFGLMK	
hLT- $\beta$	224	SHPDMDVFAIRG.KIIFFGAVMV	
hCD40L	242	TDPSQVSHGT.G.FIISFGLIK	
hTRAIL	261	TNEHLIDMDH.E.ASEEGAFHMG	
hTNRL3	188	EPW..AELKAAPEFLIMFGLFGMH	
hTNRL3	191	EPW..AELKAAPEFLIMFGLFGMH	
hTNRL1- $\beta$	229	IPRARAKLSLSPHGIFLGEVKLI	
hTNRL1- $\beta$	220	IPRARAKLSLSPHGIFLGEVKLI	
hTNRL1- $\alpha$	203	IPRENAGISLSDGVITFFGALKLI	
hTNRL1- $\alpha$	268	IPRENAGISRNEDDITFEFGALKLI	

FIG. 10B

17 / 23

NUCLEOTIDE AND AMINO ACID SEQUENCE OF FULL-LENGTH HUMAN TNRL-1 (TNRL-alpha)

1	GAAAGGCAGAAAGGAGAAATTCAGGATAA	CTCTCTGAGGGGTAGCCAAAGCCCTGCCA	60
61	TGTAGTGCACGCGACATCAACAACACAGATA	CAACAGGAATGATCCATTCCTCTGTGGT	120
121	CACTATTCTAAAGGCCCAACCTTCAAGTTCA	AGTAGTAGATGATGATGACTCCACAGAA	180
-13		M D D S T E	6
181	AGGAGCAGTCACGCTTACTTCTTGCCCTTA	AGAAAGAGAAATGNAACCTGAAGGAG	240
7	R E Q S R L T S C L K K R E E M K L K E		26
241	TGTGTTTCCATCTCCACGGAAGAAAGCCCT	CTGTCCGATCTCCAAAGACGGAAG	300
27	C V S I L P R K E S P S V R S S K D G K		46
301	CTGCTGGCTGCAACCTTGCTGTGGCCTGCT	GTCTGTGCTCAGCGTGTGTCTTTC	360
47	L L A A T L L L A L L S C C L T V V S F		66
361	TACCAGGTGGCCGCTGCAAGGGGACCTGGCC	AGCCTCCGGGAGAGTGCAGGGCCAC	420
67	Y Q V A A L Q G D L A S L R A E L Q G H		86
421	CACGGAGAGCTGCCAGCAGGAGCGCCGCGC	CGCCCTGGAGGAAGCTCCA	480
87	H K E K L P A G A G A P K A G L E A P		106
481	GCTGTACCGGGACTGAAATTCCTTGAACCA	CACAGCTCCAGGAGAGGCAACTCCAGT	540
107	A V T A G L K I F E P P A P G E G N S S		126
541	CAGAAGCAGAAATAGCGTCCGTTCAAGGTC	CAGAAGAACAGTCACCTCAAGACTGC	600
127	Q N S R N K R A V Q G P E E T V T Q D C		146
601	TTGCAACTGATGCAGACAGTGAACCAACTA	TACAAAAGGATCTTACACATTGT	660
147	L Q L I A D S E T P T I Q K G S Y T F V		166
661	CCATGGCTTCTCAGCTTTAAAGGGGAGTG	CCCTAGAGAAAGAGATAAATATTG	720
167	P W L L S F K R G S A L E E K E N K I L		186
721	GTCAAAGAACTGTTACTTTTATATATATG	TGTCAGGTTTATATCTAGTAAGACCTAC	780
187	V K E T G Y F I Y G Q V L Y T D K T Y		206
781	GCCATGGACATCTAATTCAGAGGAAGTCC	ATGCTCTTGGGATGAATTGAGTCTG	840
207	A M G H L I Q R K K V H V F G D E L S L		226
841	GTGACTTGTTCGATGTATTCAAATATGCT	GAAACACTACCCATAATTCCTGCTAT	900
227	V T L F R C I Q N M P E T L P N S C Y		246
901	TCAGCTGGCATTCGAAACTGGAAGAGGAT	GAACTCCAACTTGCATACCAAGAGAA	960
247	S A G I A K L E E G D E L Q L A I P R E		266
961	AATGCACAAATATCAGTGGATGGAGATGC	ACATTTTGGTGCAATGAAACTGCTGGA	1020
267	N A Q I S L D G D V T F F G A L K L L *		286
1021	CCTACTTACACCATGCTCTAGCTATTTCT	CCCTTCTCTGTACCTCTAAGAGAAAG	1080
1081	AATCTAACTGAA	1092	

FIG. 11A

18 / 23

Nucleotide and amino acid sequence of mTNRL1- $\alpha$ 

1	CAGGAGAGCGCTCCTGGGGGAACCCAGCCCTGCCATGCTCTGAGGGCAGTCTCCCAGGAC	60
61	ACAGATGACAGGAAATGACCCACCCCTGTGGTCACCTTACTCCAAAGGCCTAGACCTTCAA	120
121	AGTGCTCCTCGTGGAAATGGATGAGTCTGCAAAGACCCTGCCACCACCGTGCTCTGTTTT	180
-4	M D E S A K T L P P P C L C F	15
181	TGCTCCGAGAAAGGAGAAGATATGAAAGTGGGATATGATCCCATCACTCCGCAGAAAGAG	240
16	C S E K G E D M K V G Y D P I T P Q K E	35
241	GAGGGTGCTGGTTTGGGATCTGCAGGGATGGAAGGCTGCTGGCTGCTACCCTCCTGCTG	300
36	E G A W F G I C R D G R L L A A T L L L	55
301	GCCCTGTGTCCAGCAGTTTACAGCGATGTCCTTGTACCAGTTGGCTGCCCTTGCAAGCA	360
56	A L L S S S F T A M S L Y Q L A A L Q A	75
361	GACCTGATGAACCTGCGCATGGAGCTGCAGAGCTACCGAGGTTGAGCAACACCAGCCGCC	420
76	D L M N L R M E L Q S Y R G S A T P A A	95
421	GCGGGTGCTCCAGAGTTGACCGCTGGAGTCAAACCTCTGACACCGGCAGCTCCTCGACCC	480
96	A G A P E L T A G V K L L T P A A P R P	115
481	CACAACTCCAGCCGCGGCCACAGGAACAGACGCGCTTTCAGGGACCAGAGGAAACAGAA	540
116	H N S S R G H R N R R A F Q G P E E T E	135
541	CAAGATGTAGACCTCTCAGCTCCTCCTGCACCATGCCTGCCTGGATGCCGCCATTCTCAA	600
136	Q D V D L S A P P A P C L P G C R H S Q	155
601	CATGATGATAATGGAATGAACCTCAGAAACAGAACTTACACATTGTTCATGGCTTCTC	660
156	H D D N G M N L R N R T Y T F V P W L L	175
661	AGCTTTAAAAGAGGAAATGCCTTGGAGGAGAGAAACAAAATAGTGGTGAGGCAACA	720
176	S F K R G N A L E E K E N K I V V R Q T	195
721	GGCTATTCTTCATCTACAGCCAGGTTCTATACACGGACCCCATCTTTGCTATGGGTCAT	780
196	G Y F F I Y S Q V L Y T D P I F A M G H	215
781	GTCATCCAGAGGAAGAAAGTACACGTCTTTGGGGACGAGCTGAGCCTGGTGACCCCTGTTT	840
216	V I Q R K K V H V F G D E L S L V T L F	235
841	CGATGTATTGAGAATATGCCCAAAACACTGCCCAACAATTCCTGCTACTCGGCTGGCATC	900
236	R C I Q N M P K T L P N N S C Y S A G I	255
901	GCGAGGCTGGAAGAAGGAGATGAGATTGCAATTCTCGGAGAAATGCACAGATT	960
256	A R L E E G D E I Q L A I P R E N A Q I	275
961	TCACGCAACGGAGACGACACCTTCTTTGGTGCCCTAAAACCTGCTGTAACCTCACTTGCTGG	1020
276	S R N G D D T F F G A L K L L *	295
1021	AGTGCGTGATCCCTTCCCTCGTCTTCTCTGTACCTCCGAGGGAGAAACAGACGACTGGA	1080
1081	AAAACATAAAGATGGGGAAAGCCGTGACGGAAGTTTCTCGTGACCCGTTGAATCTGAT	1140
1141	CCAAACCAGGAAATATAACAGACAGCCACAACCGAAGTGTGCCATGTGAGTTATGAGAAA	1200
1201	CGGAGCCCGCGCTCAGAAAGACCGGATGAGGAAGACCGTTTCTCCAGTCCCTTTGCCAAC	1260
1261	ACGCACCGCAACCTTGCTTTTGGCTTGGGTGACACATGTTTCCAGATGTCAGGGAGATTTC	1320
1321	CTTGTTTTGGCATTTGCCATGAGAAGAGGGCCCAACCTGCAGGTCACTGAAGCATTCAC	1380
1381	GCTAAGTCTCAGGATTTACTCTCCCATCACATGCTAAGTACACACACGCTCTTTTCCAGG	1440
1441	TAATACTATGGGATACTATGGAAGGTTGTTTGTGTTTAAATCTAGAAGCTTGAAGTGG	1500
1501	CAATAGACA 1509	

FIG. 1 B

19 / 23

1	ACAACCTTCTCCCTTCTGCACCACTGCCCCGTACCCTTACCCGCCCCCGCCACCTCCTTGC	60
61	TACCCCACTCTTGAAACCAACAGCTGTTGGCAGGGTCCCCAGCTCATGCCAGCCTCATCTC	120
121	CTTTCTTGCTAGCCCCCAAGGGCTCCAGGCCAACATGGGGGCCAGTCAGAGAGCCGG	180
181	CACTCTCAGTTGCCCTCTGGTTGAGTTGGGGGCGAGCTCTGGGGCGGTGGCTTGTGCCA	240
241	TGGCTCTGCTGACCCCAACAAACAGAGCTGCAGAGCCTCAGGAGAGAGGTGAGCCGGCTGC	300
301	AGGGACAGGAGGCCCTCCAGATGGGAAGGGTATCCCTGGCAGAGTCTCCCGGAGC	360
361	AGAGTTCGATGCCCTGGAAGCTGGGAGAGTGGGAGAGATCCCGGAAAGGAGAGCAG	420
421	TGCTCACCCCAAAACAGAAAGCAGCACTCTGTCTGCACCTGGTTCCCATTAACGCCA	480
481	CCTCCAAGGATGACTCCGATGTGACAGAGGTGATGTGGCAACCAAGCTCTTAGCGGTGGGA	540
541	GAGGCCTACAGGCCCAAGGATATGTTGCCGAATCCAGGATGCTGGAGTTTATCTGCTGT	600
601	ATAGCCAGGTCTCTGTTCAAGACGTGACITTCACCATGGGTGAGTGGTGTCTCGAGAAG	660
661	GCCAAGGAAGGCAGGAGACTCTATTCGATGTATAAGAAATGCCCCCTCCACCCGGACC	720
721	GGCCTACACAGCTGCTATAGCGCAGGTGCTTCCATTACACCAAGGGATATTCTGA	780
781	GTGTCATAATTCCTCCGGGCAAGGGCGAACTTAACCTCTCTCCACATGGAACCTTCTCTGG	840
841	GGTTTGTGAAACTGTGATTGTTATAAAAAGTGGCTCCCGAGCTTGGAAAGACCAGGGTGG	900
901	GTACATACTGGAGACAGCCAGAGCTGAGTATATAAAGGAGAGGGGAATGTGCAGGAACAG	960
961	AGCGCTCTTCTGGGTTTGGCTCCCCGGTCTCTACITTTCCCTTTTCATTTCCACCCCTCT	1020
1021	AGACTTGTGATTTACGGATATCTGTCTCTGTTCCCAATGGAGCTCCGAAATCTTGCCTG	1080
1081	TGTGTAGATGAGGGGGGACGGGCGCCAGGCAATTGTCCAGACCTTGGTCTGGGGGCCAC	1140
1141	TGGAAGCATCCAGAACAGCACCACCATC 1168	

FIG. I2A

**FIG. 12B**

21 / 23

111 GTCAGTTTGGGGAGCCGGGCATCGCTGTCCGCCCCAGGAGCCTGCCAGGAGGAGCTGGTG  
 611 V S L G S R A S L S A Q E P A Q E E L V  
 121 GCAGAGGAGGACCGGTCGGACTGAATCCCGAGAGAGAAAGCCAGGATCCT  
 181 A E E D Q D P S E L N P Q T E S Q D P  
 241 GCGCTTTCCTGAACCGACTAGTTCCGCTCGCAGAGTGCACCTAAAGCCGGAACA  
 301 A P F L N R L V R P R S A P K G R K T  
 361 CGGGCTCgAaGAGCGATCGCAGCCCATTTAGATTTCATCCAGACCTGGACAGGACGGA  
 421 R A R R A I A A H Y E V H P R P G Q D G  
 481 GCGCAGGCGAGGTGTGGACGGACAGTGTGGCTGGAGGAGCCAGAAATCAACAGCTCC  
 541 A Q A G V D G T V S G W E E A R I N S  
 601 AGCCCTCTGCGCTACTACCGCAGATCGGGGAGTTTATAGTACCCGGGCTGGGCTCTAC  
 661 S P L R Y Y R Q I G E F I V T R A G L Y  
 721 TACCTGTACTGTCAGGTGCACITTTGATGAGGGGAGGCTGTCTACCTGAAGCTGGACTTG  
 781 Y L Y C Q V H F D E G K A V Y L K L D L  
 841 CTGGTGGATGGTGTGCTGGCCCTGCGCTGCCAGGAATTCAGCCACTGCGGCCAGT  
 901 L V D G V L A L R C L E E F S A T A S  
 961 TCCCTCGGGCCCGCAGCTCCGCCCTCTGCCAGGTGTCTGGGCTGTGGCCCTGCGGCCAGGG  
 1021 S L G P Q L R L C Q V S G L L A L R P G  
 1081 FCCICCTGCGGATCCGCACCCCTCCCTGGGCCCATCTCAAGGCTGCCCTTCCTCACC  
 1141 S L R I R T L P W A H L K A A P F L T  
 1201 TACTTCGGACTCTTCCAGGTTCACTGAGGGGCCCTGGTCTCCCCACAGTCGTCCAGGCT  
 1261 Y F G L F Q V H  
 1321 GCCGGCTCCCCTCGACAGCTCTCTGGGCACCCGGTCCCCTCTGCCCCACCCCTCAGCCGCT  
 1381 CTTTGGCTCCAGACCTGCCCTCCCTCTAGAGGCTGCCCTGGGCTGTTCACGTGTTTCCCA  
 1441 TCCACATAAATACAGTATTCACCTCTTATCTTACAACTCCCCACGCCCTAAGAG  
 1501 GGGCTGGACTGGCGGAGGAGCCAAAGAGCTGGCTAGGCCAGGAGTCCCAATGTG  
 1561 AGGGGCGAGAAACAAGACAAGCTCCTCCCTTGAGAAATTCCTGTGGATTTTAAACACAGA  
 1621 TATTATTTTATTATTATTGACAAAATGTTGATAAATGGATATTAAATAGAAAAAAA  
 1681 AAAAAAAA  
 1741  
 1801  
 1861  
 1921  
 1981  
 2041  
 2101  
 2161  
 2221  
 2281  
 2341  
 2401  
 2461  
 2521  
 2581  
 2641  
 2701  
 2761  
 2821  
 2881  
 2941  
 3001  
 3061  
 3121  
 3181  
 3241  
 3301  
 3361  
 3421  
 3481  
 3541  
 3601  
 3661  
 3721  
 3781  
 3841  
 3901  
 3961  
 4021

FIG. 13A



22/ 23

1 CTGGTCGTGGTCAGCCTGGGGAGCTGGGCAACGCTGCTGCGCCAGGAGCCTTCTCAGGAG 60  
 61 L V V V S L G S W A T L S A Q E P S Q E 20  
 21 GAGCTGACAGCAGGAGCCGCCGGGAGCCCCCTGAACCTGAATCCCCAGACAGAGGAAAGC 120  
 41 E L T A E D R R E P P E L N P Q T E S 40  
 121 CAGGATGTGGTACCTTCTTGGAAACAACCTAGTCGGCCTCGAAGAAGTGCTCTCTAAAGGC 180  
 41 Q D V V P F L E Q L V R P R S A P K G 60  
 181 CGGAAGGCGCGCCTCGCGAGCTATTGCAGCCCATATGAGGTTTCATCCTCGGCCAGGA 240  
 61 R K A R P R R A I A A H Y E V H P R P G 80  
 241 CAGGATGGAGCACAGCAGGTGTGGATGGGACAGTGGCTGGGAAGAGACCAAAATC 300  
 81 Q D G A Q A G V D G T V S G W E E T K I 100  
 301 AACAGCTCCAGCCCTCTGCGCTACGACCGCCAGATTGGGGAATTTACAGTCATCAGGGCT 360  
 101 N S S P L R Y D R Q I G E F T V I R A 120  
 361 GGCCTCTACTACCTGTACTGTACGTGACCTTTGATGAGGAAAGGCTGTCTACCTGAAG 420  
 121 G L Y Y L Y C Q V H F D E G K A V Y L K 140  
 421 CTGGACTTGTGGTGAACGGTGTGCTGGCCCTGCGCTGCCTGGGAAGAAATTCAGCCACA 480  
 141 L D L L V N G V L A L R C L E E F S A T 160  
 481 GCAGCAAGCTCTCCTGGGCCCCAGCTCCGTTTGTGCCAGGTGTCTGGGCTGTGGCGCTG 540  
 161 A A S S P G P Q L R L C Q V S G L A L 180  
 541 CGGCCAGGGTCTTCCCTTCGGATCCGCACCTCCCTGGGCTCATCTTAAGGCTGCCCCC 600  
 181 R P G S S L R I R T L P W A H L K A A P 200  
 601 TTCCTAACCTACTTTGGACTCTTTCAAGTTTCACTGAGGGGCTTGTCTCTCCAGATTCT 220  
 201 F L T Y F G L F Q V H  
 661 TAAACTTTCCTGGCTCCAGGAGCATCACCACACCTCCCTA 701

FIG. 13B

23 / 23




FIG. 14A




FIG. 14C

FIG. 14B

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>C12N 15/12, C07K 14/705, 14/52, 16/28, 16/18, G01N 33/68</b></p>	<p><b>A3</b></p>	<p>(11) International Publication Number: <b>WO 99/11791</b> (43) International Publication Date: 11 March 1999 (11.03.99)</p>
<p>(21) International Application Number: <b>PCT/US98/18393</b> (22) International Filing Date: <b>4 September 1998 (04.09.98)</b> (30) Priority Data: <b>08/924,634 5 September 1997 (05.09.97) US</b> (71) Applicant: <b>UNIVERSITY OF WASHINGTON [US/US]; Suite 200, 1107 N.E. 45th Street, Seattle, WA 98105-4631 (US).</b> (72) Inventor: <b>CHAUDHARY, Preet, M.; 4540 8th Avenue N.E. #402, Seattle, WA 98105 (US).</b> (74) Agents: <b>GASHLER, Andrea, L. et al.; Campbell &amp; Flores LLP, Suite 700, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).</b></p>	<p>(81) Designated States: <b>AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</b>  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  (88) Date of publication of the international search report: <b>30 September 1999 (30.09.99)</b></p>	
<p>(54) Title: <b>TUMOR NECROSIS FACTOR FAMILY RECEPTORS AND LIGANDS, ENCODING NUCLEIC ACIDS AND RELATED BINDING AGENTS</b></p> <p>(57) Abstract</p> <p>The invention provides novel receptors of the tumor necrosis factor receptor family as well as ligands of the tumor necrosis factor family. In addition to the isolated receptors and ligands of the invention, there are provided encoding nucleic acids and related selective binding agents.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/18393

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/705 C07K14/52 C07K16/28 C07K16/18  
G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 98 38304 A (ONO PHARMACEUTICAL CO ;KONISHI MIKIO (JP); TADA HIDEAKI (JP); FUKU) 3 September 1998 (1998-09-03) figure 1 page 11, line 20 - line 21 page 26, line 21 - page 27, line 5 ---	1-17
X	PAN G ET AL: "AN ANTAGONIST DECOY RECEPTOR AND A DEATH DOMAIN-CONTAINING RECEPTOR FOR TRAIL" SCIENCE, vol. 277, 8 August 1997 (1997-08-08), pages 815-818, XP002065147 sequence of DR5 the whole document --- -/--	18-22

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

20 July 1999

Date of mailing of the international search report

18. 08. 99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Galli, I

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/18393

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 98 46643 A (MILLENNIUM BIOTHERAPEUTICS INC) 22 October 1998 (1998-10-22) sequence of Tango-63d abstract claims 1-81 ---	18-22
E	WO 98 41629 A (HUMAN GENOME SCIENCES INC ;NI JIAN (US); ROSEN CRAIG A (US); GENTZ) 24 September 1998 (1998-09-24) sequence of DR5 abstract claims 1-34 ---	18-22
E	WO 98 51793 A (GENENTECH INC) 19 November 1998 (1998-11-19) abstract sequence of Apo-2 (seq. 11) claims 1-64 ---	18-22
P,X	MACFARLANE M ET AL: "IDENTIFICATION AND MOLECULAR CLONING OF TWO NOVEL RECEPTORS FOR THE CYTOTOXIC LIGAND TRAIL" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 41, 10 October 1997 (1997-10-10), pages 25417-25420, XP002065148 sequence of TRAIL-receptors 2 and 3 the whole document ---	18-27
P,X	WO 98 30693 A (HUMAN GENOME SCIENCES INC ;FENG PING (US); NI JIAN (US); EBNER REI) 16 July 1998 (1998-07-16) abstract sequence of TRID/TNFR5 claims 1-22 ---	23-27
E	WO 98 58062 A (GENENTECH INC) 23 December 1998 (1998-12-23) abstract sequence of Apo2DcR claims 1-54 ---	23-27
P,X	WO 98 30694 A (HUMAN GENOME SCIENCES INC ;FENG PING (US); NI JIAN (US); EBNER REI) 16 July 1998 (1998-07-16) abstract sequence of TNFR-6 alpha claims 1-23 ---	28-32
P,X	EP 0 861 850 A (SMITHKLINE BEECHAM CORP) 2 September 1998 (1998-09-02) abstract sequence of TR4 claims 1-25 ---	28-32
	---	
	-/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/18393

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 99 14330 A (GENENTECH INC) 25 March 1999 (1999-03-25) abstract sequence of DcR3 claims 1-66 ---	28-32
E	WO 98 55620 A (MASIAKOWSKI PIOTR ; REGENERON PHARMA (US); VALENZUELA DAVID (US)) 10 December 1998 (1998-12-10) abstract sequence of NTN-2 claims 1-20 ---	33-38
P,X	WO 98 18921 A (HUMAN GENOME SCIENCES INC ; NI JIAN (US); EBNER REINHARD (US); YU G) 7 May 1998 (1998-05-07) abstract sequence of neutrokin alpha claims 1-21 ---	33-38
P,X	WO 97 33902 A (HUMAN GENOME SCIENCES INC ; NI JIAN (US); GENTZ REINER L (US); YU G) 18 September 1997 (1997-09-18) abstract sequence of TNF-delta claims 1-30 ---	33-38
P,X	WO 98 27114 A (SCHERING CORP) 25 June 1998 (1998-06-25) abstract sequence of T cell surface Ag 63954 claims 1-10 ---	33-38
E	WO 98 55621 A (MASIAKOWSKI PIOTR ; REGENERON PHARMA (US); VALENZUELA DAVID (US)) 10 December 1998 (1998-12-10) abstract sequence of NTN-2 claims 1-20. ---	33-38
E	EP 0 911 633 A (SMITHKLINE BEECHAM CORP) 28 April 1999 (1999-04-28) abstract sequence of TL3 (seq. 4) claims 1-24 ---	33-38
P,X	WO 98 05783 A (CHICHEPORTICHE YVES ; FACULTY OF MEDICINE OF THE UNI (CH); BIOGEN I) 12 February 1998 (1998-02-12) abstract sequence of TRELL claims 1-35 ---	39-43
	---	

-/--

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/18393

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	CHICHEPORTICHE Y. ET AL.: "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis" J. BIOL. CHEM., vol. 272, no. 51, 19 December 1997 (1997-12-19), pages 32401-32410, XP002108889 sequence of TWEAK the whole document	39-43
A	CHINNAIYAN A M ET AL: "SIGNAL TRANSDUCTION BY DR3, A DEATH DOMAIN-CONTAINING RECEPTOR RELATED TO TNFR-1 AND CD95" SCIENCE, vol. 274, no. 5289, 8 November 1996 (1996-11-08), pages 990-992, XP000676685 the whole document	1-43
A	SHERIDAN J P ET AL: "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors" SCIENCE, no. 277, 8 August 1997 (1997-08-08), page 818 818 XP002075799 the whole document	1-43
A	ROKHLIN O.W. ET AL.: "Fas-mediated apoptosis in human prostatic carcinoma cell lines" CANCER RESEARCH, vol. 57, no. 9, 1 May 1997 (1997-05-01), pages 1758-1768, XP002093791 the whole document	7,8,13
A	USLU R. ET AL.: "Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis" CLIN. CANCER RESEARCH, vol. 3, no. 6, June 1997 (1997-06), pages 963-972, XP002093792 the whole document	7,8,13
A	DATABASE GENBANK [Online] Accession No. AA003356, 19 July 1996 (1996-07-19) MARRA M. ET AL.: "Mouse embryo EST clone IMAGE:427152" XP002093795 cited in the application the whole document	1-43

-/--



# INTERNATIONAL SEARCH REPORT

Inter. l. Application No

PCT/US 98/18393

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE GENBANK [Online]  Accession No. AA036247,  26 August 1996 (1996-08-26)  MARRA M. ET AL.: "Mouse embryo EST clone  IMAGE:472300"  XP002093796  cited in the application  the whole document  -----</p>	1-43

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 98/18393

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claim 8 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: (1-17) - complete

An isolated AP04 polypeptide (Seq. IDs 8,10,12,14,16) or an active fragment thereof, the corresponding nucleic acids and uses thereof.

An AP04 selective binding agent.

2. Claims: (18-22) - complete

Idem as subject matter 1, but limited to AP08 (Seq. ID 2)

3. Claims: (23-27) - complete

Idem as subject matter 1, but limited to AP0 9 (Seq. ID 6)

4. Claims: (28-32) - complete

Idem as subject matter 1, but limited to AP06 (Seq. ID 18)

5. Claims: (33-38) - complete

An isolated tumor necrosis factor-related ligand 1 (TNRL1; Seq. IDs 20,22,24,26) or an active fragment thereof and the corresponding nucleic acids.

A TNRL1 selective binding agent.

6. Claims: (39-43) - complete

Idem as subject matter 5, but limited to TNRL3 (Seq. IDs 28,30).

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The selective binding agents of claims 6,22,27,32,38,43 are not sufficiently described to allow for a complete and meaningful search.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 98/18393

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9838304	A	03-09-1998	NONE	
WO 9846643	A	22-10-1998	AU 7126498 A	11-11-1998
WO 9841629	A	24-09-1998	AU 6763598 A	12-10-1998
WO 9851793	A	19-11-1998	AU 7796398 A	08-12-1998
WO 9830693	A	16-07-1998	AU 5815798 A	03-08-1998
			AU 6238698 A	03-08-1998
			WO 9830694 A	16-07-1998
WO 9858062	A	23-12-1998	AU 8144798 A	04-01-1999
WO 9830694	A	16-07-1998	AU 5815798 A	03-08-1998
			AU 6238698 A	03-08-1998
			WO 9830693 A	16-07-1998
EP 0861850	A	02-09-1998	US 5885800 A	23-03-1999
			CA 2220852 A	03-08-1998
			JP 10215886 A	18-08-1998
WO 9914330	A	25-03-1999	AU 9497098 A	05-04-1999
WO 9855620	A	10-12-1998	AU 7608898 A	21-12-1998
			AU 7713098 A	21-12-1998
			WO 9855621 A	10-12-1998
WO 9818921	A	07-05-1998	AU 7674596 A	22-05-1998
WO 9733902	A	18-09-1997	AU 5366596 A	01-10-1997
			EP 0897390 A	24-02-1999
WO 9827114	A	25-06-1998	AU 5705898 A	15-07-1998
WO 9855621	A	10-12-1998	AU 7608898 A	21-12-1998
			AU 7713098 A	21-12-1998
			WO 9855620 A	10-12-1998
EP 0911633	A	28-04-1999	NONE	
WO 9805783	A	12-02-1998	AU 3829497 A	25-02-1998
			NO 990550 A	06-04-1999

THIS PAGE BLANK (USPTO)